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Abstract 
 
Myeloid cells express a plethora of C-type lectin receptors (CLR) that can 
regulate inflammatory responses. Dectin-1 belongs to a sub-family of CLRs that 
possesses an extracellular C-type lectin domain (CTLD) and a single YxxL 
intracellular motif (hemITAM) that allows signalling via Syk kinase and induction 
of downstream functions. Based on consensus sequences for the CTLD and 
hemITAM, we identified CLEC-2 as a dectin-1-like receptor. CLEC-2 was 
previously characterised as a Syk-coupled platelet receptor able to induce 
platelet aggregation when targeted by the snake venom rhodocytin and by cells 
expressing the endogenous protein podoplanin. I generated monoclonal 
antibodies against mouse CLEC-2 and found that CLEC-2 is also expressed on 
lymphoid and myeloid cells, including dendritic cells (DC). Notably, treatment 
with LPS increases CLEC-2 expression by myeloid cells and synergises with 
CLEC-2 signaling to induce increased secretion of IL-10 but not IL-12. This 
increased IL-10 production is also observed in the serum of mice administered 
with anti-CLEC-2 mAb and LPS, and is dependent on the presence of 
macrophages and DCs. Furthermore, I generated a CLEC-2 conditional KO 
mouse line that will provide a tool to study CLEC-2 function in myeloid cells in 
vivo. Collectively, these data indicate that CLEC-2 expression is not restricted 
to platelets and that it plays a role on the vascular development and modulation 
of TLR responses. 
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Chapter 1. Introduction 
1.1 Inflammation 
Inflammation is a multi-step process by which organisms restore tissue 
homeostasis. This inflammatory response was characterised around 3000 
years ago, as a process comprising 4 cardinal signs: redness, swelling, heat 
and pain. More recently, the loss of function of the tissue was added as the fifth 
cardinal sign of inflammation, and is the only sign that appears in all 
inflammatory processes. The physiological basis for these cardinal signs was 
described later, as a result of changes to blood flow followed by extravasation 
of blood components (leucocytes and plasma components) to the inflamed 
tissue (Medzhitov 2010). 
The inflammatory response is an ancient conserved process present in all 
multicellular organisms. As such, the innate immune system plays important 
role in inflammation. Even more considering that the adaptive immune system 
is evolutionary “younger” and only present on jawed fishes and vertebrates. 
However, in vertebrates the adaptive immune system was shown to contribute 
to the inflammatory process as a mechanism dependent of activation by the 
innate immune system (Iwasaki and Medzhitov 2010). 
The inflammatory response is initiated by changes in tissue homeostasis, 
which include different noxious conditions such as infection, trauma, toxic 
agents and metabolic changes. As a consequence, production of inflammatory 
mediators and leucocyte mobilisation happens, which subsequently leads to the 
elimination of the insult with tissue repair and restoration of homeostasis (see 
figure 1.1) (Wahl et al. 1997). 
As a multi-step process, each inflammatory step is sequentially controlled 
and dependent on each other. For example, the resolution of inflammation is 
achieved by restoration of tissue homeostasis with the effective elimination of 
the inflammatory trigger. Together with the elimination of the insult, the 
restoration of tissue homeostasis needs to be completed by the removal of the 
recruited leucocytes. This process is greatly dependent on the phagocytosis of 
dead leucocytes and the emigration of phagocytes from the tissue, with several 
Chapter 1. Introduction 
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molecular mediators involved. A significant example is the change of production 
of prostaglandins to the production of lipoxins. Prostaglandins are mediators 
that can induce vessel dilation favouring leucocyte recruitment, while the 
lipoxins can induce the phagocytosis of apoptotic leucocytes, reduce the 
vascular permeability and promote the emigration of phagocytes from the tissue 
via the lymphatics (Serhan and Savill 2005). An important aspect of this 
phagocyte emigration from the tissue is its capacity to reach secondary 
lymphoid organs and activate the adaptive immune system (Luster et al. 2005). 
Activated lymphocytes migrate to inflamed tissue where they contribute to 
elimination of the inflammatory trigger and resolution of inflammation. 
Because of the sequential nature of the inflammatory response, the 
detection of the inflammatory trigger constitutes its very first step and is crucial 
to determine the subsequent steps and types of reactions. 
 
Figure 1.1 Inflammation 
Inflammatory triggers commonly leads to tissue damage and initiate inflammation. This 
process is initiated by the production of several inflammatory mediators, which 
culminates in cellular mobilisation, activation of adaptive immunity and restoration of 
tissue homeostasis. 
Chapter 1. Introduction 
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1.2 Detectors of inflammatory triggers 
Since pathogens are one of the best characterised inflammatory triggers, 
it was proposed by Charles Janeway that the innate immune system would 
express a set of receptors that could recognise conserved features present on 
pathogens, and absent on endogenous cells, and initiate an inflammatory 
response that would culminate in the activation of adaptive responses (Janeway 
1989). The term pattern recognition receptor (PRR) was proposed to this set of 
germ-line encoded receptors that would recognise pathogen-associated 
molecular pattern (PAMP) (Janeway 1989). However as Polly Matzinger 
pointed out, tissue damage in the absence of infectious agents is capable of 
activation of innate immune cells (dendritic cells) that leads to the activation of 
adaptive immunity. Therefore, one of the functions of the innate immune system 
is to detect tissue damage (Matzinger 1994). Furthermore, Matzinger proposed 
a model whereby tissue damage would release, expose or induce components 
that would trigger inflammation (Matzinger 1998). As a matter of fact, it is now 
clear that the innate immune system expresses receptors that can recognise 
both PAMPs as well as damage-associated molecular patterns (DAMPs) to 
initiate the inflammatory response (Seong and Matzinger 2004). Among these 
innate receptors, there are four families of receptors that stand out from the rest 
according to their ability to detect and modulate inflammatory responses 
through regulation of gene expression: the Toll-like receptors (TLRs), RIG-I-like 
receptors (RLRs), Nod-like receptors (NLRs) and the signalling C-type lectin 
receptors (CLRs). 
The TLRs constitute the first family of receptors identified with a role in 
detection and initiation of inflammation, and their role in pathogen recognition 
and regulation of gene expression has been extensively studied. Besides the 
TLRs involvement in PAMPs recognition, these receptors are also involved in 
the recognition of several DAMPs (Yu et al. 2010) (see table 1). The TLRs are a 
family of receptors that contain an extracellular leucin-rich repeat (LRR) 
domain, a transmembrane domain and an intracellular motif denominated 
Toll/IL-1 Receptor (TIR) domain. This family of receptors interacts with its 
Chapter 1. Introduction 
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ligands via the LRR and signals to regulate gene expression by recruiting 
Myd88 and/or TRIF through its TIR domain that results in the activation of 
several downstream events (Takeda et al. 2003). 
Table 1 Toll-like receptors and its ligands 
TLR LOCALISATION LIGAND ORIGIN OF THE LIGAND 
TLR1 Plasma membrane Triacyl lipoprotein Bacteria 
TLR2 Plasma membrane Lipoprotein 
Bacteria, viruses, parasites, 
self 
TLR3 Endolysosome dsRNA Virus, self 
TLR4 Plasma membrane LPS Bacteria, viruses, self 
TLR5 Plasma membrane Flagellin Bacteria 
TLR6 Plasma membrane Diacyl lipoprotein Bacteria, viruses 
TLR7 Endolysosome ssRNA Virus, bacteria, self 
Human 
TLR8 
Endolysosome ssRNA Virus, bacteria, self 
TLR9 Endolysosome CpG-DNA Virus, bacteria, protozoa, self 
TLR10 Endolysosome Unknown Unknown 
TLR11 Plasma membrane Profilin-like molecule Protozoa 
 
The RLRs were identified based on its founding member retinoic acid 
inducible gene I (RIG-I), a helicase that triggers type I interferon and others 
genes by activating several transcription factors. This receptor family, besides 
its helicase domain, can express a caspase activation and recruitment domain 
(CARD) that allows activation of transcription factors by coupling with the 
adaptor protein mitochondrial antiviral signalling (MAVS). The RLRs are found 
on the cytoplasm of almost all nucleated cells and signals to gene induction 
upon recognition of viral nucleic acid (Rehwinkel and Reis e Sousa 2010). Thus 
it is a family of receptors involved in the detection and initiation of inflammation 
upon virus infection (table 2). 
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Table 2 RIG-I-like receptors and its ligands 
RLR LOCALISATION LIGAND ORIGIN OF THE LIGAND 
RIG-I Cytoplasm 5’ triphosphate RNA short dsRNA,  
RNA viruses, DNA virus 
 
MDA5 Cytoplasm RNA with secondary structure RNA viruses (Picornaviridae) 
LGP2 Cytoplasm Unknown RNA viruses 
 
 
Another family of innate receptors that is involved in the detection of 
inflammatory triggers are the NLRs. This family is constituted of proteins that 
contain a nucleotide binding and oligomerization (NACHT) domain as well as 
LRR and CARD domains. The LRR is believed to be involved in ligand 
recognition (as for TLRs) as well as in regulatory functions. The CARD is 
involved on interaction with the signalling adaptor RIP2 leading to signalling 
downstream events, including gene induction. NLRs are so called because of 
its first member: nucleotide-binding oligomerization domain 1 (NOD1). As 
cytoplasmic proteins expressed by several cell types, they can recognise 
intracellular bacterial infection and signal for initiation of inflammation (Fritz et 
al. 2006) (see table 3). Within the NLRs, there is a sub-group of receptors that 
have a pyrin domain (PYD) in addition to the other domains or replacing the 
CARD, and can stimulate a protein complex called inflammasome. The 
inflammasome causes the activation of caspase-1, which cleaves interleukin 
(IL) 1β and IL-18. The latter are precursors of inflammatory cytokines produced 
as inactive pro-form proteins. The most studied member of the NLR family that 
activates the inflammasome is NLRP3. It is activated by stimuli that lead to the 
production of reactive oxygen species, K+ efflux and/or lysosomal rupture 
(Schroder and Tschopp 2010). Thus, NLRP3 is largely considered a sensor of 
metabolic changes within cells, able to trigger the production of important 
inflammatory mediators in response to changes in cellular homeostasis 
(Schroder et al. 2010). 
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Table 3 NOD-like receptors and its ligands 
NLR LOCALISATION LIGAND ORIGIN OF THE LIGAND 
NOD1 Cytoplasm iE-DAP Bacteria 
NOD2 Cytoplasm MDP Bacteria 
NRLP3 Cytoplasm ? ? 
 
The CLR family contains some members identified that signal and 
modulate inflammatory responses, constituting the latest family of innate 
receptors involved in the detection of inflammatory triggers. This is, in great 
part, due to the discovery that the β-glucan receptor dectin-1 is able to link the 
detection of fungi and bacteria to production of inflammatory mediators 
independently of other receptors (Rogers et al. 2005; Underhill et al. 2005). The 
CLR family encompasses all proteins that contain at least one C-type lectin 
domain (CTLD), which is a structural motif that was primarily used to describe 
carbohydrate-binding proteins, but now is known to be involved in interactions 
with other molecules as well (Drickamer 1999). The CLRs include a large family 
of receptors, where only a few are membrane bound proteins with identified 
signalling domains and functions, thus the usage of the term signalling CLRs. I 
will describe here some of the features of these signalling CLRs and how they 
are involved in the modulation of inflammatory responses. On figure 1.2 is 
depicted how these four distinct families of receptor are located and can signal 
in a cell. 
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Figure 1.2 Detectors of inflammatory triggers 
Innate receptor families that detect inflammatory triggers and can signal to initiation of 
inflammation by gene induction. TLRs and CLRs are located on plasma membrane and 
endosomes. NLRs and RLRs are on the cytoplasm. TLRs can signal via its TIR domain 
by using MyD88 and/or Trif adaptor molecules. CLRs use hemITAM or ITAM-coupled 
adaptor proteins to signal via Syk. RLRs use its CARD domain to homotypic interact 
with CARD domain in the signalling molecule MAVS. NLRs also uses its CARD 
domain to homotypic interacts and activate RIP2 signalling molecule. 
 
1.3 Signalling CLRs 
The signalling CLR family comprises membrane-bound proteins that 
contain a CTLD. Among them are CLRs with identified and unidentified 
cytoplasmic signalling motifs and proteins with very short cytoplasmic tails that 
can interact and signal via receptor-associated transmembrane adaptors. The 
described signalling that originates from these CLRs can be characterised 
regarding their structural identified components: tyrosine-based and non-
tyrosine-based signalling.  
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1.3.1 Non tyrosine-based signalling 
For this group of signalling CLRs there are many proteins that mediate 
endocytosis of its ligands. Despite these endocytic CLRs, others have been 
show to modulate gene expression, which have direct implication on the 
initiation and regulation of inflammatory responses. This is so for DC-SIGN, 
which was previously implicated in diversion of its several pathogens ligands to 
non-degradative sub-cellular compartments (Van Kooyk and Geijtenbeek 2003). 
Recently, this receptor was shown to modulate TLR responses, inducing 
modulation of NFκB via Raf-1 signalling. In spite of activation of Raf-1 through 
Ras, no signalling motif on DC-SIGN has been identified to mediate Ras-Raf1 
activation (Gringhuis et al. 2007). In addition to DC-SIGN, dectin-1 was also 
reported to modulate TLR responses via activation of non-canonical NFκB 
subunits through Raf1. However, as for DC-SIGN, no signalling motif on dectin-
1 was identified (Gringhuis et al. 2009). 
Among the CLRs that mediate endocytosis there is DEC-205 (CD205) 
(Mahnke et al. 2000) and mouse DCIR2 (Dudziak et al. 2007). Importantly, 
these CLRs have been implicated on carrying their ligands to specialized 
compartments that favour antigen presentation and thus can regulate activation 
of adaptive immunity. Nevertheless, none of these CLRs have been shown to 
signal via ligand-dependent triggering or to possess a signalling motif-
dependent function. Hence, it is possible that the compartmentalization of the 
ligand by these CLRs is independent of signalling. 
Another receptor that is implicated in endocytosis and antigen 
presentation the mannose receptor (MR/CD206) (Burgdorf et al. 2007). Besides 
MR role in endocytosis, the triggering of MR by antibodies or by pathogen-
derived molecules suggests that MR can modulate cell activation (Nigou et al. 
2001; Chieppa et al. 2003; Zhang et al. 2004; Zhang et al. 2004). Despite that, 
no signalling motif in MR has been identified and implicated in cellular 
activation. 
1.3.2 Tyrosine-based signalling 
The main evidence for signalling downstream of some CLRs came from 
identification of the signalling mechanism used by dectin-1 (CLEC7A). 
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Previously, the dectin-1 tail had been shown to increase TLR-induced cytokine 
production by macrophages and dendritic cells (DCs) stimulated with zymosan, 
a cell wall extract from Saccharomyces cerevisiae (Brown et al. 2003; Gantner 
et al. 2003). Later, Rogers and colleagues showed that dectin-1, in fact, could 
couple recognition of PAMPs to induction of cytokines independently of TLRs 
via activation of spleen tyrosine kinase (Syk) signalling through its intracellular 
tail (Rogers, Slack et al. 2005). Accordingly, Underhill and colleagues also 
found that dectin-1 on macrophages could signal via Syk to generate reactive 
oxygen species (ROS), but not to promote phagocytosis of zymosan (Underhill, 
Rossnagle et al. 2005).  
Subsequently to the identification of Syk as a signalling molecule 
downstream of innate receptors, many other CLRs have been demonstrated to 
signal via Syk. The great majority of these signalling CLRs had a very short 
cytoplasmic tail with no clear signalling motif. However, these CLRs were able 
to interact with immunoreceptor-tyrosine activatory motif (ITAM) membrane 
adaptors (FcRγ and DAP12) and to signal to downstream effects via Syk 
(Underhill and Goodridge 2007). This is the case for DCAR (CLEC4B) that can 
signal via FcRγ to increase intracellular calcium and induction of tyrosine 
phosphorylation when cross-linked with antibodies (Kanazawa et al. 2003). 
Mincle (CLEC4E) has also been demonstrated to couple to Syk signalling via 
FcRγ, inducing tyrosine phosphorylation, mitogen- activated protein (MAP) 
kinase, NFAT activation and cytokine production by macrophages (Yamasaki et 
al. 2008). Interestingly, DAMPs (Yamasaki, Ishikawa et al. 2008) and PAMPs 
(Wells et al. 2008; Ishikawa et al. 2009; Yamasaki et al. 2009; Yamasaki et al. 
2009) can stimulate cells via Mincle. Another CLR that signals via FcRγ and 
Syk is dectin-2, which was reported to stimulate MAP kinase activation as well 
as cytokine (Robinson et al. 2009) and leukotriene production (Barrett et al. 
2009) upon interaction with fungi and house dust mite, respectively. Likewise, 
BDCA-2 (CLEC4C/CD303) when cross-linked with antibodies can couple to 
FcRγ and activate Syk (Röck et al. 2007), tyrosine phosphorylation and calcium 
signalling (Dzionek et al. 2001). Nevertheless, BDCA-2 signalling was reported 
to inhibit TLR-induced cytokine production (Dzionek, Sohma et al. 2001; Röck, 
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Schneider et al. 2007), in contrast with other FcRγ-Syk coupled CLRs, where 
triggering leads to cytokine production. Another ITAM signalling adaptor used 
by CLRs is DAP12. MDL-1 (CLEC5A) was shown to use DAP12 to signal, 
increasing intracellular calcium (Bakker et al. 1999) and cytokine production 
when stimulated by antibodies or dengue virus (Chen et al. 2008). 
In addition to the classical ITAM-based activation of Syk and signalling 
downstream of CLRs, dectin-1 was shown to use a similar motif on its own 
intracellular tail. The dectin-1 cytoplasmic domain was named hemITAM 
because contained a tyrosine and a leucin separated by two aminoacids 
(YXXL), which resembles half of an ITAM consensus sequence (YXXI/L X6-12 
YXXI/L), and was able to bind and signal through Syk (Rogers, Slack et al. 
2005). In table 4 it is represented the different signalling CLRs and their known 
ligand(s). 
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Table 4 Membrane-associated signalling CLRs and its ligands 
CLR SIGNALLING LIGAND 
ORIGIN OF THE 
LIGAND 
DEC-205 Non-tyrosine ? Self 
Mannose receptor Non-tyrosine Carbohydrate Fungi, helminthes 
DC-SIGN Non-tyrosine Carbohydrate 
Virus, bacteria, 
helminthes, self 
Mouse DCIR2 Non-tyrosine ? ? 
BDCA-2 Tyrosine (FcγR) ? ? 
Dectin-2 Tyrosine (FcγR) Carbohydrate Fungi, mite 
MINCLE Tyrosine (FcγR) 
proteins, 
glycolipid 
Bacteria, fungi, self 
DCAR Tyrosine (FcγR) ? ? 
CLEC5a/MDL-1 
Tyrosine 
(DAP12/DAP10) 
? Virus 
DNGR-1/ CLEC9a Tyrosine (hemITAM) ? Self 
Dectin-1 Tyrosine (hemITAM) Carbohydrate Fungi, bacteria, self 
CLEC-2 Tyrosine (hemITAM) Protein Snake venom, self 
DCIR Tyrosine (ITIM) ? Self 
CLEC12B Tyrosine (ITIM) ? ? 
MICL/DCAL-
2/CLEC12A 
Tyrosine (ITIM) ? Self 
 
 
Therefore, the hemITAM signalling downstream of CLRs constitutes a 
new mechanism of innate receptor signalling to initiation of inflammatory 
responses. A computational search for transmembrane proteins that resemble 
Chapter 1. Introduction 
 23 
dectin-1 with respect to its single CTLD domain and intracellular hemITAM motif 
identified 4 other transmembrane CLRs (clec1b/CLEC-2, clec9a/DNGR-1, 
clec12a/MICL/DCAL-2 and clec12b) that contain hemITAM motif (see figure 
1.2A). Furthermore, all these CLRs are clustered together on human 
chromosome 12 and on mouse chromosome 6 (figure 1.3B). However, the 
YxxL motif on clec12a and clec12b is flanked by valine and isoleucine (yellow 
residues on figure 1.3A), which constitutes an immunoreceptor-tyrosine 
inhibitory motif (ITIM). In fact, clec12a and clec12b have been shown to recruit 
the protein tyrosine phosphatase SHP-1 (Hoffmann et al. 2007; Pyż et al. 
2008). 
 
Figure 1.3 Dectin-1-like CLRs 
(A) Alignment of dectin-1-like receptors intracellular tails. The * and colours mean 
conservation of amino acid residue. Boxes show conservation of signalling motifs. (B) 
Dectin-1-like genes are clustered in a genomic region of human chromosome 12 and 
mouse chromosome 6. 
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1.4 HemITAM signalling in the regulation of inflammation 
The search for dectin-1-like receptors uncovered 2 other CLRs that 
contained the hemITAM motif. Furthermore, at the start of this thesis DNGR-1 
had not been described yet, whilst CLEC-2 had been described as a mRNA 
expressed by myeloid cells (Colonna et al. 2000) and a platelet receptor that 
signals via its hemITAM and Syk (Suzuki-Inoue et al. 2006). The published 
literature on CLEC-2 indicated a potential role for this receptor on the 
modulation of myeloid cell function and inflammatory responses via the 
hemITAM motif, like dectin-1. Therefore, I decided to focus my attention on 
CLEC-2 as a potential dectin-1 like receptor. In the next section I will describe 
what is known about dectin-1 function and signalling and how this relates to 
new findings about CLEC-2. 
1.4.1 Dectin-1 
Dectin-1 (or DC-associated C-type lectin-1) was first described as an 
mRNA preferentially expressed on DCs with an unidentified ligand on 
stimulated T cells (Ariizumi et al. 2000). More specifically, dectin-1 belongs to 
group V of CLRs, which includes NK-cell receptors and are type II 
transmembrane receptors containing a stalk region (also termed neck region) 
and a single CTLD that lacks Ca2+ binding capacity and interacts with protein 
ligands (Zelensky and Gready 2005). Thus, it was surprising that, in a screen 
for β-glucan receptors, Brown and Gordon demonstrated that dectin-1 could 
bind to β-glucans present on zymosan. Furthermore, dectin-1 recognition of β-
glucans could mediate phagocytosis of Candida albicans  (Brown and Gordon 
2001). A subsequent analysis determined that all myeloid cells expressed 
dectin-1, and that it is expressed at higher levels on macrophages and 
neutrophils than on DCs (Taylor et al. 2002).  
The identification of dectin-1 as a receptor that binds β-glucans and 
mediates phagocytosis of fungi had important implications, as dectin-1 
deficiency in humans had been implicated on increased susceptibility to 
mucocutaneous fungal infections (Ferwerda et al. 2009). Due to the complex 
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composition of zymosan, it is likely that multiple receptors could be involved in 
responses against it. Dectin-1 blockade greatly impaired zymosan binding 
indicating that dectin-1 is the key β-glucan receptor on macrophages (Brown et 
al. 2002). In fact dectin-1 and TLR2 could mediate some of the zymosan 
effects, with dectin-1 enhancing TLR-mediated tumour necrosis factor (TNF) 
production (Brown, Herre et al. 2003; Gantner, Simmons et al. 2003). This 
could mean simply that dectin-1 increased binding of zymosan could be 
involved in the increased TNF production observed. Nevertheless, it was 
determined that the dectin-1 intracellular tyrosine was necessary for an 
increasing cytokine production and NFκB activation (Brown, Herre et al. 2003; 
Gantner, Simmons et al. 2003). Additionally, zymosan particles induced normal 
amounts of IL-10 in DCs deficient of TLR signalling (Myd88-/-) (Edwards et al. 
2002), suggestive of a TLR-independent and dectin-1-dependent effect.  
The discovery that Syk could mediate dectin-1-induced cytokine and ROS 
production (Rogers, Slack et al. 2005; Underhill, Rossnagle et al. 2005) gave 
possible insights into the molecular mechanism of dectin-1-mediated functions. 
Rogers and colleagues formally demonstrated that the dectin-1 single 
phosphorylated YxxL motif was able to bind Syk. Furthermore, this dectin-1 
motif mediated Syk phosphorylation and cytokine production upon zymosan 
treatment. Also, Syk, but not Myd88, was necessary for induction of IL-2, IL-10 
and IL-12/IL-23p40 by DCs stimulated with zymosan (Rogers, Slack et al. 
2005). Consistently, Underhill and colleagues showed that src kinases and 
dectin-1 hemITAM, but not the ITAM adaptors DAP12 and FcRγ, were 
necessary for zymosan induction of Syk activation. Selective dectin-1 triggering 
or zymosan stimulation induced ROS production by macrophages, a 
phenomenon that is src kinase- and Syk-dependent. In addition, both the 
dectin-1 hemITAM as well as the tri-acidic motif preceding the hemITAM were 
necessary for dectin-1-mediated zymosan internalization (Underhill, Rossnagle 
et al. 2005). 
Accumulating evidence pointed to the fact that dectin-1 could mediate 
NFκB activation and induction of cytokine production via a hemITAM motif, src 
kinases and Syk activation. However, the molecular link of Syk to NFκB 
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activation was only elucidated upon the identification of CARD9 as a signalling 
molecule on myeloid cells. CARD9, in a complex with BCL10 and MALT1, was 
shown to be required to induce NFκB activation following dectin-1 triggering 
(Gross et al. 2006), similarly to the lymphocyte receptor (BCR and TCR) 
activation of src kinases, Syk/Zap70 and CARMA1/BCL10/MALT1 leading to 
NFκB activation (Thome 2004). Of great importance is the fact that CARD-/- 
mice are highly susceptible to Candida albicans infection, probably due to the 
defect on the production of inflammatory cytokines by myeloid cells, as there is 
normal lymphocyte activation in the absence of CARD9 (Gross, Gewies et al. 
2006). Remarkably, a CARD9 homozygous deficiency in humans is correlated 
with an increased susceptibility to fungal infections (Glocker et al. 2009). In 
addition to this activation of NFκB, dectin-1-Syk signalling can activate the 
NFκB-Inducing Kinase (NIK) complex and induce a canonical NFκB activation. 
Nevertheless, it is still unclear the requirement for CARD9 to activate this 
pathway (Gringhuis, den Dunnen et al. 2009). Furthermore, a Syk-independent 
Raf1-dependent dectin-1 signalling can activate non-canonical NFκB sub-units 
(Gringhuis, den Dunnen et al. 2009). 
Macrophages and DCs respond to zymosan triggering by producing 
cytokines. The scenario is different when curdlan selectively trigger dectin-1. 
DCs still produce cytokines, but macrophages do not. This differential response 
is due to the differential use of CARD9 by DCs and macrophages, where the 
latter cannot properly use CARD9 (Goodridge et al. 2009). Furthermore, 
macrophages do not use Syk to phagocyte yeast particles (Herre et al. 2004), 
whilst dectin-1-mediated phagocytosis in DCs is dependent of Syk (Rogers et 
al. 2005; Gross, Gewies et al. 2006). This differential use of Syk between 
macrophages and DCs might reflect different expression of receptors for yeast 
particles: macrophages might express Syk-independent yeast phagocytic 
receptor that DCs do not express. 
The remarkable similarities between the lymphocyte receptor and dectin-1 
signalling were expanded with the demonstration that dectin-1 triggering leads 
to calcium signalling. DCs stimulated with curdlan (a large β-glucan particle) 
increased intracellular Ca2+ concentrations. This Ca2+ increase was dependent 
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on phopholipase C γ2 (PLCγ2) activation, which was only observed upon src 
kinases and Syk activation (Xu et al. 2009). In addition to Ca2+ signalling 
downstream of dectin-1 triggering, it was demonstrated that this pathway could 
lead to activation of the transcription factor, nuclear factor of activated T cells 
(NFAT). This dectin-1-mediated NFAT activation is important to induce 
cyclooxygenase 2 (COX-2) and its product prostaglandin E2 (PGE2), in addition 
to IL-10, IL-2 and IL-12p70, but not TNF or IL-6 (Goodridge et al. 2007). 
Furthermore, dectin-1 was shown to localise to lipid rafts upon triggering 
with zymosan and lipid raft disruption impaired IL-2, IL-10 and TNF production 
by DCs (Xu et al. 2009). Another study showed that dectin-1 co-localises, on 
membrane micro domains, with the tetraspanin CD37. Additionally, CD37 
deficiency diminished dectin-1 surface expression, while increased IL-6 
production by dectin-1 (Meyer-Wentrup et al. 2007). Thus, independent studies 
indicate that dectin-1 localisation on membrane domains is important for its 
downstream function of cytokine production. Additionally, the presence of 
distinct dectin-1 isoforms, with or without the neck, in both mice (Heinsbroek et 
al. 2006) and humans (Willment et al. 2001) points to different expression and 
signalling abilities. In this regard, utilisation of β-glucan microparticles or the 
large β-glucan particle curdlan indicated that the capacity of dectin-1 to 
internalise its agonist correlates with diminished ability to signal and induce 
cytokine production (Rosas et al. 2008; Hernanz-Falcón et al. 2009).  
Confirmation of the role of dectin-1 in β-glucan recognition of fungi came 
with the generation of two different dectin-1 deficient mice lines (dectin-1-/-) by 
two independent groups. Dectin-1 was only partially required for cytokine 
production on DCs upon zymosan stimulation, while it was a crucial mediator of 
ROS production on macrophages. This crucial role of dectin-1 on the induction 
of ROS by macrophages was also observed upon stimulation with the fungi 
Candida albicans or Pneumocyctis carinii (Saijo et al. 2007). Moreover, dectin-
1-/- macrophages were profoundly impaired in the production of TNF upon 
Candida albicans or Aspergillus fumigatus stimulation (Taylor et al. 2007). 
Although both mice lines showed increased susceptibility to fungi infection, it 
was against different fungi. Nevertheless, dectin-1-/- mice on a BALB/cA 
Chapter 1. Introduction 
 28 
background were susceptible to Pneumocyctis carinii infection. However, these 
mice were not increasingly susceptible to Candida albicans infection, the same 
phenomenon was also observed with C57BL/6J dectin-1-/- mice (Saijo, 
Fujikado et al. 2007). On the other hand, Taylor and colleagues reported that 
dectin-1-/- mice on a mixed 129/Sv C57BL/6 background were highly 
susceptible to Candida albicans, showing increased fungal burden and 
diminished recruitment of myeloid cells to the inflamed site (Taylor, Tsoni et al. 
2007). Overall, dectin-1 has been shown to play an important role in the 
detection of fungi, mediating production of several inflammatory mediators that 
are important to resistance to infection in humans (Ferwerda, Ferwerda et al. 
2009) and mice (Saijo, Fujikado et al. 2007; Taylor et al. 2007). 
Dectin-1 has been clearly demonstrated to be directed involved on the 
detection and induction of inflammation by recognition of fungi and induction of 
inflammatory mediators and cellular recruitment. However, in addition to these 
aspects, dectin-1-induced inflammation has also been shown to control 
adaptive responses. Stimulation of DCs with curdlan induces increased T cell 
activation, determined by increased proliferation and production of IL-17 and 
interferon-γ by these T cells. Intriguingly, the comparison between dectin-1 and 
TLR9 activation of DCs showed that different T cell responses are obtained; 
where there is higher IL-17 production stimulated by dectin-1-activated DCs 
compared to TLR9. This data evidences the role of dectin-1 on the activation of 
DCs, inducing antigen processing and presentation to activate adaptive immune 
responses measured by immunoglobulin (Ig) production, T cell production of 
cytokines and proliferation (LeibundGut-Landmann et al. 2007). Nevertheless, 
analysis of dectin-1-/- mice in cortisone-treated immunocompromised mice did 
not show a role for adaptive responses in dectin-1-mediated fungal resistance 
(Saijo, Fujikado et al. 2007). Furthermore, analysis of cytokine production by 
Candida albicans-restimulated T cells of Candida albicans-infected mice did not 
reveal any differences in the production of IFN-γ (Th1) or IL-17 (Th17) cytokines 
(Robinson, Osorio et al. 2009), suggesting that dectin-1 does not affect 
adaptive responses. Additionally, dectin-1-/- mice did not show any defect in T 
cell and antibodies responses (Saijo, Fujikado et al. 2007; Taylor, Tsoni et al. 
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2007) despite dectin-1 was implicated in recognition of a T cell ligand and 
increasing T cell proliferation (Ariizumi, Shen et al. 2000)  
In summary, dectin-1 triggering by β-glucans induces ROS, inflammatory 
cytokines, antigen processing and presentation in a signalling pathway that 
resembles the antigen receptor signalling (fig.1.4). The identification of this 
signalling pathway and its implications on myeloid cell function are of great 
value for the understanding of qualitative differences between different innate 
receptors. 
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Figure 1.4 Dectin-1 signalling to downstream function 
Dectin-1 CTLD interacts with β-glucan particles, which leads to phosphorylation of its 
hemITAM motif allowing Raf1 signalling and Syk recruitment and activation. Syk 
signalling downstream of dectin-1 leads to Ca2+ increase, MAPK, NFAT and NFκB 
activation. Dectin-1 signalling via Syk leads to NFκB-Inducing Kinases (NIK) and 
Card9-Bcl10-Malt1 complex to activate NFκB. Raf-1 signalling downstream of dectin-1 
is independent of Syk and leads to non-canonical NFκB activation. 
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1.4.2 CLEC-2 
CLEC-2 was identified in a screen for receptors homologous to the natural 
killer (NK) cell receptors CD94, NKG2A and NKG2D (Colonna, Samaridis et al. 
2000). A report showed that in ectopic expression assays, CLEC-2 was on the 
surface of cells, and mRNA was found on human samples of bone marrow, 
granulocytes, DCs, NK cell clones and peripheral blood mononuclear cells 
(Colonna, Samaridis et al. 2000).  
Prior to the start of this thesis Suzuki-Inoue and colleagues demonstrated 
that rhodocytin, a platelet aggregation-inducing snake venom toxin, interacted 
with a 32KDa protein identified as CLEC-2. Further analysis of CLEC-2 
expressed on platelets revealed it as a three protein bands ranging from 32 
KDa to 40 KDa. These different sizes might be related to differential 
glycosylation of CLEC-2, as there are 3 potential N-glycosylation sites, and n-
glycosidase treatment of CLEC-2 collapses all the bands into one 26 KDa band, 
which correspond to the predicted size of the polypeptide chain (Suzuki-Inoue, 
Fuller et al. 2006). Furthermore, mouse and human clec1b gene (CLEC-2) 
show a similar genomic structure with 6 exons. Exon 1 and part of exon 2 
encode the intracellular domain, while the majority of exon 2 encodes the 
transmembrane domain, exon 3 with a part of exon 4 encodes the neck and 
exons 4, 5 and 6 encodes the CTLD (fig.1.5A and 1.5B). Additionally, mouse 
CLEC-2 mRNA transcripts have three alternative transcripts (isoforms CLEC-
2A, CLEC-2B and CLEC-2C) that differs in the presence of the transmembrane 
domain and part of the CTLD (Xie et al. 2008) (see figure 1.5C). Isoform A, the 
full length transcript, is highly expressed on the liver and spleen, while the 
isoforms B and C transcripts are found on the kidney and lung. However, 
isoforms B and C are not expressed on the membrane nor are they secreted, 
but instead are found on the cytoplasm of cells. In addition the full length mouse 
CLEC-2 can be cleaved from the plasma membrane and made soluble. This 
cleaved mouse CLEC-2 forms a dimer, dependent on disulfide bridges within 
cysteine residues in the neck region (Xie, Wu et al. 2008). In addition, human 
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CLEC-2 is also described as a dimer, although this was proposed as 
independent of disulfide bridges (Watson et al. 2009). 
 
Figure 1.5 CLEC-2 gene and protein structure 
(A) Mouse and human CLEC-2 gene are made of six exons. Colours correlate with (B) 
the structural domains of mouse CLEC-2. (C) Mouse CLEC-2 alternative transcripts 
differs on the presence transmembrane domain and part of CTLD  
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As mentioned above, CLEC-2 was identified as a platelet receptor that 
mediates aggregation upon interaction with rhodocytin. The endogenous protein 
podoplanin (also known as gp38, aggrus, OTS-8 and T1α) can also bind to 
CLEC-2 and mediate platelet aggregation (Suzuki-Inoue et al. 2007). 
Podoplanin (PDPN) is an O-glycosylated protein described on human kidney 
podocytes (Breiteneder-Geleff et al. 1997), rat lung type I cells (Rishi et al. 
1995), lymphatic endothelial cells and some tumour cells (Breiteneder-Geleff et 
al. 1999). CLEC-2 on platelets was also shown to bind human 
immunodeficiency virus (HIV). This was independent of viral protein, which 
suggests that HIV particles budding from cells carry with them an endogenous 
CLEC-2 ligand on the viral envelope (Chaipan et al. 2006). In fact, the cell lines 
used to produce HIV were demonstrated to express PDPN (Christou et al. 
2008). The interaction of CLEC-2 with rhodocytin or PDPN does not depend on 
the glycosylation of CLEC-2, as recombinant non-glycosylated CLEC-2 
produced in bacteria can bind to rhodocytin (Watson et al. 2007) and to PDPN 
as efficiently as glycosylated CLEC-2 or N-glycosidase treated CLEC-2 
(Christou, Pearce et al. 2008). 
Several studies have focused on the signalling and function of CLEC-2 on 
platelets. The interaction of CLEC-2 with rhodocytin, PDPN or a polyclonal anti-
CLEC-2 antibody induces a downstream signal that culminates in platelet-
aggregation in a Syk-dependent manner (Suzuki-Inoue, Fuller et al. 2006; 
Suzuki-Inoue, Kato et al. 2007). The proposed ITAM-based Syk signalling is a 
classical pathway that has been extensively studied downstream of lymphocyte 
receptors (TCR and BCR) and also Fc receptors. The current ITAM signalling 
model proposes that src family kinases phosphorylate the two tyrosines 
residues on ITAM-associated receptors, allowing Syk double src homology 2 
(SH2) domains to interact with it. Sequentially, Syk is phosphorylated either by 
itself or by src kinase family members becoming activated resulting in the 
phosphorylation of downstream tyrosine kinases (Mócsai et al. 2010). The 
presence of a single tyrosine on hemITAM-bearing receptors raised the 
question of whether Syk can get activated through recruitment of a single SH2 
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domain. Nevertheless, a study with point mutations on Syk SH2 domains 
indicated that CLEC-2 signalling required both Syk SH2 domains to transduce 
signal (Fuller et al. 2007), which can be explained by the fact that CLEC-2 may 
act as dimer and activate Syk after dimerisation upon stimulation (Hughes et al. 
2010). 
CLEC-2 becomes tyrosine phosphorylated following stimulation with 
rhodocytin or anti-CLEC-2 (Suzuki-Inoue, Fuller et al. 2006). These stimuli also 
lead to phosphorylation of Syk, linker of activated T cells (LAT), PLCγ2 and 
SH2 domain containing leukocyte protein of 76 KDa (SLP-76) (Suzuki-Inoue, 
Fuller et al. 2006; Spalton et al. 2009). CLEC-2 hemITAM phosphorylation 
following activation with rhodocytin is dependent on both Syk and src kinases, 
with src kinases being proposed to contribute to Syk activation (Spalton, Mori et 
al. 2009). Rac1, another known Syk target, is also involved in rhodocytin-
induced platelet aggregation, suggesting a role for CLEC-2 in rac1 activation 
(Pleines et al. 2009).  
Similarly to dectin-1, CLEC-2 was shown to localise to lipid raft upon 
stimulation, where it is phosphorylated by a mechanism dependent on rac1, Syk 
and src kinases. Interestingly, translocation of CLEC-2 to lipid rafts is 
independent of actin polymerisation and src kinases (Pollitt et al. 2010). This 
model proposes that CLEC-2 stimulation with rhodocytin results in CLEC-2 
translocation to lipid rafts where there are several src kinases members that 
contribute to CLEC-2 phosphorylation together with rac1 signalling and actin 
polymerisation.  
Besides CLEC-2 studies on platelets, other groups have reported CLEC-2 
expression on myeloid cells, such as neutrophils and monocytes (Kerrigan et al. 
2009) (Kerrigan et al. 2009)and Kupffer cells on the liver (Tang et al. 2010). In 
addition, CLEC-2 function was studied on a chimeric receptor that had CLEC-2 
CTLD swapped by dectin-1 CTLD. Therefore, B-glucan binding to this chimeric 
receptor leads to CLEC-2 signalling. On this system CLEC-2 intracellular tail 
could signal to phagocytosis and production of TNF (Kerrigan, Dennehy et al. 
2009), which resembles the functions of dectin-1. However, despite CLEC-2 
and dectin-1 sharing very similar signalling motifs (as depicted on figure 1.3), 
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CLEC-2 signalling is unable to induce ROS production (Kerrigan, Dennehy et 
al. 2009). 
The first demonstration of a CLEC-2-mediated effect in vivo came from the 
report of May and colleagues. They showed that depletion of CLEC-2 from the 
surface of platelets using anti-CLEC-2 antibodies is associated with longer 
bleeding times and reduced thrombus formation (May et al. 2009). 
Nevertheless, injection of a soluble form of CLEC-2 did not significantly affect 
the bleeding time of mice (Tang et al. 2010). The recent generation of CLEC-2 
deficient mice by three independent groups revealed a crucial role for CLEC-2 
during vascular development. These groups reported an increased lethality of 
embryos, which was associated with increased haemorrhage and defect 
vessels formation (Bertozzi et al. 2010; Suzuki-Inoue et al. 2010; Tang, Li et al. 
2010). Remarkably, the phenotype of CLEC-2 deficient mice resembles the 
phenotype of mice deficient in Syk and Slp-76 (Turner et al. 1995; Abtahian et 
al. 2003), two molecules involved in CLEC-2 signalling. 
In summary, CLEC-2 induces signalling by translocation to lipid rafts that 
leads to activation of its hemITAM motif culminating in Syk activation. CLEC-2 
has been largely characterised as a platelet receptor that possess two distinct 
ligands that induces platelet aggregation. Furthermore, CLEC-2 function in vivo 
had been linked to normal clotting and vascular development. 
1.5 Thesis hypothesis 
CLEC-2 and dectin-1 share many structural and signalling features. Both 
receptors show similarities on their CTLD structure (Zelensky and Gready 2005) 
and are clustered together in the same gene locus in mouse and humans 
(figure 1.3). Furthermore, CLEC-2 and dectin-1 have similar intracellular motifs 
and use the hemITAM to couple to Syk signalling. At the start of this thesis 
CLEC-2 had been identified as a platelet Syk-coupled receptor targeted by a 
snake venom toxin. Moreover, CLEC-2 transcripts had been found in human 
myeloid cells but its functions had not been explored. In light of these findings, I 
hypothesized that CLEC-2 and dectin-1 similarities were related to similar 
functions. Therefore, I sought to characterise CLEC-2 as an innate receptor in 
myeloid cells involved in inflammatory responses. More specifically I wanted to: 
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• Identify CLEC-2 ligand(s) 
• Determine CLEC-2 expression in the immune system 
• Study CLEC-2 function and signalling in myeloid cells 
• Develop mouse models to study CLEC-2 function in vivo 
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Chapter 2. Materials and Methods 
 
2.1 Reagents 
2.1.1 Buffers, solutions and media 
 
PBS (GIBCO-BRL, Gaithersburg, MD) 
PBS-EDTA: PBS containing 5mM EDTA (Sigma, Poole, UK) 
Foetal calf serum (FCS) (batch 154-161457: Autogen Bioclear, Mile Elm Calne, 
UK) 
MACS-buffer: PBS-EDTA and 1% FCS heat-inactivated for 30 minutes at 56oC . 
FACS-buffer: MACS-buffer containing sodium azide (NaN3) 0.05%  
RPMI 1640 medium (GIBCO-BRL) 
R10: RPMI 1640 medium containing 10% FCS, L-glutamine 0.3µg/ml, penicillin 
100U/ml, streptomycin 100U/ml (GIBCO-BRL) and 50µM β-mercaptoethanol. 
Dulbeccos Modified Eagle Medium (DMEM) (GIBCO-BRL) 
D10: DMEM containing 10% FCS, L-glutamine 0.3µg/ml, penicillin 100U/ml, 
streptomycin 100U/ml (GIBCO-BRL) 
Wash buffer: PBS with 0.05% tween-20 (Sigma) 
Elisa block: PBS with 2.5% FCS and sodium azide 0.05% 
Western block buffer: wash buffer with 3% dried skimmed milk (Marvel)  
TAE buffer: 0.04M tris-acetate (Sigma) and 0.002M EDTA 
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2.1.2 Innate receptors agonists 
LPS from Salmonella abortus was purchased from Alexis Biochemicals 
(San Diego, CA) and zymosan and Pam3CSK4 were purchased from 
InvivoGen. Curdlan was purchased from Wako Pure Chemicals Industries Ltd 
(Osaka, Japan). Rhodocytin was a kind gift from Stephen Watson (University of 
Birmingham). Fixed Staphylococcus aureus and Mycobacterium tuberculosis 
were commercially purchased. The Schistosoma egg antigen (SEA) and the 
Toxoplasma gondii extract soluble tachyzoite antigen (STAg) were a gift from 
Alan Sher (National Institute of Health – USA). 
2.2 Molecular biology and cloning 
2.2.1 Transformation of competent bacteria 
The competent bacteria used throughout my studies were the Escherichia 
coli strain TOP10 (Invitrogen). One vial of TOP10 was incubated with a plasmid 
for 20 minutes on ice and then transferred to a 42oC water bath for 45 seconds. 
Next the vial was returned to ice for additional 2 minutes before the addition of 
500µl of SOC medium (Invitrogen) and 37oC 900 RPM shaking for 60 minutes. 
After shaking, the bacteria were plated on LB agar plates (Cancer Research UK 
media services) with appropriate antibiotic resistance. 
2.2.2 Plasmid isolation  
Single resistant clones were picked with sterile pipette tip and transferred 
to 200mL of LB medium (Cancer Research UK media services) containing the 
appropriate antibiotic. Then it was incubated overnight at 37oC shaking before 
applying the maxiprep plasmid isolation kit (QIAGEN). For small-scale plasmid 
isolation, single colonies were incubated in 5mL of LB medium and the 
purification was performed by Cancer Research UK miniprep service. 
2.2.3 PCR and PCR product isolation 
All PCR were performed using Taq polymerase manufacturer’s 
instructions. I used PWO (Roche) and High-fidelity system (Roche) Taq 
polymerase enzymes. After the completion of cycles of denaturing, annealing 
and amplification, the DNA loading dye buffer (Sigma) was added to the final 
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PCR product and loaded into an agarose gel. After applying 100V voltage to the 
gel I excised the band of the corrected size and purified it by Gel extraction kit 
(QIAGEN). 
2.2.4 Restriction enzyme digestion and ligation 
The restriction enzyme digestion was performed on PCR products and 
plasmid to generate complementary ends for DNA ligation. The digestions were 
performed by incubating the desired DNA with an appropriate buffer, enzyme(s) 
and, when required, BSA following manufacturer’s instructions. All the 
restriction enzymes were acquired from New England Biolabs. 
The DNA ligation was done by incubating the PCR product with the 
plasmid (20-50ng) at a molar ratio of 3:1, respectively. The usage of the buffer 
and the T4 DNA ligase enzyme was done accordingly to the instructions 
manual (PROMEGA). 
2.2.5 Cloning of CD3ζ.mouse CLEC-2-HA, CD3ζ.human CLEC-2 and 
mouse CLEC-2-Fc 
Matthew Robinson (Immunobiology lab- CRUK/LRI) performed the mouse 
CLEC-2 cloning from GMCSF BMDC cDNA library and added the mouse 
CLEC-2 Y7F mutation. The cloning of mouse and human CLEC-2 performed by 
me followed his initial cloning and is described below. 
I sub-cloned mouse CLEC-2 WT and mouse CLEC-2 Y7F into the pFB 
retroviral vector using the following primers: C1b F MR1 and 
C2CTLDNotIRVSTOP. Underlined are the mouse CLEC-2 specific 
sequences and on small caps are the restriction sites.  
A PMSCV2.2-CMV-IRES-GFP (pMCIG) plasmid containing CD3ζ 
intracellular and NKR-P1B was obtained from James Carlyle (University of 
Toronto). I added mouse CLEC-2 extracellular portion tagged with HA to this 
plasmid using Xho I and Not I sites with the following primers: C1B F MRZ1 
(Small caps is depicting XhoI site and underlined is the CLEC-2 sequence ) and 
C1B R MR HA Stop (Small caps is depicting Not I site, underlined is the CLEC-
2 sequence and in red is the HA sequence). 
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I chose to add a part of Exon 2 (predicted to encode the transmembrane 
domain) to the construct to make sure that I was choosing all the extracellular 
portion of CLEC-2 (encoded by Exons 3 to 6) 
Sequencing using C1b R1 primer checked the correct in frame cloning. 
To clone human CLEC-2 into the CD3ζ/NKR-P1B plasmid I firstly cloned 
human CLEC-2 from the human DC library of the Immunobiology lab. I used the 
following primers and cloned it on the PGEM-T vector (PROMEGA): FW hc2 full 
and Rv hc2 full. Underlined is the human CLEC-2 sequence and small caps is 
the restriction sites. 
After this cloning I used the following primers to clone the extracellular 
portion of human CLEC-2 into CD3ζ/NKR-P1B. The primers were: fw hc2 
ec z and Rv hc2 ec z. Underlined are the human CLEC-2 specific 
sequences and on small caps are the restriction sites. 
The following primers were used to check the sequence of human CLEC-
2:  hCLEC-2 seq Fw and hCLEC-2 seq Rv. 
To generate mouse CLEC-2 CTLD soluble, I used a plasmid (mutFc 
pSecTag2(C)) kindly donated by Philip Taylor (University of Cardiff). This 
plasmid is a pSecTag2(C) vector (Invitrogen) containing a human IgG1 Fc 
mutated on 4 residues for less Fc receptor binding and complement activation 
(McGreal et al. 2006). I used the following primers for this cloning: C2CTLD 
EcoRI FW and C2CTLD NotI RV. Underlined are the CLEC-2 specific 
sequences and on small caps are the restriction sites. 
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Mouse CLEC-2: 
ATG CAG GAT GAA GAT GGG TAT ATC ACT TTA AAC ATC AAG CCC CGG 
AAA CAA GCT CTC AGC TCA GCG GAA CCT GCC TCT TCT TGG TGG CGT 
GTG ATG GCT TTA GTT CTG CTG ATC TCA TCC ATG GGG CTG GTT GTT 
GGA CTC GTG GCT CTG GGG ATC ATG TCG GTC ACA CAG CAA AAG TAT 
CTA CTG GCG GAG AAG GAA AAT CTC TCA GCG ACT CTG CAA CAA TTG 
GCC AAG AAA TTC TGC CAA GAG TTG ATT AGA CAA TCA GAA ATT AAG 
ACA AAG AGC ACT TTT GAG CAC AAG TGC AGC CCC TGC GCC ACG AAG 
TGG AGA TAC CAT GGA GAT AGT TGC TAC GGG TTC TTC AGG CGT AAC 
CTA ACA TGG GAA GAG AGC AAG CAG TAT TGC ACT GAG CAG AAT GCA 
ACA CTT GTG AAG ACT GCC AGC CAG AGC ACC CTG GAC TAC ATT GCA 
GAA AGG ATT ACT TCA GTC CGT TGG ATT GGA TTA TCA CGC CAG AAC 
TCT AAG AAA GAC TGG ATG TGG GAG GAT AGC TCA GTT CTT CGC AAG 
AAC GG G ATT AAT CTT TCT GGG AAT ACA GAA GAA AAC ATG AAT TGT 
GCT TAT CTT CAT AAT GGA AAA ATC CAT CCA GCT TCC TGT AAA GAG 
AGA CAT TAC TTA ATA TGT GAG AGA AAT GCT GGC ATG ACA AGA GTG 
GAC CAA CTG CTT TAA 
Exon1 Exon2 Exon3 Exon4 Exon5 Exon6 
Figure 2.1 Primer design and strategy to sub-clone mouse CLEC-2 
Underlined are the primers used to fuse the extracellular portion of mouse CLEC-2 with 
CD3ζ/NKR-P1B and in shaded gray is the portion of CLEC-2 used to fuse to the human IgG1 
Fc and generate CLEC-2.Fc chimera. 
 
2.2.6 Cloning of PDPN, PDPN T34A and Fc chimeric protein 
To obtain mouse PDPN DNA I generated colo 26 cDNA library by growing 
colo 26 cells (obtained from Cancer Research UK cell services) and extracting 
RNA by RNeasy kit (QIAGEN). The RNA was subjected to reverse transcription 
using Superscript II (Invitrogen) standard protocol. Next I used the following 
primers to clone mouse PDPN into the pFB-NEO vector (Stratagene): mPDPN 
FW and mPDPN Rv. Underlined are the mouse PDPN specific sequences and 
in small caps are the restriction enzymes sites used. 
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After cloning it I generated a point mutation on the amino acid residue 34 
(T34A) by QuikChange Site-Directed mutagenesis kit (Stratagene) standard 
protocol. For this I used the following primers: mPDPN T34A Fw and mPDPN 
T34A Rv. In bold is depicted the nucleotide change inserted: from A to a G. 
To generate PDPN soluble I used primers described by Suzuki-Inoue and 
colleagues that showed a soluble PDPN able to bind to CLEC-2 (Suzuki-Inoue, 
Kato et al. 2007). After amplification of this PDPN region I cloned on the mutFc 
pSecTag2(C) as described for mouse CLEC-2. The primers are as follow: 
PDPN EC EcoRI Fw and PDPN EC NotI RV. Underlined are the mouse PDPN 
specific sequences and on small caps are the restriction enzyme sites. 
Table 5 Primers 
Primer name        Primer sequence 
C1b F MR1 GcacctcgagggtacccccgccaccATGCAGGATGAAGATG
G 
C2CTLDNotIRVSTOP GGGAAAgcggccgcttaaagCAGTTGGTCCACTCTTG 
C1B F MRZ1 ATGCctcgagGGGATCATGTCGGTCACACAGC 
C1B R MR HA STOP ATGCgcggccgcTCAGGCGTAATCGGGCACATCGTAA
GGGTAAAGCAGTTGGTCCACTCTTGTC 
C1b R1 AAGCAGTTGGTCCACTCTTG 
FW hc2 full  TATATAgtcgacCCCGCCACCATGCAGGATGAAGATG
GATAC 
Rv hc2 full ATATAgaattcTTAAGGTAGTTGGTCCACCTTG 
fw hc2 ec z  TATATActcgagAATTACCTACAAGATGAGA 
Rv hc2 ec z  TATATAgcggccgcTTAAGGTAGTTGGTCCACCT 
hCLEC-2 seq Fw  AGCTGCTATGGGTTCTTCAG  
hCLEC-2 seq Rv  TCTCTTCCCATGTTAAGTTG 
C2CTLD EcoRI FW  GGGAAAgaattcACAAAGAGCACTTTTGAGCAC 
 
C2CTLD NotI RV  GGGAAAgcggccgcAGCAGTTGGTCCACTCTTG 
 
mPDPN FW TATATAgaattcCCACCATGTGGACCGTGCCAGTGT 
mPDPN Rv TATATActcgagTTAGGGCGAGAACCTTCCAG 
mPDPN T34A Fw gtgaatgaagatgatattgtgGccccaggtacaggagacggcatg 
mPDPN T34A Rv  catgccgtctcctgtacctggggCcacaatatcatcttcattcac 
PDPN EC EcoRI Fw  GGGAAAgaattcGGGAGCGTTTGGTTCTG 
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PDPN EC NotI RV  
 
GGGAAAgcggccgCGGCGAGAACCTTCCAGAAA 
Clec1b BAC Fwd TATTACCTGATGCTGTTACATCTCAGCTCTGCAGTA
TTTAGCCACCTTAGAGTTCCTAGCTGCTGACTCTGG
GTACCGAGCTCGAATTCTACCG 
Clec1b BAC Rev CTGGGTTCTTTCCAGCTTCTGGCTATTATAAATAAG
GCTGTTATGAACATAGTGGAGCATGTGTCCTTCTTG
CGGCCGCCACCGCGGTGGAGCTCCA 
1st loxP FW AAAACCCAAAACCAAAAAACCAAAACCAACAACAAA
ACAAAAAAACAGATAATTAACCCTCACTAAAGGGCG 
1st loxP RV ACTTATTCTCTGTCCATTCTAACATATAACTGGCTAC
CAAGGCCACGTGtTAATACGACTCACTATAGGGCTC 
FW Rb2 
 
TCCCATGTCAAGCATTTTGGAATGCTGAGGGGAAA
CATTGAAATGCTGTTAATTAACCCTCACTAAAGGGC 
 
Rv Rb2 
 
TCTCAGAGGAGCACACAGTGCAAACCATTAAGAAA
CACATGAAAAGGAAATAATACGACTCACTATAGGG
CTCG 
 
Fwd seq 5’flxNeo agggatgcaaaaacaaaaacaaaac 
Rv seq 3’flxNeo tttataccacccatccattgccact 
Seq FRT FW Rb2 ggtaactggagagaggtcca 
Seq Rv FRT agcatccctagcagactcat 
Seq Neo Fw ATTCGGTACCAATAAAAGAG 
Seq PGK RV CTAGGGGAGGAGTAGAAGGT 
 
 
2.3 Cell culture 
2.3.1 Stable cell line generation 
Stable cell lines were generated by using retroviral transduction. Firstly, I 
transfect GP2-293 cells (Clontech) with the retroviral vector (I used the pMSCV 
and pFB) containing the desired protein and the pVSV-G plasmid that contains 
the virus structural proteins. This transfection is performed using Lipofectamine 
2000 (Invitrogen) according to protocol in manufacturer’s manual instructions. 
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Next, 24, 48 and 72 hours after transfection I harvest the supernatant of these 
transfected cells and filtered it on a 0.45µM Millex-HV PVDF filter (Millipore) and 
added 5µg/ml of polybrene (Sigma). This virus-containing supernatant is used 
to replace the medium of Phoenix cells, and then this is centrifuged at 2600 
RPM at 26oC for 90 minutes. These Phoenix cells will stably express the 
desired protein as well as produce virus to infect other cells. I used the virus-
containing supernatant of Phoenix cells to induce ectopic expression of the 
desired protein in other cells. 
2.3.2 Cells 
B3Z cells: Mouse CD8 T cell hybridoma B3Z cells expressing the NFAT-LacZ 
reporter (referred as B3Z cells throughout the document) were a gift from Nilabh 
Shastri (University of California - Berkeley). B3Z cells expressing ζdectin-1-HA 
were generated by David Sancho (Immunobiology lab – CRUK/LRI). These 
cells were cultured in R10. 
B3Z.ζCLEC-2-HA and B3Z.ζhumanCLEC-2: Stable cell line obtained by FACS 
sorting (CRUK FACS Lab) and cultured in R10.  
B3Z.Syk cells: B3Z cells expressing ectopically expressing Syk generated by 
Patricia Hernanz-Falcon (Immunobiology lab – CRUK/LRI). These cells were 
cultured in R10. 
B3Z.Syk CLEC-2 WT and B3Z.Syk CLEC-2 Y7F: Generated by stably 
transfecting B3Z.Syk cells. Cell population was enriched by MACS (described 
below) 
LK: mouse B cell line. 
LK CLEC-2 WT and LK CLEC-2 Y7F: LK cells stably expressing CLEC-2 WT 
and Y7F. Cell population was purified by FACS sorting. 
3T3: mouse fibroblast cell line obtained from CRUK cell services cultured in 
D10 
293.T: human kidney fibroblast cell line cultured in D10 
RBL: RBL-2H3 is a rat basophilic leukaemia cell line cultured in R10 
RBL ζCLEC-2-HA:  RBL cells stably expressing stably expressing ζ.CLEC-2-HA  
RMA-S: mouse thymoma cell line cultured in R10 
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CHO K1 and CHO mutants: hamster ovarian fibroblast cell line. The parental 
cell line CHO-K1 was obtained from CRUK cell services. The mutant CHO 
pgsD-677 was obtained from Holger Gerhardt lab (Vascular Biology laboratory -
CRUK/LRI). The mutant CHO H661 was from Jeffrey Esko (UCSD). The mutant 
pgsF-17 was from Nancy Hogg lab (Leukocyte adhesion lab – CRUK/LRI). 
CHO H661 Ext1 was stably transfected with human Ext1-pcDNA3 (Gift from 
Holger Gerhardt lab) and selected with 100µg/ml of G418 (Gibco). All cells were 
cultured on D10. 
 
2.3.3 B3Z assay for ligand screening 
B3Z cell clones were cultured at 1x105 cells on a 96-well flat-bottom plate 
and the final volume of the assay was always 200µl. After 18 hours of culture 
the supernatants were discarded and the cells were resuspended in 100µL of 
CPRG buffer for measurement of enzymatic activity. CPRG buffer contains 
300nM of CPRG (Roche), 0.1% of NP-40 and 10µM of MgCl2. CPRG changes 
colour from yellow to red according to LacZ activity. This colour change can be 
detected on different time points by spectrophotometer readings of red at 
595nm wavelength subtracted by unspecific readings at 650nm. Commonly 
monoclonal anti-HA antibody (clone HA-7 ascites fluid – Sigma) was used at 
1:400 dilution as positive control. Also, ionomycin was used at 0.5µg/ml as 
positive control for LacZ induction on B3Z clones. 
3T3 cells were used as a source of CLEC-2 ligand and for studies of 
CLEC-2 ligand biology. For inhibition assays, 3T3 cells were treated for 18 
hours with tunicamycin, anysomyciyn and actinomycin D (all from Sigma). Next 
the cells were washed in R10 before being cultured with B3Z cell clones. For 
the transwell assay, a 24-well plate was used with a corning transwell insert 
with a membrane pore size of 8µm. On this assay 4x105 B3Z cells were 
cultured on the bottom part of the well with 1x105 3T3 cells separated or not by 
the transwell insert. Cells were resuspended on 500µl of CPRG buffer, 
transferred to a 96-well plate and spectrophotometer readings were performed. 
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2.3.4 Generation, production and staining with Fc chimeric proteins. 
Vectors carrying PDPN.Fc, PDPN T34A.Fc and dectin-1.Fc were 
transfected into CHO K1 cells and CLEC-2.Fc was transfected into CHO H661 
cells. All transfections were performed using Lipofectamine 2000 (Invitrogen). 
The cells were plated at limiting dilutions and selected with 100µg/ml of G418 
until confluent growing in 96-well plates. The supernatants of culture were 
screened for binding to ligands. I incubated 50µl of supernatants for 20 minutes 
with zymosan, B3Z.ζCLEC-2-HA or LK PDPN cells. This was washed by adding 
200µl of FACS buffer and centrifuging for 5 minutes at 1500 RPM. Next, I 
stained with F(Ab’)2 goat anti-human IgG (H+L) Cy5 (Jackson Immunoresearch 
Laboratories) for another 20 minutes. This was washed as before and analysed 
on the FACScalibur. 
Selected clones were grown on two compartments Bioreactor (CELLine 
CL 1000 – Integra Bioscience) and cells were changed and concentrated 
supernatants collected every week. 
2.3.5 Western blot and immunoprecipitation 
Protein extracts were mixed with SDS loading buffer and loaded into a 4-
20% Tris-glycine gel (Invitrogen) run at 100V on a Tris-glycine-SDS buffer 
(Biorad). Next, the separated proteins were transferred to a PVDF membrane 
by applying a constant current of 250mA on a wet chamber containing a tris-
glycine buffer with 20% methanol. The membrane was blocked for 30 minutes 
with 3% dried skimmed milk (Marvel) in wash buffer followed by an overnight 
incubation of the blocked membrane with specific antibodies. The antibody-
probed membrane is washed 4 times with wash buffer and then a secondary 
reagent coupled with the peroxidase enzyme is added for 60 minutes. After this 
incubation, the membrane is washed again and developed with SuperSignal 
West Pico Chemiluminescent Substrate (Pierce).  
For detection and immunoprecipitation of mouse CLEC-2, B3Z and B3Z 
cells expressing CLEC-2 Y7F were lysed on RIPA lysis and extraction buffer 
(Pierce). Half of each lysate was added SDS loading buffer and the other half 
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was incubated with 2µg of anti-CLEC-2 mAb for 18 hours. Next, there was 60 
minutes incubation with GammaBind Plus Sepharose (GE Healthcare. After 3 
rounds of centrifugation and washes on RIPA Buffer, the precipitated was 
resuspended on SDS loading buffer. After running the gel, the membrane was 
probed with 2µg/ml biotinylated anti-CLEC-2 mAb on wash buffer. The 
secondary reagent used was ExtrAvidin-peroxidase (Sigma) diluted 1:5000 in 
wash buffer. 
For the anti-phosphorylated Tyrosine it was used the mouse monoclonal 
antibody clone 4G10 (Milipore) followed by a secondary rabbit anti-mouse-HRP 
(1:5000). For the anti-phosphorylated Syk (Tyr352) it was used a rabbit 
polyclonal (Cell Signaling, cat. 2701) and for anti-Syk blots it was used a rabbit 
polyclonal (2131, gift from Victor Tybulewicz - NIMR). The secondary reagent 
used was a goat anti-rabbit-HRP (Santa Cruz) 1:5000 dilution. 
2.3.6 Generation of FLT3L and GMCSF BMDCs 
Bone marrow was obtained from femur and tibias by flushing the bones 
with R10. For FLT3L BMDC the cells were centrifuged at 15000 RPM for 5 
minutes and then resuspended in 2ml of red blood cell lysis buffer (Sigma) and 
incubated for 2 minutes in ice. Next, I added 25ml of R10 and centrifuged cells 
at 1500RPM for 5 minutes. After centrifugation cells were resuspended in R10 
containing 100ng/ml of mouse FLT3L (R&D Systems) at 1.5x106 cells/ml and 
cultured in 4ml in a 6-well culture plate for 9 days. 
For GMCSF BMDC I cultured 4ml of R10 containing 1:2000 dilution of 
GM4 (GMCSF-from Cancer Research UK services) and 1.5x106 cells/ml in a 6-
well culture plate. Two days later 2ml of the culture medium was taken off and 
replenished with fresh 2.5ml R10 containing 1:10000 GM4. On the next day all 
culture medium was replenished with fresh 4ml of R10 and 1:20000 GM4. Two 
days later the cells were harvested and enriched for CD11c by MACS. 
2.3.7 MACS enrichment 
For GMCSF BMDC enrichment I harvest the GMCSF culture and 
centrifuged the cells at 1500 RPM for 5 minutes. The cells were then 
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resuspended in 140µl MACS buffer containing 60µl of CD11c MicroBeads 
(Miltenyi Biotec) and incubated for 15 minutes on ice. After the incubation I 
added 20ml of MACS buffer and centrifuged cells at 1500RPM for 5 minutes. 
The cells were resuspended in 1ml of MACS buffer and passed through a 70µm 
cell strainer (BD). The cells were then loaded into LS column (Miltenyi Biotec) 
that had been equilibrated with 5ml of MACS buffer and attached to a 
MidiMACS Separator on a MACS MultiStand (both from Miltenyi Biotec). Next I 
washed the column with 3mls of MACS buffer to and waited for all the liquid to 
drain, allowing the unstained cells to drain off the column. This wash was 
repeated two more times. After the third wash I loaded 5 ml of R10 and flushed 
the cells into a tube by applying force with the column plunger. 
For CD11c enrichment from splenocytes, the spleen were obtained from 
C57BL/6J mouse and treated for 20 minutes with Collagenase II (Roche) and 
DNase (Roche) and passed through a 45µm cell strainer (BD Pharmingen). I 
added 20 ml of MACS buffer and centrifuged cells at 1500 RPM for 5 minutes. 
Next cells were resuspended in 190µl of MACS buffer and 10µl of CD11c 
MicroBeads (Miltenyi Biotec). In the sequence I followed the same procedures 
as described above. 
For B3Z.Syk CLEC-2 enrichment, I resuspended harvested cells into 
200µl of MACS buffer containing 10µg/ml of anti-CLEC-2 biotinylated. After 15 
minutes incubation I added 20 ml of MACS buffer and resuspended the cells in 
180µl of MACS buffer and 20µl of Streptavidin MicroBeads (Miltenyi Biotec). 
Next I followed the same procedures described above. 
2.3.8 CLEC-2 triggering 
The indicated cells were cultured in R10 with the indicated concentration 
of LPS or Pam3Cys. For PDPN.Fc triggering, the cells were cultured on 240 
mJ/cm2 UV-irradiated ELISA plates (Nunc) that had been coated overnight with 
50µl PBS containing 40µg/ml of F(Ab’)2 donkey anti-human IgG (Jackson 
Immunoresearch Laboratories). After overnight incubation the coated wells 
were washed by adding and discarding 200µl of PBS for four times. The wells 
Chapter 2. Materials and Methods 
 49 
where then coated with supernatants from Bioreactors of PDPN.Fc, PDPN 
T34A.Fc or dectin-1.Fc (control Fc). 
For triggering with anti-CLEC-2, the cells were cultured on 240 mJ/cm2 
UV-irradiated ELISA plates (Nunc) that had been coated overnight with 50µl 
PBS containing 40µg/ml of anti-CLEC-2 or isotype mAb. For triggering with 
Fabs, 240 mJ/cm2 UV-irradiated ELISA plates (Nunc) had been coated 
overnight with 50µl PBS containing 40µg/ml of F(Ab’)2 goat anti-rat IgG 
(Jackson Immunoresearch Laboratories). After incubation the coated wells were 
washed by adding and discarding 200µl of PBS for four times. The wells where 
then coated with 20µg/ml of anti-CLEC-2 or control Fab. 
For CLEC-2 triggering and western blot analysis, 1x105 cell/well in 200µl 
were centrifuged at 1000RPM for 30 seconds into wells coated with anti-CLEC-
2 or isotype mAbs (4 wells per treatment). The medium was discarded at the 
indicated time point and the cells were lysed on in 30µl RIPA buffer containing 
100mM NaF and 1µM of Na3VO4. The corresponding wells were pooled 
together and analysed by western blot as described above. 
2.3.9 Quantitative PCR (qPCR) 
GMCSF BMDCs were treated as described above and the RNA was 
extracted at the indicated time point by RNeasy Midi Kit (Qiagen) instructions. 
The extracted RNA was subjected to reverse transcription (RT) by following 
instructions of Superscript II (Invitrogen). I used 1µg of RNA and random 
primers to in a 20µl reaction to generate cDNA. Next, I added 80µl of 0.1µg/ml 
of glycogen (Aqueous solution from Blue Mussels) (Sigma).  
For qPCR using sybr green as dye, 3µl of cDNA was added to wells on 
96-well plates containing 10µl of 2X SYBR Advantage qPCR Premix (Clontech), 
6.8µl of water and 0.2µl of 10µM primer mix. The primers used were designed 
by past members of the Immunobiology Lab. 
For qPCR using Taqman system, 3µl of cDNA was added to wells on 96-
well plates containing 10µl of 2X Taqman Universal PCR Master Mix (Applied 
Biosystems), 6.8µl of water and 1µl of primer mix. The primers were acquired 
with FAM dye from Applied Biosystems. 
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On both qPCR applications I obtained CT values an used the ∆ct method 
to analyse the data. 
2.3.10 ELISA 
ELISA was performed by overnight incubation of primary coating antibody 
in 50µl PBS per well in 96 well Maxisorb immunoplates (Nunc, Denmark). Next, 
wells wee washed four times with wash buffer and incubated with blocking 
buffer for a minimum of 60 minutes. Wells were then incubated for 4 hours with 
supernatants and standard concentrations of recombinant cytokines diluted in 
culture medium. After the incubation, wells were washed five times and 
incubated with secondary detection antibody diluted in blocking buffer for 1 hour 
followed by five washes. Next, wells were incubated with Streptavidin – Alkaline 
phosphatase (Sigma) diluted 1:5000 in blocking buffer for 60 minutes. The next 
step was to washed the wells for six times with wash buffer and proceed with 
developing with SIGMAFAST™ p-Nitrophenyl phosphate Tablets tablet (Sigma). 
Readings were made on spectrophotometer at 405nm. 
The following antibodies were used: 
Table 6 Antibodies used for ELISA 
Antibodies Capture Detection 
IL2 
JES6-1A12 (4µg/ml) 
(BD Pharmingen) 
JES6-5H4-Biotin (1µg/ml) 
(BD Pharmingen) 
IL12/IL23p40 
C15.6 (5µg/ml) 
(BD Pharmingen) 
C17.8-Biotin (1µg/ml) 
(BD Pharmingen) 
IL10 
JES5-2A5 (4ug/ml) 
(BD Pharmingen) 
SXC-1- Biotin (1.5ug/ml) 
 
(BD Pharmingen) 
TNF 
AF-410-NA (2µg/ml) 
(R&D) 
BAF410-Biotin (250ng/ml) 
(R&D) 
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2.3.11 Cytometric Bead Array (CBA) 
CBA was performed following manufacturer’s instructions. All CBA were 
performed by using mouse flex set (BD Pharmingen) for measuring the 
indicated inflammatory mediators. The assay was performed on a FACScalibur 
and analysed by FlowJo (TreeStar) 
2.4 Generation of monoclonal antibody against mouse CLEC-2 
2.4.1 Immunisation and serum testing 
I immunised Wistar rat with 240 mJ/cm2 UV-irradiated 10x106 RBL- 
ζ.CLEC-2-HA and 1µg/ml of LPS via intraperitoneal injection. This procedure 
was repeated another two times with 10 days interval. Two days after the last 
immunisation I obtained blood sample from the tail vein of rat and generated 
serum. The serum was tested for the presence anti-CLEC-2 antibodies. For 
this, I incubated B3Z. ζ.CLEC-2-HA-GFP mixed to B3Z cells with or without 
several serum dilutions (in FACS buffer) for 20 minutes. After the incubation, 
cells were washed in FACS buffer and incubated for another 20 minutes with 
10µg/ml of F(Ab’)2 goat anti-rat-Cy5 (Jackson Immunoresearch laboratories) 
(fig.2.2). 
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Figure 2.2 Serum from immunised rat contains anti-CLEC-2 antibodies 
B3Z. ζ.CLEC-2-HA-GFP and B3Z cells mixed at 1:1 ratio were incubated with or 
without (0) the indicated dilution of serum from immunised rat. After 20 minutes the 
cells were washed and incubated for 20 minutes with 10µg/ml of F(Ab’)2 goat anti-rat-
Cy5. Cells were analysed by FACS for GFP and anti-rat staining. 
  
2.4.2 Hybridoma fusion 
Two days after the test bleed I sacrificed the rat and obtained the spleen. 
The Splenocytes were obtained by flushing the spleen with injections of DMEM. 
After several flushings the spleen was mashed and passed through a 70µm cell 
strainer (BD Europe). The cell suspension was centrifuged at 1400 RPM for 5 
minutes. Cells were resuspended on 10ml of Red Blood Cells Lysis Buffer 
(Sigma) for 5 minutes to lyse erythrocytes. Cells were washed twice on DMEM 
by centrifugation at 1400 RPM for 5 minutes. Rat Y3 myeloma cells were used 
to fuse with rat splenocytes. These cells were grown on D10 and washed twice 
on DMEM by centrifugation at 1400 RPM for 5 minutes. 
I mixed the splenocytes and Y3 cells at a ratio of 2:1 (splenocytes:Y3), 
using all splenocytes. The mixture was centrifuged and resuspended in 1.2ml of 
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DMEM. The fusion was performed with continuous stirring on 12 minutes on a 
37oC water bath by the following procedures: 
0-1min – addition of 1.2ml of PEG1500 (Boehringer) 
1-2min – stirring 
2-3 min – addition of 1ml of DMEM 
3-4min - addition of 4ml of DMEM 
4-5mim - addition of 5ml of DMEM 
5-7min - addition of 10ml of DMEM 
7-12min - stirring 
Next, cells were centrifuged at 1400 RPM for 5 minutes 25oC with low 
break and resuspended in 240ml of DMEM supplemented with 20%FCS, 
2ng/ml of rat IL-6 (hybridoma medium). Cells were plated in 8 U-bottom 96-well 
plates in 200µl. Next I added another 80ml of hybridoma medium and plated the 
rest of cells in 200µl in U-bottom 96-well plates. 
The culture medium was changed every 2 days by removing 120µl and 
adding 150µl of hybridoma medium. This procedure was repeated until 
confluent grow of cells in most of wells. 
2.4.3 Screen and cloning 
The screen for anti-CLEC-2-producing hybridomas was performed by 
capturing rat antibodies from supernatants of hybridoma culture medium. This 
was done by adding 120µl supernatants to flat bottom 96-well plates coated 
overnight with 50µl of PBS containing 20µg/ml of goat anti-rat IgG (H+L) 
(Jackson Immunoresearch laboratories). The supernatant was incubated for 4 
hours followed by three washes with 200µl of PBS. On each plate two wells 
were incubated only with mouse monoclonal anti-HA diluted 1:400 (ascites fluid 
from Sigma) for use as a positive control. Next, a B3Z assay for ligand screen 
was performed (as described previously and shown below on figure 2.3). 
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Figure 2.3 B3Z assay for screening for anti-CLEC-2 antibody 
B3Z. ζ.CLEC-2-HA cells were cultured for 18 hours on wells coated with anti-HA or 
anti-rat IgG and hybridoma supernatant. High LacZ activity indicates wells containing 
anti-CLEC-2 antibodies. 
 
All wells tested positive on the assay had the cells collected and expanded 
for further analysis. Supernatant of these cells were tested for specific staining 
of B3Z.ζ.CLEC-2-HA in a mix with B3Z cells (as described on the previous 
section, figure 2.1).  
Next, the supernatants were tested for specific staining of CLEC-2 and not 
the HA tag. This was done by comparing staining of B3Z.ζ.CLEC-2-HA with 
B3Z.ζ.dectin-1-HA. Consequently, I selected two cell populations (5F11 and 
17D9) that selectively stained CLEC-2-expressing cells. 
These two cell populations were plated at one cell per well in five different 
U-bottom 96-well plates until grow to 90% confluence. Each clone was tested 
for selectively CLEC-2 staining. This process was repeated three times, until all 
the clones tested positive for CLEC-2 staining. Finally the cells were considered 
derived from the same unique clones. 
2.4.4 Antibody purification and Fab generation 
Hybridoma clones were cultured on two-compartments disposable 
bioreactor (Integra bioscience) according to manufacturer instructions. The cells 
were cultured on R10 and the medium was changed every three days. 
Concentrated supernatant was collected by centrifuging cells at 2000 RPM for 5 
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minutes and filtering through 0.45µm Millex-HV PVDF filter (Millipore). Both rat 
anti-mouse CLEC-2 (IgG2b) monoclonal antibody (mAb) and a rat IgG2b mAb 
(isotype with irrelevant specificity) were purified using GammaBind Sepharose 
Plus (GE Healthcare) following manufacturer’s instructions. Purity was tested 
on a 4-20% Tris-glycine gel followed by a coomassie blue staining (fig.2.3). 
For generation of anti-CLEC-2 or control Fab I used the Pierce Fab 
preparation kit (Pierce-Thermo Scientific) following manufacturer’s instructions. 
The purity was tested by separation on a 4-20% Tris-glycine gel followed by a 
coomassie blue staining (fig.2.3). 
 
 
Figure 2.4 Analysis of Fab and mAb purification 
 1 µg of mAb or Fab were loaded into a 4-20%Tris-Glycine gel with (reducing) or 
without (non-reducing) 10mM β-mercaptoethanol. Gel was run at 100V, stained with 
coomassie blue solution (water 0.01%coomassie, 40%methanol, 10%glacial acetic acid) 
for 20 minutes and washed on destaining solution (water 10% glacial acetic acid 
20%methanol). 
 
2.4.5 Anti-CLEC-2 modifications 
I generated anti-CLEC-2 biotinylated by following instructions on DSB-X 
Biotin Protein Labelling Kit (Molecular Probes-Invitrogen). For anti-CLEC-2 
coupling to Alexa 647 I followed instruction on Alexa Fluor 647 Protein Labelling 
Kit (Molecular Probes – Invitrogen). 
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2.5 Microarray 
GMCSF BMDCs were cultured with 10ng/ml of LPS on wells coated with 
control or anti-CLEC-2 Fab, as described above. After 3 or 6 hours, 
corresponding wells were pooled together and RNA was extracted using 
RNeasy Midi Kit (Qiagen). This assay was performed twice and extracted RNA 
was pooled together and sent to microarray analysis at Cancer Research UK 
Paterson Institute Microarray Service. In summary, I performed genome-wide 
analysis of genes derived from RNA samples of LPS-stimulated GMCSF BMDC 
treated either with anti-CLEC-2 Fab for 3 and 6 hours or control Fab treated for 
3 or 6 hours. The RNA is a product of 2 independent assays. 
2.5.1 Microarray Analysis 
Gavin Kelly and Probir Chakravarty (Bioinformatics and Biostatistics 
Services – CRUK/LRI) performed all microarray analysis.  The Affymetrix 
GeneChip Mouse Genome MOE430_2 was used to define gene expression 
profiles in each sample. Probe synthesis and microarray hybridization were 
performed according to standard Affymetrix (Santa Clara, CA) protocols. 
Data was analysed using Bioconductor 1.9 running on R 2.6.0. 
Normalised probe-set expression measures were calculated using the 'affy' 
package's Robust Multichip Average (RMA) default method. Differential gene 
expression was assessed between anti-CLEC-2 vs control at each time point 
and different response between time-points using two-way ANOVA, with 
empirical Bayes (limma package) to help estimate variance; p values were 
adjusted for multiple testing using the Benjamini-Hocberg method. Any probe-
sets that exhibited an adjusted p value of 0.05 were called differentially 
expressed. There was total of 274 probe-sets, which showed differential 
expression between 3 hours and 6 hours time points. 
2.5.2 Gene Set Enrichment Analysis 
Differentially expressed probes were used to determine enrichment using 
Genego pathways and processes within Metacore pathway tool (Genego Inc, 
St.Joseph, MI). The analysis employs a hyper-geometric distribution to 
determine the most enriched gene-set. A number of processes and pathways 
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appeared to be enriched when using the 274 probe-set list. Metacore was used 
to determine a list of experimentally derived target genes for the transcription 
factor NFAT1. 
2.5.3 Heatmaps 
Two-dimensional (2D) hierarchical clustering of expression data using 
differentially expressed genes that occurred in Immune response - NFAT 
signalling biological processes or NFAT1 target genes was performed. Genes 
were clustered using a Euclidean distance matrix and average linkage 
clustering using Cluster and visualised using Java TreeView. Samples were not 
subjected to any clustering methods. 
2.6 FACS acquisition 
All staining were done on V-bottom 96-well plates in 100µl. The cells were 
acquired either at FACScalibur (BD) or LSR II (BD). Samples were analysed by 
FlowJo (TreeStar). 
2.6.1 Anti-CLEC-2 staining on splenocytes and lymph node cells 
Four C57BL/6J mice were injected intravenously with 5µg of LPS (2 mice) 
or PBS (2 mice) and spleen and lymph nodes were obtained 18 hours later. The 
organs were treated for 20 minutes with collagenase II (Roche) and DNase 
(Roche) and then passed through a 40µm cell strainer (BD Pharmingen), added 
10 ml of FACS buffer and centrifuged at 1500 RPM for 5 minutes. Splenocytes 
were resuspended in 5ml red blood cell lysis buffer (Sigma), incubated for 5 
minutes, added 20 ml of FACS buffer and centrifuged as before. Cells were 
plated at 1x106 cells/well in FACS buffer containing 10µg/ml of purified rat anti-
mouse CD16/CD32 (BD Pharmingen) and incubated for 15 minutes. Next cells 
were washed with 200µl of FACS buffer. Cells were than stained for 20 minutes 
with 10µg/ml anti-mouse CLEC-2 biotinylated or rat IgG2b biotinylated (BD 
Pharmingen) and different combinations of 5µg/ml antibodies: 
• Hamster anti-mouse CD11c-APC, rat anti-mouse CD45R/B220-
PE, rat anti-mouse CD41-FITC 
• Rat anti-mouse CD11b-Percp, rat anti-mouse CD41-FITC, rat anti-
mouse Gr1 (Ly6G and Ly6C)-PE 
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• Rat anti-mouse CD41-FITC, rat anti-mouse NK1.1-PE, rat anti-
mouse CD3-APC 
After incubation cells were washed as before and incubated for 20 
minutes with 2µg/ml of Streptavidin-PE-Cy7. Next cells were washed as before 
and 5µg/ml of DAPI was added to FACS acquisition tubes prior to acquisition. 
Data represented in the thesis correspond to DAPI negative (dead cells) 
and SSC-W high negative (correspondent of doublets). 
2.6.2 Calcium flux 
B3Z.Syk clones were harvested form culture plates and centrifuged and 
resuspended in RPMI with 1mg/ml of BSA (Cell-loading buffer – CLM). Next, 
1x106 cells were resuspended in 1ml CLM with 2µM of Indo-1 (Molecular 
Probes – Invitrogen) for 30 minutes at 37oC in a water bath. After, I washed 
cells by adding 14ml of RPMI and centrifuging cells at 1500RPM for 5 minutes. 
After wash I stained the cells with anti-CLEC-2 biotinylated or rat IgG2b 
biotinylated (BD Pharmingen) in PBS for 20 minutes in ice. In the sequence, 
cells were washed in PBS and resuspended in 500µl of RPMI and acquired on 
the LSR II. Calcium flux was induced by addition of 2µg of Streptavidin-PE (BD 
Pharmingen) or 0.5µg of ionomycin. Data was analysed by FlowJo. 
2.7 Mouse model of LPS responses 
C57BL/6J mice were injected intraperitoneally with 20µg of LPS and the 
indicated amount of anti-CLEC-2 or isotype mAb. Mice were sacrificed and 
blood was obtained by cardiac puncture. Sera were generated by incubating 
blood at 37oC for 30 minute, followed by centrifugation at 2000 RPM for 5 
minutes and collection of supernatants. 
2.7.1 Phagocytes depletion 
C57BL/6J mice were injected intraperitoneally with 300µl of clodronate-
loaded liposomes or PBS-loaded liposomes. Four days later mice were treated 
as described in “Mouse model of LPS responses” above. Depletion of myeloid 
cells were analysed by FACS. 
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Nico Van Rooijen provided loaded liposomes (Van Rooijen and Sanders 
1994; van Rooijen and van Kesteren-Hendrikx 2003) and Roche Diagnostics 
provided clodronate. 
2.7.2 Dendritic cell depletion 
C57BL/6J (WT) mice were irradiated with a total of 1100 Rad, given in 2 
doses of 550 Rad. On the next day I intravenously injected 5x106 bone marrow 
cells from CD11c-DTR-GFP (Jung et al. 2002) or WT mice. Chimerism was 
confirmed by analysing GFP expression on CD11c cells on the spleen. Ten 
weeks later mice were injected intraperitoneally with 100ng of diphtheria toxin 
(Sigma). On the next day (16-18 hours later) mice were treated as described in 
“Mouse model of LPS responses” above.  
Depletion of DCs was confirmed after the endotoxic shock model by 
analysing GFP expression and staining splenocytes with hamster anti-mouse 
CD11c-APC (BD Pharmingen). 
Bone marrows from CD11c-DTR-GFP were kindly donated by Clare 
Bennett (UCL). 
2.8 Statistical analysis 
The statistical analyses were performed using Graphpad Prism 5 for Mac. 
The tests and the significance comparison used are stated on the legend of 
figures. 
2.9 CLEC-2 conditional knockout mouse generation 
The BAC clone R248K14 (NCBI nomenclature, purchased from 
Invitrogen) was used as a source of C57BL/6J genomic DNA containing the 
CLEC-2 gene (clec1b). The targeting vector region was obtained from the BAC 
clone by using Quick and Easy BAC modification Kit (Gene Bridges, Dresden – 
Germany) instructions. Briefly, the method by which the system works is based 
on E. coli expressing specific exonucleases and annealing proteins. The 
expression of homologous DNA regions on these bacteria allows homologous 
recombination between different DNA vectors.  
Therefore, a PCR product containing homologous regions to the BAC can 
be recombined by expression of the linearized vector pFloxRI+TK (from 
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transgenic lab – Cancer Research UK) with a stretch of DNA (on each end) 
homologous to BAC regions. This allows homologous recombination between 
the two DNA pieces and the generation of pFloxRI+TK – Clec1b. The primers 
used for this were: Clec1b BAC Fwd and Clec1b BAC Rev. The regions in red 
represent the homology to the pFloxRI+TK vector. Neil Rogers (Immunobiology 
Lab – CRUK/LRI) cloned the targeting region in pFloxRI+TK. 
Next, I started modifying the pFloxRI+TK-Clec1b (targeting region) to 
express DNA sequences to be inserted into the mouse genome. I used the 
following selection cassette loxP-gb2-pgk-NEO-loxP (Gene Bridges, Dresden – 
Germany) to insert between exons 1 and 2 of the targeting region by the 
method described above (fig.1.5 – step 1). The primers used were 1st loxP FW 
and 1st loxP RV. The regions in red represent the homology to the selection 
cassette. 
The next step that I performed was to delete this selection cassette by 
expressing the vector on EL350 (a CRE-expressing E. coli). This induced the 
deletion of the cassette, leaving one loxP in the desired position (fig.1.5 – step 
2). 
The final step for generation of the targeting vector was to insert a 
selection cassette and a second loxP site. I used the FRT-gb2-pgk-frt-loxp 
selection cassette (Gene Bridges, Dresden – Germany) and the following 
primers to induce homologous recombination in bacteria (fig.1.5 – step 3) (as 
described above): FW Rb2 and Rv Rb2. 
The regions in red represent the homology to the selection cassette. 
All insertions and deletion were confirmed by selection of E. coli with 
appropriate antibiotic and by sequencing with the following primers: 
Designed for sequencing the insertion and deletion of loxP-PGK-gb2-Neo-
loxP cassette: Fwd seq 5’flxNeo and Rv seq 3’flxNeo  
Designed for sequencing the insertion of FRT-PGK-gb2-Neo-FRT-loxP 
cassette: Seq FRT FW Rb2, Seq Rv FRT, Seq Neo Fw and Seq PGK RV.  
Finally, the targeting vector was obtained. A maxiprep was performed and 
the targeting vector was linearized by digestion with SfiI restriction enzyme 
(New England Biolabs). 
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Figure 2.5 Targeting vector construction 
The targeting region of CLEC-2 (clec1b) gene was cloned into pFLOXRI+TK vector that 
contains thymidine kinase gene controlled by pgk promoter. CLEC-2 regions (green and purple 
between exons 1 and 2) in this plasmid were chosen to accommodate loxP-NEO-loxP cassette 
generated with the homolog regions. The recombination in bacteria generated a plasmid 
containing loxP-NEO-loxP cassette in the desired region (Step 1). Next this plasmid was 
expressed in CRE-expressing bacteria to induce recombination loxP sites, generating a plasmid 
containing a single loxP in the desired region (Step 2). In the final step the FRT-NEO-FRT-loxP 
cassette was generated containing regions homolog to CLEC-2 regions desired for 
recombination (black and orange regions between exons 4 and 5). This cassette was recombined 
with loxP-CLEC-2 plasmid generated in step 2, generating the final targeting construct that 
contains a loxP site between exons 1 and 2 and FRT-NEO-FRT-loxP between exons 4 and 5.  
 
 
The targeting vector was transfected into C57BL/6N embryonic stem (ES) 
cells PRX-B6N (Primogenix Inc, Missouri – US), cloned and selected by 
the Transgenic Lab – Cancer Research UK. The Transgenic lab provided 
96-well plates with ES cell lysed in 50µl of cell lysis buffer (10mM TRIS 
pH7.5, 10mM EDTA, 10mM NaCl, 0.5% sarcosyl, 2mg/ml proteinase K). 
I obtained ES cell DNA from 96-well plates by precipitating by 
addition of 50µl of isopropanol and 30 minutes incubation. Next I 
centrifuged the plates at 1200g for 5 minutes. Wells were washed three 
times with 200µl of 70% ethanol followed by centrifugation as before. 
Plates were emptied and air-dried for 20 minutes at room temperature. 
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Wells were resuspended in 50µl of water and DNA was screened by PCR 
(primers locations are depicted on figure 2.4) 
 
 
Figure 2.6 Targeting and typing strategy 
(A)ES cells were transfected with the targeting vector and selected for resistance to G418 and 
gancyclovir. (B) ES cells and chimeric mice were screened for the presence of a PCR product of 
a NEO primer with a primer close to exon 6 (outside the targeting vector). Transmission of 
targeted allele was confirmed by PCR product of loxP site. Arrows represent primers. 
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Chapter 3. CLEC-2 ligands and CLEC-2 cellular 
distribution 
 
3.1 Introduction  
The CLR CLEC-2 belongs to the group V of CLR, which contain CTLD that 
interact with proteins and carbohydrate ligands (Zelensky and Gready 2005). 
Besides, CLEC-2 and dectin-1 share similar CTLD and signalling motifs, 
suggestive of related functions. Nevertheless, there is a lack of information 
regarding CLEC-2 ligands and CLEC-2 expression in the immune system.  
At the beginning of this thesis, CLEC-2 had been identified as mRNA 
expressed on human dendritic cells, monocytes, granulocytes and some NK 
cell clones (Colonna, Samaridis et al. 2000). Moreover, CLEC-2 was identified 
as a platelet receptor targeted by the snake venom toxin rhodocytin (Suzuki-
Inoue, Fuller et al. 2006).  
Collectively, several reports pointed out that CLEC-2 is expressed on 
different cell types, including myeloid cells. Furthermore, CLEC-2 ligand was 
identified to be a snake venom toxin that exploits CLEC-2 expression on 
platelets to induce toxicity, suggesting that CLEC-2 might recognise a different 
ligand. 
Herein I will describe a screen to identify new CLEC-2 ligands. Moreover, I 
generated rat anti-mouse CLEC-2 monoclonal antibodies and I will use it to 
analyse CLEC-2 expression on myeloid cells and other leucocytes on normal 
and inflammatory conditions. 
3.2  CLEC-2 ligand screening assay 
To screen for CLEC-2 ligands I decided to use a method described by 
Carlyle and colleagues (Carlyle et al. 2004) used for finding NK cell receptor 
ligands. This method involves the generation of a chimeric protein, ζCLEC2-HA, 
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which is a fusion of the intracellular domain of CD3ζ (mentioned as ζ throughout 
the document), the transmembrane domain of NKR-P1B and the HA-tagged 
extracellular portion of mouse CLEC-2. This chimeric ζCLEC-2-HA allows 
signalling by CD3ζ whenever there is interaction between CLEC2 and a ligand. 
The expression of ζCLEC2-HA on B3Z cells, an NFAT-LacZ reporter T cell line 
(Karttunen et al. 1992), allows for measuring NFAT activation as readout for 
CLEC-2 interaction with a ligand (see figure 3.1A). Because of chimeric ζCLEC-
2-HA the activation of NFAT-LacZ will indicate binding/clustering of the 
receptor. As there is no CLEC-2 signalling motif expressed, the assay does not 
indicate actual agonist of CLEC-2. The quantification of LacZ induction by a 
colorimetric assay gives a rapid observation of the interaction of CLEC-2 and its 
putative ligands. 
As the ζCLEC-2-HA expression vector contains an IRES-GFP, both the 
ζCLEC-2-HA and the GFP are made as a single mRNA allowing correlation of 
the expression of both proteins. To validate the expression of on the surface of 
B3Z cells, I analysed the anti-HA staining and the expression of GFP on these 
cells before enriching these cells by sorting. By doing this I will have two 
populations of cells, a GFP negative and HA- negative and a population that will 
be GFP- and HA- positive. The anti-HA staining indicates that the extracellular 
portion of CLEC-2 is expressed on the surface of cells, while GFP negative 
cells do not show HA staining (fig.3.1B). Making use of the HA tag on ζCLEC-2-
HA, I used the anti-HA antibody to induce cross-linking and signalling 
downstream of the chimeric receptor. As observed on figure 3.1C, anti-HA 
antibody treatment of B3Z ζCLEC-2-HA, but not B3Z cells, induces NFAT 
activation on a level similar to ionomycin. Ionomycin had been broadly used as 
an inductor of intracellular calcium increase because of its capacity to bind and 
transport calcium to the cytoplasm (Liu and Hermann 1978), which induces 
NFAT activation. 
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Figure 3.1 CLEC-2 ligand screen 
(A) Scheme illustrating the B3Z cells stably expressing an NFAT-lacZ reporter and 
extracellular CLEC-2 HA-tagged fused to NKRP1B and CD3ζ. (B) B3Z and B3Z. 
ζ.CLEC-2.HA stained with anti-HA antibody and analysed for HA and GFP expression 
by FACS. (C) 1x105 B3Z and B3Z. ζ.CLEC-2.HA were cultured for 18 hours on the 
presence of different dilution of anti-HA monoclonal antibody (higher concentration of 
1:50 and two-fold dilution until 1:102.400) or left untreated (control) before 
quantification of LacZ activity. Data are means ± SD of duplicate wells of at least three 
independent assays. 
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3.2.1 Screen for CLEC-2 ligands on pathogens 
As dectin-1 recognises β-glucans derived from bacteria and fungi, I 
hypothesized that CLEC-2, as a dectin-1-like receptor, might also be involved 
on the recognition of microbes. First of all, I tested different classes of microbes, 
such as heat-killed gram negative and positive bacteria (Escherichia coli and 
Staphylococcus aureus, respectively), Mycobacterium tuberculosis and the 
fungi Candida albicans. To control the specificity of the assay, I used B3Z cells 
expressing ζdectin-1-HA. As shown on figure 3.2, none of the tested pathogens 
induced NFAT activation in B3Z ζCLEC-2-HA cells whilst anti-HA treatment 
activated the reporter and Candida albicans stimulated NFAT in B3Z ζ.dectin-1-
HA cells (fig.3.2A). Zymosan or Escherichia coli LPS also did not induce NFAT 
in B3Z ζCLEC-2-HA cells, but zymosan did in B3Z ζdectin-1-HA cells (fig.3.2B). 
This assay indicates that CLEC-2, differently to dectin-1, does not interact with 
any obvious bacteria or fungi-derived molecules. In addition, I decided to look 
for immunostimulatory complex derived from protozoans or helminthes, such as 
Toxoplasma gondii antigen (STAg) and Schistosoma Egg Antigen (SEA). The 
SEA has been demonstrated to stimulate Th2 responses by acting on DCs 
(MacDonald et al. 2001) while STAg was shown to induce IL-12 from DCs on a 
TLR-11-dependent way (Yarovinsky et al. 2005). Nevertheless, neither SEA nor 
STAg induced NFAT activation in B3Z ζCLEC-2-HA cells, indicating that CLEC-
2 does not interact with it (figure 3.2C).  
Another class of microbes assayed for binding to CLEC-2 was viruses. The 
CLR DC-SIGN was already shown to interact with HIV, with the virus exploiting 
this interaction for infecting DCs (Geijtenbeek et al. 2000). Additionally the CLR 
CLEC5a was demonstrated to interact with Dengue virus (Chen, Lin et al. 
2008). I tested different viruses representing distinct virus families with different 
genome and capsid types, as: alphavirus single strand positive RNA-strand 
Semliki Forest Virus (SFV), the paramyxoviridae single strand positive RNA-
strand Sendai Virus (SeV), the poxvirus double strand DNA Vaccinia Virus 
(VV), the double strand DNA Adenovirus (adenoviridae family), the 
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orthomyxoviridae influenza virus (negative single strand RNA) and the 
picornavirus positive RNA strand encephalomyocarditis virus (EMCV). As 
represented on figure 3.2D, none of the live viruses tested induced NFAT 
activation, implying that CLEC-2 does not bind viruses.  
Overall, screen for putative CLEC-2 ligands in different classes of microbes 
was unable to identify any microbe-derived molecule that interacts with CLEC-
2. In addition I decided to look for specific pathogens that induce Th17 
immunity, a response that is stimulated by the CLR dectin-1 (Leibundgut-
Landmann et al. 2007). Consequently, I tried the murine pathogen Citrobacter 
rodentium and Klebsiella pneumonie, which induce strong Th17 responses 
(Mangan et al. 2006) (Happel et al. 2005). Nevertheless, as for the other 
microbes tested, these two bacteria did not bind to CLEC-2 (fig.3.2E).  
In summary, I screened different classes of microbes that contain distinct 
molecular features, such as bacteria, viruses, protozoans and helminthes. 
Nonetheless, none of the microbes tried interacted with CLEC-2, suggesting 
this receptor do not recognise microbe-derived molecules. 
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Figure 3.2 CLEC-2 does not interact with microbes 
1x105 B3Z and B3Z. ζ.CLEC-2.HA were cultured for 18 hours on culture medium 
(control) or on the presence of different stimuli before quantification of LacZ activity. 
(A) 1x106 fixed Candida albicans, 10µg/ml of Mycobacterium tuberculosis extract, 
100µg/ml of Staphylococcus aureus extract, 20µl of fixed overnight Escherichia coli 
overnight culture. (B) 100µg/ml of zymosan, 100ng/ml of LPS. (C) Schistosoma egg 
antigen (SEA) and soluble tachyzoite antigen (Stag) from Toxoplasma gondii were 
added at indicated concentrations. (D) Semliki forest Virus (SFV), Sendai Virus (Sev), 
Vaccinia Virus West Nile Reserve (VV WR), Adenovirus (AdV), Influenza virus (Flu) 
and Encephalomyocarditis virus (EMCV) were added at the indicated concentrations. 
(E) Overnight cultures of Klebsiella pneumoniae and Citrobacter rodentium were fixed 
with paraformaldehyde (PFA) and added to the cells at the indicated dilution. Data are 
means ± SD of duplicate wells of at least three independent assays. 
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3.2.2 Endogenous molecules screen for CLEC-2 ligands 
As the ligand screen did not show any obvious role for CLEC-2 in the 
recognition of microbe molecules, I decided to test whether CLEC-2 could 
interact with endogenous molecules. In fact, many CLRs interact with 
endogenous molecules, as the case of several NK cell receptors (Raulet and 
Vance 2006) and the CLR CLEC12a (Pyż, Huysamen et al. 2008). Moreover, 
dectin-1 was shown to bind to an unidentified ligand on T cells (Ariizumi, Shen 
et al. 2000).  
To screen for endogenous molecules, I cultured the B3Z ζCLEC-2-HA with 
cell lines from different species, such as monkey, human or mouse (fig.3.3A). 
Interestingly, among the cell lines tested, the mouse fibroblast cell line 3T3 and 
the B16 mouse melanoma cell line specifically activated NFAT in B3Z ζCLEC-2-
HA cells. 3T3 and B16 cells are transformed cells making it impossible to 
determine if the ligand(s) represent self or altered self-molecules. To resolve 
this issue, I obtained cell suspensions from organs isolated from C57BL/6. By 
doing this I expected to be testing rather self than altered self-molecules. 
Amongst the cell suspensions tested, the lung cells showed strong NFAT 
activation in B3Z ζCLEC2-HA, indicative of expression of CLEC-2 ligand(s) 
(fig.3.3B).  
The lung is a mucosal surface that is constantly exposed to airborne 
microbes and is composed of leucocytes and endothelial cells. Therefore, I 
decided to test if inflammatory leucocytes could be a source of the endogenous 
CLEC-2 ligand(s). Thus, I isolated inflammatory peritoneal macrophages by 
challenging mice with thioglycollate. The co-culture of B3Z ζCLEC-2-HA and 
thioglycollate-elicited macrophages induced the activation of the reporter, 
indicating that a CLEC-2 ligand is expressed by these macrophages (fig.3.3C). 
On this experiment I used the 3T3 cells as positive control for the activation of 
NFAT in B3Z ζCLEC2-HA cells and tried another endothelial-derived cell, the 
Chinese Hamster Ovarian (CHO) cells. This experiment demonstrated that 
CHO cells could, as efficiently as 3T3 cells and thioglycollate-elicited 
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macrophages, induce NFAT in B3Z ζCLEC2-HA (fig.3.3C). In order to 
determine if the CLEC-2 ligand(s) expressed by monocytes was generally 
expressed in myeloid cells, I generated bone marrow derived macrophages 
(BMM) or bone marrow derived dendritic cells (BMDC). I cultivated Raw 264.7 
(macrophage cell line), BMM and BMDCs with B3Z ζCLEC-2-HA. On these co-
cultures, unstimulated Raw 264.7 and BMMs, but not BMDC, induced NFAT 
activation (fig.3.3D), demonstrating that macrophages express a CLEC-2 
ligand. 
The understanding that CLEC-2 interacts with a self-molecule needed to be 
expanded to determine if this ligand is a membrane-bound or a soluble 
molecule. Thus, by culturing B3Z ζCLEC-2-HA with supernatant from 3T3, live 
or fixed 3T3 cells I tested for the presence of a soluble CLEC-2 ligand 
(fig.3.3E). This assay showed that live and fixed 3T3 cells, but not 3T3 
supernatant, activated NFAT. Furthermore, culture of 3T3 with B3Z ζCLEC-2-
HA separated by a permeable membrane showed the requirement of physical 
interaction between both cells for NFAT activation (fig.3.3F). Overall these two 
assays indicate that CLEC-2 ligand on 3T3 cells is not a soluble factor, and is in 
fact a membrane-bound molecule.  
To better characterise the specificity of CLEC-2 to its ligand, the human 
CLEC-2 extracellular portion was fused to the CD3ζ chain on the same way as 
the mouse CLEC-2 and stable B3Z cells were generated (B3Z.ζ.humanCLEC-2-
HA). The human CLEC-2 was compared with its mouse equivalent for 
specificity for ligands. The figure 3.3G shows that the mouse and the human 
CLEC-2 have the same specificity and both recognise a ligand on the 3T3, 
CHO and B16 cells, as well as on human endothelial 293.T and the mouse 
tumour colo 26 cell lines.  
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Figure 3.3 Self-molecule(s) bind to CLEC-2 
1x105 B3Z and B3Z.ζ.CLEC-2.HA were cultured for 18 hours on culture medium 
(control) or on the presence of different stimuli before quantification of LacZ activity. 
(A) The corresponding cell lines were added at the cell line: B3Z ratio indicated. (B) 
C57BL/6J tissues were obtained and digested with collagenase and DNase to obtain cell 
suspensions. From this, 1x105 cells were co-cultured with B3Z clones. (C) 0.25x105 
CHO or 3T3 cells or 1x105 thioglycollate-elicited peritoneal lavages cells were added to 
B3Z clones culture. (D) 1x105 Raw 264.7, bone marrow macrophages (BMM) or 
FLT3L BMDC were cultured with B3Z clones. (E) 0.25x105 live or PFA fixed 3T3 cells 
were culture with B3Z clones (F) 3T3 cells were cultured with B3Z clones separated or 
not by transwell membrane inserts with 8µm pore size and supernatant from 3T3 cell 
culture was obtained and used to culture B3Z clones. (G) B3Z.ζ.humanCLEC-2.HA cell 
were tested as the other B3Z clones for induction of lacZ activity by co-culture with 
1x105 LK cells or 0.25x105 CHO, 3T3, 293T or colo26 cells. Data are means ± SD of 
duplicate wells of at least three independent assays. 
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3.2.3 Biochemical inhibition of CLEC-2 ligand 
Mouse and human CLEC-2 recognises a membrane-bound ligand on 
macrophages, tumour cells and endothelial cell lines. Nevertheless, the 
biochemical nature of the CLEC-2 ligand is largely unknown.  
In order to have an insight into the molecular nature of CLEC-2 ligand, I 
treated 3T3 cells with protein or mRNA synthesis inhibitors (anisomycin and 
actinomycin D, respectively). The inhibition of mRNA or protein synthesis 
impaired the binding of 3T3 to CLEC-2 (fig.3.4A). This suggested that the 
CLEC-2 ligand expressed by 3T3 cells needs a constant production of protein 
to be expressed. To exclude that the inhibitor-treated cells had carried over the 
inhibitor and this way impairing the reporter on B3Z cells, I added the anti-HA 
antibody to wells with co-cultures with inhibitors. As observed, the response to 
anti-HA antibody is equal, irrespectively of the presence of inhibitor-treated 
cells, indicating no carrying over of drugs.  
Lectin receptors are largely characterised as carbohydrate-binding proteins 
(Drickamer 1999). Hence, I decided to treat 3T3 cells with glycosylation 
inhibitors to check if this could impair NFAT activation, indicative of lack of 
CLEC-2 ligand(s). Tunicamycin is a drug that inhibits the first enzyme 
responsible for N-glycosylation of proteins. As a result of N-glycosylation 
inhibition on 3T3 cells there was an impaired NFAT activation in B3Z ζCLEC2-
HA cells (fig.3.4B). This implies that carbohydrate chains on proteins are 
needed for optimal expression of CLEC-2 ligand. Therefore I decided to 
evaluate if the specific blockade of certain carbohydrates could block the 
binding of 3T3 to CLEC-2. Lectins extracted from plants have been commonly 
used to determine the carbohydrate composition of glycoproteins due to their 
high specificity for certain sugar chains. Based on this, I incubated 3T3 cells 
with two different plant lectins: the GlcNAcβ1-4GlcNAcβ1-4GlcNAc, Neu5Ac 
binding lectin WGA (wheat germ agglutinin) and the Neu5Ac, Galß1-3N-GalNAc 
(“T antigen”) binding lectin Jacalin. These two sugar are expressed in different 
cell types, and the “T antigen” is found to be differentially expressed by MUC1 
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in tumour cells (Taylor-Papadimitriou et al. 1999). The treatment of 3T3 cells 
with jacalin impaired the activation of the reporter by 3T3 cells, suggesting that 
carbohydrate chains composed of sialylated galactose and N-
acetylgalactosamine are required for optimal binding of CLEC-2 and its ligand 
on 3T3 cells (fig.3.4C).  
 
Figure 3.4 Analysis of carbohydrate interaction with CLEC-2 
1x105 B3Z and B3Z. ζ.CLEC-2.HA were cultured for 18 hours on the presence of 
culture medium (control) or with 0.25x105 3T3 cells treated with different inhibitors 
before quantification of LacZ activity. (A) 3T3 were overnight treated with indicated 
amounts of anisomycin (aniso) or actinomycin D (actD) or (B) 2µg/ml of tunicamycin. 
(C) 3T3 with the indicated amounts of lectins jacalin or WGA before co-culture with 
B3Z clones. Data are means ± SD of duplicate wells of at least three independent 
assays. 
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To continue assessing the role of specific carbohydrate chains on proteins, I 
made use of glycosylation deficient CHO cells. These CHO-deficient cells were 
generated by EMS treatment, a mutagenic compound that induces single 
nucleotide mutations (Esko 1986). I used four different CHO mutants: CHO 
pgsD-677 and CHO H661 cells are defective on the generation of heparan 
sulfate chains (Lidholt et al. 1992; Wei et al. 2000), CHO pgsF-17 are defective 
on sulfation of heparan sulfate (Bai and Esko 1996) and CHO pgsA-745 are 
defective on the production of all glycosaminoglycans, including heparan sulfate 
(Lugemwa and Esko 1991). The co-culture of CHO mutant cells with B3Z 
ζCLEC-2-HA revealed that the mutants CHO H661 or CHO pgsD-677 did not 
induce activation of the reporter cells, indicating a lack of CLEC-2 ligand(s) 
(fig.3.5A). These two CHO lines are defective in Ext1, an enzyme responsible 
for the generation of heparan sulfate chains (Wei, Bai et al. 2000). Although 
these two deficient CHO cells suggested that heparan sulfate chains were part 
of the CLEC-2 ligand, CHO pgsA-745 cells that are also defective in heparan 
sulfate generation induced the activation of the reporter (fig.3.5A). Staining for 
heparan sulfate confirmed that the cells correctly identified (fig.3.5B). Reverse-
transcription analysis of PDPN expression in CHO cells failed as proper primers 
for hamster sequences were lacking. Thus it is possible that CHO pgsA-745 still 
have a CLEC-2 ligand because of PDPN expression. As the presence of the 
heparan sulfate or other GAGs did not correlate with CLEC-2 ligand presence, I 
decided to check if the Ext1 enzyme could be responsible to CLEC-2 
generation. Hence, I reconstituted expression of Ext1 on CHO H661 cells and 
tracked its activity by monitoring the surface heparan sulfate (fig.3.5D). Two 
populations of heparan sulfate-expressing cells are observed, which might be 
due to a high- and low-expressing Ext1 clones (right and left peaks in figure 
3.5D). Given that Ext1 was active and able to produce heparan sulfate I tested 
these CHO H661-Ext1 on the ligand screen. The Ext1 reconstituted CHO cells 
were now able to activate the reporter, suggesting that Ext1 is involved in the 
generation of CLEC-2 ligand(s). As  
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Figure 3.5 The glycosyltransferase Ext1 is involved in CLEC-2 ligand generation 
1x105 B3Z and B3Z. ζ.CLEC-2.HA cells were cultured for 18 hours on the presence of 
culture medium (control) or with different stimuli before quantification of LacZ 
activity. (A) 0.25x105 CHO clones (B) CHO clones stained for heparan sulfate. (C) 
CHO H661 or CHO H661 stably expressing human Ext1 (H661 Ext1) were culture at 
different numbers with B3Z clones. (D) CHO H661 Ext1 staining for heparan sulfate. 
Data are means ± SD of duplicate wells of at least three independent assays. 
 
 
3.2.4 The glycoprotein podoplanin is a CLEC-2 ligand 
During the time that I was screening for the involvement of Ext1 and 
glycoproteins on the binding to CLEC-2, Suzuki-Inoue and colleagues published 
a paper demonstrating that the endogenous protein podoplanin is a ligand for 
CLEC-2 (Suzuki-Inoue, Kato et al. 2007). Podoplanin (PDPN) is a mucin-like 
type I transmembrane glycoprotein largely O-glycosylated (Wicki and Christofori 
2007) that had been associated with induction of platelet aggregation via 
specific extracellular O-glycosylation site named platelet-aggregation (PLAG) 
domain (Kaneko et al. 2006). The expression of PDPN was described on 
several human tissues, such as lung (Rishi, Joyce-Brady et al. 1995), kidney 
(Breiteneder-Geleff, Matsui et al. 1997), skin (Durchdewald et al. 2008) and 
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lymphatic vessel (Schacht et al. 2003). In addition to these tissues, PDPN 
expression had been described on the surface of cancer cells promoting 
metastasis through regulation of spreading and adhesion (Wicki and Christofori 
2007). Because of the differential expression of PDPN on lymphatic, but not 
blood vessels, this protein has been commonly used as a marker for lymphatic 
endothelia.  
In face of this newly reported CLEC-2 ligand, I sought to determine if PDPN 
was expressed on the cell lines that activated the CLEC-2 reporter on the ligand 
screen. I stained all the cells tested on the ligand screen for the expression of 
PDPN. As shown on figure 3.6A, the stimulated peritoneal cells as well as 3T3, 
colo 26 and B16 cell lines all expressed PDPN. In contrast, the cell lines testing 
negative in the B3Z assay (B3Z and LK cells) did not show PDPN staining 
(compare figure 3.3G with 3.6A). The human cell line 293.T and the hamster 
cell line CHO also did not show PDPN staining, although the anti-podoplanin 
antibody (anti-PDPN) used for staining was raised against mouse PDPN and 
probably does not cross-react with human or hamster PDPN. Human 293 cells 
were later reported to express PDPN and bind to CLEC-2 (Christou, Pearce et 
al. 2008).  
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Figure 3.6 The endogenous glycoprotein podoplanin is a CLEC-2 ligand 
(A) The indicated cell lines were stained with rat IgG2a-FITC (isotype) or anti-mouse 
podoplanin-FITC (anti-PDPN). Peritoneal lavages cell were obtained from C57BL/6J 
mouse and treated overnight with 1µg/ml of LPS before being stained. (B) 1x105 B3Z 
and B3Z.ζ.CLEC-2.HA were cultured for 18 hours in the presence of culture medium 
(control), 1µg/ml of ionomycin or 1x105 LK clones before quantification of LacZ 
activity. (C) B3Z or B3Z. ζ.CLEC-2.HA were incubated for 20 minutes with dectin-
1.Fc, PDPN.Fc or PDPN T34A.Fc supernatants before wash and addition of anti-human 
IgG-Cy5 antibody for another 20 minutes. (D) 1x105 B3Z or B3Z.ζ.CLEC-2.HA cells 
were incubated with CHO H661, CHO H661 expressing mouse podoplanin (H661 
PDPN) or H661 Ext1 cells at different ratios and LacZ activity was quantified after 18 
hours. (E) H661 PDPN cells were stained with dectin-1.Fc or CLEC-2.Fc supernatant as 
described above. (F) H661 PDPN cells were incubated with isotype or anti-PDPN for 
20 minutes before staining with dectin-1.Fc or CLEC-2.Fc as described above. Data are 
means ± SD of duplicate wells of at least three independent assays. 
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Although I could not formally demonstrate that PDPN was the CLEC-2 
ligand on the cell lines tested, I decided to do a gain of function experiment to 
demonstrate the sufficiency of PDPN to induce CLEC-2 binding. The figure 
3.6B indicates that ectopic expression of PDPN on LK cell (negative on ligand 
screen and for PDPN expression) is sufficient to induce activation of the 
reporter in B3Z ζCLEC-2-HA, suggestive of binding to CLEC-2 (fig.3.6B).  
Ectopic expression of PDPN on cells was sufficient to stimulate binding to 
CLEC-2. As my previous results pointed to a role of glycoproteins on CLEC-2 
interaction, I decided to investigate the requirement of PDPN glycosylation for 
CLEC-2 binding. Mouse PDPN threonine 34 was shown to be an O-
glycosylation site required to induction of platelet aggregation (Kaneko, Kato et 
al. 2006). Therefore, I mutated this aminoacid and asked whether PDPN was 
still able to bind to CLEC-2. The ectopic expression of PDPN T34A on LK cell 
and culture with B3Z ζCLEC-2-HA cells lead to reporter activation, suggesting 
that PDPN T34A still binds to CLEC-2 (fig.3.6B). Additionally, I cloned and 
produced PDPN or PDPN T34A as a soluble protein tagged with human IgG1 
Fc portion. Staining of CLEC-2 expressing cells with these proteins allowed me 
to assess the binding of this mutated PDPN to CLEC-2. Both PDPN.Fc and 
PDPN T34A.Fc stained B3Z ζCLEC-2-HA cells, but not to B3Z cells (fig.3.6C), 
indicating that PDPN binds to CLEC-2 independent of this platelet aggregation-
inducer O-glycosylation site.  
As a result of failing to determine the site of PDPN responsible for CLEC-2 
interaction, I asked about the involvement of Ext1 on the generation of 
glycosylated PDPN able to interact with CLEC-2. For this, I expressed mouse 
PDPN on CHO H661 cells and assayed these cells for activation of NFAT in 
B3Z ζCLEC-2-HA cells. As shown on figure 3.6D, the ectopic expression of 
PDPN on Ext1-deficient CHO H661 is sufficient to induce NFAT activation. Due 
to PDPN and Ext1 being expressed by different vector and, presumably, at 
different levels it is difficult to state if there are significant differences between 
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ectopic expression of PDPN and Ext1 in CHO H661 cells. This demonstrated 
that there is no obvious involvement of Ext1 on glycosylation of PDPN and 
interaction with CLEC-2. To further verify this fact I produced soluble CLEC-
2.Fc chimeric protein and stained CHO H661-PDPN cells. CLEC-2.Fc, but not 
dectin-1.Fc, stained CHO H661-PDPN cells (fig.3.6E), confirming that Ext1 
deficiency does not impair PDPN-CLEC-2 binding. 
 After determining that the binding of the cell lines to CLEC-2 could be 
explained by PDPN expression by the cell lines, I tried to determine if PDPN 
was the only ligand on these cells by specifically blocking PDPN-CLEC-2 
interaction. To do this, I needed cells that knowingly express PDPN as the only 
CLEC-2 ligand and a method to assess this interaction. I decided to treat CHO 
H661-PDPN with an anti-PDPN antibody or an isotype-matched antibody and 
then add CLEC-2.Fc to these cells. On figure 3.6F it is shown that anti-PDPN 
antibody did not block the interaction of PDPN with CLEC-2, thus not being 
suitable as a tool to determine if PDPN is the only CLEC-2 ligand. Other ways 
of interfering with CLEC-2-PDPN interaction are yet to be tested such as 
incubating B3Z ζCLEC-2-HA with PDPN.Fc and incubating PDPN-expressing 
cells with CLEC-2.Fc before performing the B3Z assay. 
3.2.5 Summary and discussion 
Previous studies had identified rhodocytin as a CLEC-2 agonist (Suzuki-
Inoue, Fuller et al. 2006). Rhodocytin is a known snake venom protein that 
induces platelet aggregation, and for many other snake venoms this is regarded 
as the mechanism of toxicity (Andrews et al. 2001). It is reasonable to speculate 
that CLEC-2 has ligands others than rhodocytin. I decided to look for CLEC-2 
ligands by using an established cell-based screen (Carlyle, Jamieson et al. 
2004). As CLEC-2 has a structural similarity with the β-glucan receptor dectin-1, 
I hypothesized that CLEC-2 might recognise pathogens-derived molecules and 
thus, I screened several microbes for CLEC-2 binding. Remarkably, I could not 
find any microbe that bound to CLEC-2, which diverted my screen to examine 
possible CLEC-2 interactions with self-derived molecules. As is the case for 
other CLRs from the same sub-group, I found that CLEC-2 interacted with a 
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self-derived molecule present on the surface of endothelial cells and 
macrophages (Zelensky and Gready 2005).  
Several approaches were used to characterise the self-molecule that 
could bind to CLEC-2. An important finding came from the fact that a ligand was 
present on CHO cells, but not a CHO mutant defective on the heparan sulfate 
polymerase enzyme Ext1 (Wei, Bai et al. 2000). Heparan sulfate (HS) is a 
member of the glycosaminoglycans (GAGs) family that are complex sugars 
found covalently attached to proteins, forming proteoglycans (Bernfield et al. 
1999; Gandhi and Mancera 2008). Notably while this work was ongoing, the 
heavily glycosylated mucin-like protein podoplanin (PDPN) was described as a 
CLEC-2 ligand and agonist (Suzuki-Inoue, Kato et al. 2007). However, PDPN 
binding to CLEC-2 was not dependent of Ext1 or HS, suggesting that there 
might exist two distinct CLEC-2 ligands: PDPN and an Ext1-dependent ligand. 
Alternatively, it is possible that Ext1 is involved in promoting PDPN expression, 
although this involvement was not observed upon ectopic over-expression of 
PDPN. Hence, it would be attractive to evaluate normal PDPN expression on 
mouse and human cells deficient of Ext1. Unfortunately, I did not have access 
to neither human Ext1-deficient cells nor Ext1 knockout mouse cells. 
Furthermore my approaches to knockdown Ext1 by siRNA failed, as I could not 
make sure about siRNA transfection efficiency. 
The O-glycosylation site (threonine 34) of PDPN is involved on its platelet-
aggregation activity, as mutation on this site does not abolish PDPN expression 
but impair platelet aggregation induced by PDPN (Kato et al. 2003). However, 
mutations in this O-glycosylation site (T34A) did not impair CLEC-2 binding 
(Figure 3.6). As a matter of fact, PDPN T34A remained a CLEC-2 ligand, 
suggesting that PDPN O-glycosylation is likely to play a role in triggering other 
receptors to induce platelet aggregation.  
Intriguingly, my assays showed that sialylated galactose (ß 1-3) N-
acetylgalactosamine, (or “T antigen”) could be involved in CLEC-2 binding, as 
the lectin jacalin bound to this sugar inhibit CLEC-2 binding (Figure 3.4C). 
Accordingly, “T antigen” is expressed by PDPN and is necessary for platelet-
aggregation activity (Kaneko et al. 2004). It is thus suggestive that “T antigen” 
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expression on PDPN is involved on CLEC-2 interaction and induction of 
platelet-aggregation. Nevertheless, jacalin binding to “T antigen” could 
allosterically inhibit CLEC-2 interaction with the ligand. Thus, “T antigen” does 
not necessarily need to be part of the ligand. 
N-glycosylation inhibition blocked 3T3 binding to CLEC-2 (see figure 
3.4B), indicating a role for N-linked carbohydrate chains in CLEC-2 binding. 
Analysis of PDPN glycosylation sites predicted that mouse PDPN have an N-
glycosylation site but it is not present on human PDPN indicating that it might 
not be involved on CLEC-2 interaction. Even so, it is conceivable that PDPN N-
glycosylation site might affect its correct folding and expression on the cell 
surface. Thus it would be interesting to evaluate PDPN expression upon N-
glycosylation inhibition. 
Many cancer cells have abnormal expression and activities of 
glycosyltransferases, which changes the expression of different glycoproteins. 
This is the case for MUC1 (Taylor-Papadimitriou, Burchell et al. 1999), a heavily 
O-glycosylated protein like PDPN. It is thus conceivable that PDPN 
glycosylation is differentially regulated between steady-state conditions and 
upon inflammation or cancer, and Ext1 could be involved in some of these 
modifications. Nevertheless, Kaneko and colleagues showed that both 
lymphatic endothelial cells (LECs) and cancer cells induced platelet-
aggregation. Moreover, western blot analysis of PDPN showed the same profile 
when compared LECs and cancer cells (Kaneko, Kato et al. 2004), indicating 
no differences on PDPN on normal and cancer cells. 
Overall, I tried several approaches to biochemically characterise the 
CLEC-2 ligand. Many of these approaches were based on the fact that CLEC-2, 
as a CLR, could recognise carbohydrates. As described above, there is no clear 
answer whether CLEC-2 recognise N-linked, O-linked or an Ext1-dependent 
carbohydrate. Interestingly, the CLEC-2 ligand rhodocytin does not have any 
predicted glycosylation site and no glycosylation confirmed by mass 
spectrometry analysis (Watson, Brown et al. 2007). Accordingly, the CTLD of 
CLEC-2 lacks a consensus carbohydrate recognition domain (CRD) and, as 
many other members of the same sub-group of CLR, may interact with proteins 
Chapter 3. CLEC-2 ligands and CLEC-2 cellular distribution 
 82 
rather than sugars (Zelensky and Gready 2005). Therefore it is possible that 
glycosylation modifications might play a role on the exposure of amino acid 
sequences that interact with CLEC-2. 
3.3 CLEC-2 distribution on the immune system 
3.3.1 Anti-CLEC-2 antibody specificity  
 CLEC-2 expression has been largely investigated on human and mouse 
platelets and by mRNA expression. Therefore, I decided to generate 
monoclonal antibodies to better characterise CLEC-2 expression in the immune 
system (see chapter 2, section 2.4). 
 Monoclonal antibodies have been used for many years on a range of 
applications, including flow cytometry staining and western blots. I decided to 
validate the newly generated anti-mouse CLEC-2 antibodies for these two 
applications. The screen for hybridomas producing anti-mouse CLEC-2 allowed 
isolating two clones producing rat IgM and rat IgG2b anti-mouse CLEC-2 
(described and shown chapter 2). For reasons of stability of antibody and 
purification I chose to primarily use the rat IgG2b anti-mouse CLEC-2, which will 
be referred throughout this document as anti-CLEC-2. 
 In order to clearly demonstrate the specificity of anti-CLEC-2 I used B3Z 
ζCLEC-2-HA cells mixed to the parental B3Z cells. As B3Z ζCLEC-2-HA cells 
co-express GFP, CLEC-2-HA cells appear as GFP positive, while the parental 
B3Z cells do not express either GFP or HA and appear as GFP negative. On 
figure 3.7A, it is shown that anti-CLEC-2 antibody biotinylated can selectively 
label GFP positive cells, like the anti-HA antibody. This demonstrates that anti-
CLEC-2 can be used as a tool to determine CLEC-2 expression on mouse cells. 
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Figure 3.7 Anti-CLEC-2 monoclonal antibody specificity 
(A) Biotinylated anti-mouse CLEC-2 monoclonal antibody (anti-CLEC-2) or rat IgG2b 
(isotype) were incubated with at a concentration of 5µg/ml in a mixture of B3Z or 
B3Z.ζ.CLEC-2.HA cells. After wash streptavidin-PE was added to the cells for another 
20 minutes before further washing and analysis. (B) lysates (left side) or CLEC-2 
immunoprecipitations (right) from B3Z or B3Z.CLEC-2 cells were separated in 
denaturing non-reducing gels and membrane blots were probed with 2 µg/ml of anti-
CLEC-2. In the left side membrane was probed with anti-rat IgG-HRP and in the right 
side membrane was probed with streptavidin-HRP. Arrows indicate specific band and 
number represent molecular weight in KDa. 
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 Subsequently, I analysed the ability of this antibody to detect CLEC-2 by 
western blot. The western blot analysis of CLEC-2 protein can allow me to 
verify the molecular weight of CLEC-2, thus determining whether CLEC-2 is 
glycosylated or is expressed as a monomer or dimer. To achieve this, I lysed 
B3Z cells ectopically expressing full length CLEC-2 (B3Z-CLEC-2) or not (B3Z) 
and separated the proteins by SDS-PAGE, transferred to a membrane and 
probed with anti-CLEC-2. As shown on figure 3.7B, there is a specific band on 
B3Z-CLEC-2 lysate with a molecular weight of approximately 30KDa. Further 
bands are observed, which might be due to the cross-reactivity of the 
secondary antibody (anti-rat HRP conjugated antibody) to other proteins. 
Immunoprecipitation of CLEC-2 also showed that anti-CLEC-2 antibody has a 
high specificity as it pull-down a CLEC-2 specific band (fig.3.7B, right). 
Accordingly, the western blot approach revealed that mouse CLEC-2 is 
expressed as a protein of approximately 30KDa, which is similar as the reported 
human CLEC-2 found on platelets (Suzuki-Inoue, Fuller et al. 2006).  
3.3.2 CLEC-2 expression on myeloid cells 
 Around one decade ago, Colonna and colleagues described human 
CLEC-2 as a transcript expressed on all myeloid cells in addition to a NK cell 
clone (Colonna, Samaridis et al. 2000). Some years after this, human CLEC-2 
protein was found on the surface of platelets (Suzuki-Inoue, Fuller et al. 2006). 
Remarkably, CLEC-2 expression was more recently reported on the surface of 
myeloid cells (Kerrigan, Dennehy et al. 2009; Tang, Li et al. 2010). Using the 
newly developed anti-CLEC-2 mAb I assessed CLEC-2 expression throughout 
the immune system. 
 I decided to firstly determine CLEC-2 expression on myeloid cells. I 
stained peripheral blood with Gr1 and CD11b, and identified neutrophils as a 
cell population that is Gr1hi and CD11bhi. The anti-CLEC-2 staining confirmed 
the previous report (Kerrigan, Dennehy et al. 2009) that neutrophils express 
CLEC-2 (fig.3.8B). To analyse CLEC-2 expression on macrophages, I induced 
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macrophage recruitment to the peritoneal cavity by treating mice with 
thioglycollate. With this method I identified macrophages by size and by 
expression of F4/80 marker. These thioglycollate-elicited macrophages showed 
CLEC-2 expression (fig.3.8C). Finally, I checked for CLEC-2 expression on 
dendritic cells (DCs) isolated from spleen, by isolating CD11c cells by magnetic 
enrichment.  The analysis of FSChi and CD11c+ cells indicate that CLEC-2 is 
expressed on the dendritic cell population (fig. 3.8A). Splenic DCs are not a 
homogenous population, and they can be sub-divided into at least four subsets 
by expression of CD4, CD8α, and B220. Conventionally splenic DC subsets are 
named according to the expression or not of the CD4 and CD8α marker, thus 
generating the double negative DCs, the CD4+ DCs and the CD8+ DCs. The 
other subset is the plasmacytoid DC, which is identified by the lower expression 
of CD11c and by the presence of the B220. By analysing CLEC-2 expression 
on the splenic DC subsets, I determined that CLEC-2 is homogeneously 
expressed on all DC subsets, as indicated by the general analysis of splenic 
CD11c+ cells (fig.3.8A). 
 To finalise, I verified the expression of CLEC-2 on some myeloid cell 
models, which are generally used to study macrophages and DCs function on in 
vitro culture experiments. The RAW 264.7 (mouse macrophage cell line), 
GMCSF and FLT3L bone marrow-derived DCs (BMDCs) showed CLEC-2 
expression (fig.3.8D). This confirms previous report that showed CLEC-2 mRNA 
expression on human samples of myeloid cells (Colonna, Samaridis et al. 
2000), indicating that mouse CLEC-2 might show a similar expression profile. 
Additionally, it characterises myeloid cell models that will be used further on to 
study CLEC-2 signalling and function. 
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Figure 3.8 CLEC-2 expression on myeloid cells 
(A) DCs were isolated from spleen of C57Bl/6J mouse by MACS and staining with 
anti-CD11c, anti-CD4, anti-CD8, anti-B220 and anti-CLEC-2 or isotype biotinylated. 
Numbers in graphs indicate the percentage of cells in the gated region. (B) Blood from 
C57Bl/6J mouse was obtained and stained with anti-Gr1, anti-CD11b and anti-CLEC-2 
or isotype biotinylated. (C) Peritoneal lavage from thioglycollate-elicited C57Bl/6J 
mouse was obtained and stained with anti-F4/80 and anti-CLEC-2 or isotype 
biotinylated. Regions and arrows indicate the population depicted on histograms (D) 
GMCSF BMDC, FLT3L BMDC or Raw 264.7 were stained with anti-CLEC-2 or 
isotype biotinylated antibodies.  
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3.3.3 CLEC-2 cellular distribution on normal or inflammatory conditions 
 Several proteins change expression during inflammation, I sought to 
determine if CLEC-2 expression could be modulated during inflammatory 
conditions. To do so, I challenged C57Bl/6 mice with PBS or 5µg of LPS intra-
venously and analysed CLEC-2 expression on spleen, bone marrow or lymph 
node cell suspensions 16 hours after. 
 The spleen is a secondary lymphoid organ that can be used as a source of 
several mature hematopoietic cells, like myeloid and lymphoid cells. I used the 
staining of CLEC-2 on platelets as a positive control, and I identified platelets by 
analysing FSC low (small cells) and staining with CD41 marker (an integrin 
highly expressed on platelets). Hence, platelets showed a high CLEC-2 
expression, which did not change upon LPS challenge in vivo (fig.3.9A).  
 I also analysed CLEC-2 expression on lymphoid cells by staining with 
B220, NK1.1 and CD3.  B220 identifies B cells, while the latter markers identify 
NK cells (NK1.1+ and CD3-), NKT cells (NK1.1+ and CD3+) and T cells (NK1.1- 
and CD3+). As seen on figure 3.9A, CLEC-2 is found on steady state condition 
on a minor population of NK cells. When CLEC-2 expression is analysed after 
challenge with LPS, we observe that the B cells up-regulated CLEC-2 
expression, but not T, NK or NKT cells. Intriguingly, the frequency of NK cells 
expressing CLEC-2 increased after LPS challenge, although CLEC-2 
expression was not up regulated (fig.3.9A). 
  Myeloid cells were also analysed in the spleen with CD11c+ cells being 
identified as DCs, and CD11b and Gr1 identifying neutrophils and monocytes. 
DCs showed expression of CLEC-2, which was greatly increased upon LPS 
challenge (fig.3.9A). Neutrophils (Gr1 hi CD11b hi) showed a similar phenotype, 
with increased CLEC-2 expression upon LPS treatment of mice (fig.3.9A). 
Monocytes on the spleen can be identified by the lower expression of CD11b, 
compared to neutrophils, and/or presence of the Gr1 marker. The analysis of 
CLEC-2 expression on these monocytes showed no CLEC-2 expression. 
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Nevertheless, upon LPS challenge CLEC-2 expression was observed on these 
populations (fig.3.9A). 
 The lymph nodes are secondary lymphoid organs where the activated 
antigen-presenting cells (APCs) encounter and activate naïve T cells. For the 
analysis of CLEC-2 expressing cells on these sites, I extracted the inguinal and 
brachial lymph nodes of resting or LPS-challenged mice. Analysis of CLEC-2 
expression on T cells showed no CLEC-2 expression in resting or LPS-treated 
mice (fig.3.9B). B cells in lymph nodes do not express CLEC-2 in resting mice 
and, differently from the splenic B cells, in LPS-treated mice (fig.3.9B). Also 
distinct from the DCs found in the spleen, a very small DC population express 
CLEC-2 at the steady state (fig.3.9B, compare shaded grey with thin black line 
histogram). But, upon LPS challenge all DC express CLEC-2 at increased 
levels. 
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Figure 3.9 Inflammation modulates CLEC-2 expression 
C57Bl/6 mice were injected intravenously with 5µg of LPS or with PBS. After 16 hours 
(A) splenocytes were stained with anti-CLEC-2 biotinylated or with isotype matched 
control antibody and anti-CD41, anti-CD11c, anti-B220, anti-NK1.1and anti-CD3. (B) 
Lymph node cells were stained with anti-CD3, anti-B220 and anti-CD11c. Regions on 
scatter plots indicate the population analysed for CLEC-2 expression on histograms. 
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3.3.4 Summary and discussion 
 The generation of an anti-mouse CLEC-2 mAb allowed me to analyse 
mouse CLEC-2 biochemically and its expression. Analysis of mouse CLEC-2 by 
western blot identified it as a monomer of approximately 30 KDa. However, the 
aminoacid sequence of mouse CLEC-2 predicts a polypeptide chain of 26 KDa, 
which suggests that mouse CLEC-2 might by expressed as a glycosylated 
protein. Interestingly, human CLEC-2 was identified as a N-glycosylated protein 
of approximately 32 KDa (Suzuki-Inoue, Fuller et al. 2006). 
 Using anti-CLEC-2 mAb I could expand previous finding of CLEC-2 
expression on platelets. I showed that CLEC-2 was expressed on all myeloid 
cells (DCs, macrophages and neutrophils) and NK cells. This confirmed 
previous reports that showed CLEC-2 in human myeloid and NK cells (Colonna, 
Samaridis et al. 2000) and in mouse neutrophils and monocytes (Kerrigan, 
Dennehy et al. 2009; Tang, Li et al. 2010). Interestingly, I found that 
inflammation induced by LPS in mice could increase CLEC-2 expression in 
myeloid and B cells. Additionally, LPS did not increase CLEC-2 expression on 
NK cells, but increased the frequency of CLEC-2 positive NK cells. This might 
be because LPS induce the expansion of this population of NK cells. 
Accordingly, Colonna and colleagues demonstrated that CLEC-2 transcripts 
were only found on particular human NK cell clones (Colonna, Samaridis et al. 
2000). The increased frequency of NK cells after LPS challenge might be due to 
induction of a mediator, such as IL-15, which induces NK cell development and 
proliferation (Colonna 2009). This increased frequency of NK cells might be 
important to increase the chances of a NK cell to get in contact with a PDPN-
expressing tumour cell during developing tumour.  
 Analysis of monocytes in the spleen showed CLEC-2 expression upon 
LPS-treatment, but not in resting conditions. Although I could demonstrate that 
CLEC-2 can be expressed on monocytes in the spleen, these cells are 
knowingly auto-fluorescent, which might have impaired the analysis on steady 
state conditions. 
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 Additionally I found that, in lymph nodes, CLEC-2 is expressed only on a 
minor subset of DCs. Nevertheless, upon LPS-induced inflammation B cell did 
not up-regulate CLEC-2, while DCs did. It is interesting that CLEC-2 is not 
found similarly regulated on the spleen and lymph nodes. It is tempting to 
speculate that on the steady state, CLEC-2 expressed on a minor DCs subset 
represents migratory DCs. PDPN expression on afferent lymphatic vessel 
(Pflicke and Sixt 2009) and lymph node stroma (Lee et al. 2007) might play a 
role in the migration of DCs from tissues to lymph nodes. 
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Chapter 4. Study of CLEC-2 signalling and function 
on myeloid cells 
 
4.1 Introduction 
Most studies on CLEC-2 function and signalling have been performed 
using platelets and focusing on the role of CLEC-2 on the induction of platelet 
aggregation. Nevertheless, the finding that CLEC-2 is expressed on a variety of 
myeloid cells suggests that it might have other functions beside platelet 
aggregation. CLEC-2, as dectin-1, is a hemITAM Syk-coupled receptor and 
might therefore behave similarly to dectin-1 in terms of its ability to activate 
myeloid cells. Syk signalling downstream of dectin-1 can lead to cytokine 
(Rogers, Slack et al. 2005) and ROS production (Underhill, Rossnagle et al. 
2005). Indeed, a chimeric dectin-1 receptor bearing the intracellular tail of 
CLEC-2 was recently described as able to induce TNF, but not ROS production 
(Kerrigan, Dennehy et al. 2009).  
However, studies of signalling and function of the intact receptor in 
myeloid cells are limited. The only report available focused on the role of CLEC-
2 on neutrophils and used rhodocytin as a CLEC-2 agonist (Kerrigan, Dennehy 
et al. 2009).  
In this chapter I will focus on the function of CLEC-2 on myeloid cells, 
using DCs as a model. I will primarily concentrate on the fact that CLEC-2 is a 
dectin-1-like receptor, thus allowing Syk signalling and modulation of gene 
induction. I will use a system to study the agonistic activity of different CLEC-2 
agonists and study its consequences in terms of signalling and function. 
4.2 Rhodocytin as a CLEC-2 agonist 
 The snake venom toxin rhodocytin was the first reported agonist for 
CLEC-2 function, inducing a strong Syk-dependent signalling and platelet 
aggregation (Suzuki-Inoue, Fuller et al. 2006); therefore I decided to test it as a 
selective CLEC-2 agonist able to induce cytokine production by DCs.  
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The analysis of cytokine production via Myd88 or Syk pathways can 
indicate the ability of an agonist to activate the TLR or the CLR family. As 
shown on figure 4.1A, the stimulation of BMDCs with the dectin-1 agonist 
curdlan leads to TNF production on WT DCs and Myd88-deficient (Myd88-/-) 
DCs, but not on Syk-deficient (Syk-/-) DCs. Additionally, the TLR4 agonist LPS 
induce TNF production on WT and Syk-/- DCs but not on Myd88-/- DCs. 
Despite no dose response was observed, LPS at 10 ng/ml is already at 
saturating levels (Fig.4.1A). To test rhodocytin-dependent DC activation, I 
incubated increasing amounts of rhodocytin with WT, Syk-/- or Myd88-/- DCs 
and measured IL-10, TNF and IL12/IL23p40. Dectin-1-Syk signalling in DCs 
induces such cytokines (Rogers, Slack et al. 2005; LeibundGut-Landmann, 
Gross et al. 2007). As observed on figure 4.1B, rhodocytin induced increased 
production of these cytokines. Nevertheless, such production was severely 
impaired on Myd88-/- DCs, suggesting that rhodocytin is inducing cytokine 
production via TLRs. Moreover, Syk-/- DCs were not impaired on the production 
of these cytokines, supporting the notion that rhodocytin is not inducing cytokine 
production via Syk signalling.  
Rhodocytin was demonstrated to bind CLEC-2 and induce Syk-
dependent signalling on platelets and B cell line (Suzuki-Inoue, Fuller et al. 
2006; Fuller, Williams et al. 2007), thus I decided to further characterise 
rhodocytin as a CLEC-2 agonist of gene induction. Rhodocytin selectivity was 
tested with the generation of a gain of function assay, exploiting the ability of 
CLEC-2 to signal to downstream function by its intracellular hemITAM motif 
(tyrosine 7 of YxxL motif) (Fuller, Williams et al. 2007). This assay consist of 
expressing CLEC-2 (WT) or tyrosine-mutant CLEC-2 (Y7F) on the mouse B cell 
line LK (expression levels shown on figure 4.1C right). I chose LK cells because 
of their ability to produce cytokines, express an intact Syk signalling pathway 
and their previous use to study dectin-1 signalling (Rogers, Slack et al. 2005). 
The incubation of LK CLEC-2 WT cells with rhodocytin induced increased 
production of IL-2 (fig.4.1C). Furthermore, the co-treatment of LK cell with the 
TLR4 agonist LPS increased the production of this cytokine, reminiscent of 
reports showing collaboration of dectin-1 and TLR signalling (Gantner, 
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Simmons et al. 2003; Dennehy et al. 2008). However, the treatment with high 
amounts of rhodocytin induces IL-2 production on LK CLEC-2 Y7F cells at 
similar levels of LPS, indicating that my rhodocytin preparation is likely to be 
contaminated with a TLR agonist. The ability of low amounts, but not high 
amounts, of rhodocytin to collaborate with TLR agonist also suggests that 
rhodocytin is triggering multiple receptors.  
In conclusion, rhodocytin is able to act as a CLEC-2 agonist and 
suggests that CLEC-2 is likely to collaborate with TLRs to induce increased 
cytokine production. However, rhodocytin preparations also activate TLRs and 
therefore are not a suitable tool to selective trigger CLEC-2 and study its 
function in myeloid cells. 
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Figure 4.1 Rhodocytin triggers cytokine production via multiple receptors 
(A) C57Bl/6J (WT), Myd88-/- or Syk-/- GMCSF BMDC were incubated for 18 hours in 
culture medium (control) or the indicated concentrations of curdlan and LPS. TNF was 
measured in the supernatants by ELISA. (B) WT, Myd88-/- or Syk-/- GMCSF BMDC 
were incubated for 18 hours with indicated amounts of rhodocytin. IL-10, TNF and 
IL12/IL23p40 were measured in the supernatants by ELISA. (C) 1x105 LK CLEC-2 
WT or Y7F were cultured for 18 hours in culture medium (control) or with the indicated 
concentrations of rhodocytin, LPS or 1µg/ml of soluble anti-mouse IgG (anti-BCR). 
Right panel shows an anti-CLEC-2 staining of LK CLEC-2 WT and Y7F. IL-2 was 
quantified in the supernatants by ELISA. Data are means ± SEM of duplicate wells of at 
least three independent assays. 
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4.3 Study of Podoplanin as stimulator of gene induction by 
DCs 
CLEC-2 was reported to have two different agonists, the snake venom 
toxin rhodocytin and the endogenous glycoprotein PDPN (Suzuki-Inoue, Kato et 
al. 2007). As rhodocytin did not show to be a selective CLEC-2 agonist in 
myeloid cells, I decided to test the role of PDPN. 
To evaluate the potential of cells expressing PDPN to act as a CLEC-2 
agonist, I co-cultured PDPN-expressing cells with LK cells expressing CLEC-2 
WT or Y7F with or without LPS. I chose to use LK PDPN cells because it only 
binds to CLEC-2 when ectopically expressing PDPN (figure 3.6B). Increased IL-
2 amounts were observed on co-cultures with CLEC-2 WT cells, suggesting 
that PDPN-expressing cells can act as agonist of CLEC-2 (fig.4.2A).  
Based on that, I cultured one LK or LK PDPN cell for each BMDC on 
culture. The quantification of cytokine production after overnight co-culture 
showed no differences to co-cultures of LK or LK PDPN with BMDCs. 
Furthermore, no differences on the production of IL-10, TNF or IL-12/IL-23p40 
were observed when the co-cultures were treated with different concentration of 
LPS (fig.4.2B). This result suggests that PDPN-expressing cells are not major 
stimulators or modulators of IL-10, TNF or IL12/IL23p40 production.  
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Figure 4.2 Cells expressing PDPN are CLEC-2 agonists but do not stimulate 
cytokine production by DCs 
(A) 1x105 LK CLEC-2 WT or Y7F were cultured for 18 hours on culture medium (0) or 
with indicated numbers of LK PDPN with or without 1µg/ml of LPS. (B) 1x105 
GMCSF BMDCs were cultured with 1x105 LK PDPN cells and indicated amounts of 
LPS for 18 hours. Cytokines were measured on the supernatants by ELISA. Data are 
means ± SEM of duplicate wells of at least three independent assays. Unpaired t test 
was performed on all the samples and statistical differences (p<0.05) between CLEC-2 
WT+LPS and CLEC-2 Y7F+LPS are indicated by * while statistical differences 
between CLEC-2 WT and CLEC-2 WT+LPS is indicated with +. 
 
 
 
To avoid the use of cells expressing PDPN and exclude multiple receptor 
triggering, the ideal scenario would be to incubate DCs with PDPN protein and 
then measure cytokine production. For this, I made use of concentrated 
supernatant from PDPN.Fc-secreting mammalian cells on wells coated with 
Fab2 anti-human IgG. I cultured DCs on these wells with increasing amounts of 
LPS. AS the purification of Fc-tagged proteins involves flow through columns of 
microbe-derived protein A and elution with acid buffer I decided to capture 
PDPN.Fc on the plate and avoid a possible contamination or degradation of 
PDPN.Fc during purification. As shown on figure 4.3A, the incubation of LK 
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CLEC-2 WT cell on PDPN.Fc-coated wells leads to increased IL-2 amounts that 
are not observed with CLEC-2 Y7F LK cells or control stimulations (dectin-1.Fc-
coated wells). Furthermore, it shows that LPS increased IL-2 production 
induced by PDPN.Fc by PDPN.Fc. This indicates that PDPN.Fc can induce 
CLEC-2 signalling in LK cells over expressing the receptor and that PDPN.Fc-
coated wells are suitable for inducing this signalling. Thus I sought to use the 
same system to stimulate DCs. The incubation of BMDCs in PDPN.Fc-coated 
wells did not lead to production of IL-10, TNF or IL-12/IL-23p40 or modulated 
LPS-induced cytokine production (fig.4.3B). In conclusion, PDPN can act as a 
CLEC-2 agonist in LK cells over expressing CLEC-2, but not in DCs. 
 
Figure 4.3 No effects of PDPN on gene induction by DCs 
(A) 1x105 LK CLEC-2 WT or Y7F were cultured for 18 hours with or without 
increasing amounts of LPS in wells coated with Fab2’ anti-human IgG and culture 
medium (control) or supernatants containing PDPN.Fc or dectin-1.Fc. ELISA. (B) 
GMCSF BMDCs were culture as in (A). All cytokines were measured by ELISA. Data 
are means ± SEM of duplicate wells of at least two independent assays. Statistical 
Unpaired t test was performed in all samples and * indicates statistical differences 
(p<0.05) between dectin-1.Fc and PDPN.Fc. 
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4.4 Anti-CLEC-2 monoclonal antibody as agonist of CLEC-2 
Several monoclonal antibodies against CLRs have been used as 
selective agonists to study responses induced by these receptors (Caparrós et 
al. 2006; Chen 2006; Suzuki-Inoue, Fuller et al. 2006; Röck, Schneider et al. 
2007; Chen, Lin et al. 2008; Robinson, Osorio et al. 2009). Moreover, polyclonal 
anti-human CLEC-2 antibodies have been used as agonists to trigger CLEC-2 
signalling (Suzuki-Inoue, Fuller et al. 2006). Based on these findings, I sought 
to determine if anti-CLEC-2 mAb was able to induce gene changes on DCs. To 
do so, I cultured FLT3L BMDCs that are considered to be representative of all 
DCs subsets found in mouse spleen (Xu et al. 2007). The culture of FLT3L 
BMDC on plates coated with anti-CLEC-2 mAb or an isotype-matched antibody 
and measured IL-10 and IL12/IL23p40 after overnight incubation. No cytokine 
was observed on the supernatants upon this treatment. However, when DCs 
were cultured on anti-CLEC-2-coated wells, but not on isotype-matched-coated 
wells, in the presence of LPS or Pam3Cys (TLR2 agonist), an increased 
production of IL-10 was observed (fig.4.4A). Noteworthy, anti-CLEC-2 treatment 
of BMDCs increased the production of IL-10 at all concentrations of TLR 
agonists tested. Remarkably, no differences on the production of IL-12/IL-23p40 
were observed, indicating that anti-CLEC-2 treatment was inducing the 
modulation of certain genes only (fig.4.4A). This indicates that anti-CLEC-2 
induced a qualitative change rather than a quantitative change of TLR 
responses by DCs. 
Antibodies can induce increased IL-10 production together with LPS 
treatment by engaging Fc receptors (Gerber and Mosser 2001). Even though 
the isotype-matched control mAb treatment did not induce increased IL-10 
production, I decided to design an experiment to rule out the possibility that the 
anti-CLEC-2 mAb treatment was engaging Fc receptors. I generated anti-
CLEC-2 and control Fab (chapter 2, section 2.4.4) to make sure that the 
stimulus for increased IL-10 production was coming by signalling mediated by 
CLEC-2 and not from Fc triggering. The incubation of BMDCs on wells coated 
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with anti-CLEC-2 Fab and LPS led to an increased production of IL-10, but not 
of IL-12/IL-23p40 (fig.4.4B). The DCs cultured on uncoated or wells coated with 
control Fab did not show any difference on the production of IL-10 or IL-12/IL-
23p40 (fig.4.4B). Overall, this experiment indicates that CLEC-2 cross-linking 
can modulate TLR responses on DCs. Furthermore, no changes on IL-6 and 
TNF were observed on samples treated with LPS, LPS and anti-CLEC-2 Fab 
and LPS and control Fab (data not shown). 
 
Figure 4.4 Anti-CLEC-2 modulates TLR-induced cytokine production 
(A) 1x105 FLT3L BMDCs were culture for 18 hours on wells coated with isotype or 
anti-CLEC-2 mAb with increasing amounts of LPS (left) or Pam3CSK4 (right). (B) 
1x105 FLT3L BMDCs were cultured on wells coated with control or anti-CLEC-2 Fab 
for 18 hours in the presence of increasing amounts of LPS. (C) GMCSF BMDCs were 
cultured as in B. (D) Raw 264.7 cells were cultured as in B. All cytokines were 
quantified on supernatants by ELISA. Data are means ± SEM of duplicate wells of at 
least three independent assays. 
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To exclude the possibility that CLEC-2 modulation of TLR response was 
observed only with a specific DC model, I repeated the experiments using 
GMCSF BMDC instead of FLT3L BMDC. Interestingly, on GMCSF BMDC the 
ligation of CLEC-2 on the presence of LPS induced increased IL-10 and 
reduced IL-12/IL-23p40 production (fig.4.4C). Moreover, the same anti-CLEC-2 
Fab and LPS treatment induced increased IL-10 production by the macrophage 
cell line RAW 264.7 (fig.4.4D). Collectively, these data suggests that CLEC-2 
ligation by mAbs can modulate TLR responses in different myeloid cell models 
(FLT3L BMDC, GMCSF BMDC and RAW 264.7) with a reproducible 
phenomenon of increased IL-10 production. 
4.5 Molecular requirements for CLEC-2 modulation of LPS 
responses 
As anti-CLEC-2 ligation on different myeloid cells was able to modulate 
TLR responses, I sought to determine which molecular requirements on CLEC-
2 and downstream of CLEC-2 were necessary for this modulation. 
 Here, I made use of LK cells expressing CLEC-2 (WT) or the hemITAM 
mutant CLEC-2 (Y7F), to determine the need for CLEC-2 intracellular tyrosine 
on the modulation of LPS responses. The culture of these LK cells on wells 
coated with anti-CLEC-2 or control Fab on the presence of LPS led to increased 
IL-10 and IL-2 production only when the cells were CLEC-2 WT and treated 
with anti-CLEC-2 Fab (figures 4.5A and 4.5B). Importantly, LK CLEC-2 Y7F and 
WT cells were equally able to produce IL-2 and IL-10 when stimulated in a 
CLEC-2-independent manner (anti-BCR antibody). Additionally, no difference 
on the expression of CLEC-2 WT or Y7F was observed on the surface of LK 
cells (fig.4.5D), indicating that CLEC-2 hemITAM is necessary for modulation of 
LPS response and increased production of IL-10. These data again confirm that 
the phenomenon is not an artefact from Fc receptor cross-linking. 
Noteworthy, LK cells are able to produce IL-10 once treated with LPS, 
but CLEC-2 ligation was able to signal to an increased production of IL-10 
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(fig.4.5A). Moreover, CLEC-2 ligation and LPS treatment induced increased IL-
2 production by CLEC-2 WT cell, but not CLEC-2 Y7F cells (fig.4.5B), on a 
phenomenon similar to the treatment of these cells with rhodocytin and PDPN 
(fig.4.2 and 4.3). Seeing that expression of CLEC-2 on LK cells confer them the 
ability to respond to CLEC-2 ligation with the production IL-2, I decided to use 
these cells to compare the agonistic activity of different CLEC-2 ligands. As 
shown on figure 4.5C, LK CLEC-2 WT cells were able to produce low levels of 
IL-2 when stimulated with anti-CLEC-2 antibodies (the rat IgG2b or the rat IgM) 
or PDPN.Fc or PDPN T34A.Fc. Noteworthy, the anti-CLEC-2 (IgG2b) was the 
best for inducing IL-2 production without LPS, suggesting that it might be the 
best to cross-link CLEC-2, inducing downstream signalling and modulation of 
LPS response. 
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Figure 4.5 CLEC-2 hemITAM is required for modulation of IL-10 production 
(A) and (B) 1x105 LK CLEC-2 WT or Y7F were cultured for 18 hours on wells coated 
with control or anti-CLEC-2 Fab or 1µg/ml of soluble anti-mouse IgG (anti-BCR) in the 
presence of increasing amounts of LPS. (C) LK cell clones were cultured as in A on 
wells coated with anti-CLEC-2 IgG2b or IgM, PDPN.Fc or PDPN T34A.Fc, anti-BCR 
was added soluble at 1µg/ml. LPS was added at 1µg/ml to the indicated groups. Data 
are means ± SEM of duplicate wells of at least three independent assays. (D) CLEC-2 
staining of LK CLEC-2 WT or Y7F cells. 
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In order to understand how anti-CLEC-2 mAb ligation modulates the TLR 
response, I decided to evaluate the induction of downstream signalling 
emanating from CLEC-2. To do so, I cultured FLT3L BMDC on wells coated 
with anti-CLEC-2 or isotype mAb and analysed the activation of downstream 
signalling molecules. I analysed the protein lysate on a western blot, probing 
the membrane with an antibody that detects phosphorylated tyrosine. As 
observed on figure 4.6A, CLEC-2 ligation on DCs by anti-CLEC-2 mAb, but not 
an isotype-matched mAb, induces the phosphorylation of, at least, two different 
proteins: one of approximately 70Kda and another of around 20Kda. Given that 
CLEC-2 was demonstrated to be a Syk-coupled receptor and Syk is a 72Kda 
protein that is tyrosine-phosphorylated when active (Mócsai, Ruland et al. 
2010), I decided to evaluate if anti-CLEC-2 was inducing Syk activation on DCs. 
When I probed the western blot with a specific anti-phosphorylated Syk 
antibody, I observed that phosphorylated (active) Syk is present only on cells 
treated with anti-CLEC-2 and not with isotype mAb (fig.4.6B). Total Syk 
(inactive or active) is present at very similar levels on all samples tested, 
indicating that the difference on the activation of Syk is due to signalling and not 
to differential protein content (fig.4.6C). Several proteins of 20KDa can be 
tyrosine phosphorylated and I did not pursue the identity of this proteins, 
nevertheless an attractive hypothesis is that this might correspond to caveolin-1 
and CLEC-2 is localised to caveolae. 
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Figure 4.6 Anti-CLEC-2 induces tyrosine phosphorylation and Syk activation in 
DCs 
FLT3L BMDCs were centrifuged on wells coated with isotype or anti-CLEC-2 mAb 
and incubated at 37oC for the indicated time before lysis. Proteins were separated by 
non-reducing denaturing gels and analysed by western blot with (A) mouse anti-
phospho tyrosine (4G10 antibody) (B) rabbit anti-phospho Syk (Tyr352) or (C) rabbit 
anti-Syk. 
 
 
 
To test if CLEC-2 signalling can induce Ca2+ flux by anti-CLEC-2 mAb 
cross-linking I expressed CLEC-2 WT or Y7F on B3Z cells expressing Syk 
(B3Z.Syk cells), and I loaded these cells with indo-1, a dye that changes 
fluorescence in a Ca2+-binding dependent manner. Thus, FACS acquisition of 
indo-1-loaded cells can immediately indicate the changes on the ratio between 
indo-1 free Ca2+ and bound Ca2+. The method that I chose to test anti-CLEC-2 
cross-linking on cell suspension was to stain the indo-1-loaded cells with the 
biotinylated anti-CLEC-2 antibody, and induce the mAb cross-linking by adding 
streptavidin (protein with four biotin binding sites). Hence, the addition of 
streptavidin can cross-link anti-CLEC-2 biotinylated mAb to induce signalling. 
As shown on figure 4.7A, the addition of streptavidin to anti-CLEC-2-stained 
CLEC-2 WT cells induced a strong calcium flux on these cells. Remarkably, 
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CLEC-2 WT cells stained with an isotype antibody, or CLEC-2 Y7F cells stained 
with anti-CLEC-2 did not increase cytoplasmic calcium upon antibody cross-
linking by streptavidin addition. Moreover, both CLEC-2 WT and Y7F cells 
expressed similar levels of CLEC-2 on their surface and fluxed calcium upon 
ionomycin treatment (fig.4.7A bottom and 4.7C). As shown, ionomycin induced 
normal calcium flux on CLEC-2 WT and Y7F cells, indicating that CLEC-2 Y7F 
cells calcium flux deficiency is only for CLEC-2 specific stimulation. 
 
 
Figure 4.7 CLEC-2 triggering leads to calcium flux and NFAT activation on a 
hemITAM dependent manner 
(A) 2x106 B3Z.Syk CLEC-2 WT or Y7F cells were loaded with indo-1 and the calcium 
flux was analysed by FACS. (B) 1x105 B3Z.Syk CLEC-2 WT or Y7F cells were 
cultured for 18 hours with 1µg/ml of ionomycin or on wells coated with of isotype or 
anti-CLEC-2 mAb. NFAT induction was quantified by measuring LacZ activity as for 
the ligand screen. (C) B3Z.Syk CLEC-2 WT and B3Z.Syk CLEC-2 Y7F were stained 
with anti-CLEC-2-Alexa647 or isotype-matched-Alexa647.  
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Intracellular calcium fluxing is able to mediate activation of the 
calcineurin-NFAT pathway. To quantify NFAT activation by CLEC-2 I quantified 
LacZ activity induced by the NFAT-LacZ reporter stably expressed on B3Z cells 
(described in chapter 3). As shown on figure 4.7B, plate-coated anti-CLEC-2 
antibody strongly induced the NFAT reporter on B3Z.Syk expressing CLEC-2 
WT, but not Y7F. Furthermore, the treatment with an isotype-matched control 
antibody did not activate the reporter. Treatment with ionomycin induced normal 
NFAT activation on cells expressing CLEC-2 WT or Y7F. Collectively, this data 
demonstrate the need for the hemITAM of CLEC-2 for calcium flux and NFAT 
activation in response to receptor cross-linking. 
Using NFAT activation as a parameter, I compared different CLEC-2 
agonists for their ability to activate CLEC-2. I used B3Z.Syk CLEC-2 cells to test 
the ability of anti-CLEC-2, rhodocytin or PDPN-expressing cells to activate 
NFAT (figure 4.8). The anti-CLEC-2 mAb proved to be the best stimulator of 
NFAT activation. Intriguingly, B3Z.Syk CLEC-2 WT cells showed an increased 
basal activation of NFAT (compare control on different cells on figure 4.8), 
suggesting a ligand independent activation of NFAT on a CLEC-2 hemITAM 
dependent way. 
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Figure 4.8 Comparison of NFAT activation by CLEC-2 agonists 
(A) 1x105 B3Z.Syk CLEC-2 WT or Y7F cells were cultured for 18 hours with 1µg/ml 
of ionomycin, on wells coated with anti-CLEC-2 mAb, co-culture with 1x105 RMAS 
cells expressing PDPN (RMAS.PDPN) or rhodocytin. NFAT induction was quantified 
by measuring LacZ activity. (B) CLEC-2 expression on B3Z clones was determined by 
FACS with isotype or anti-CLEC-2 biotinylated staining. 
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Altogether, the data show that CLEC-2 triggering can induce Ca2+ flux 
and NFAT activation in hemITAM-dependent fashion indicating that a CLEC-2-
Syk-NFAT axis pathway might be responsible for CLEC-2 modulation of TLR 
responses.  
As mentioned previously, dectin-1 signalling via Syk was demonstrated 
to collaborate with TLR signalling for induction of cytokines (Dennehy, Ferwerda 
et al. 2008) (Gantner, Simmons et al. 2003). Nevertheless, a Syk-independent 
Raf1 signalling has also been implicated on dectin-1 modulation of TLR 
responses (Gringhuis, den Dunnen et al. 2009). Curiously, the CLR DC-SIGN 
was reported to modulate TLR-induced IL-10 production via Raf1-dependent 
signalling (Gringhuis, den Dunnen et al. 2007). Therefore, I analysed the 
requirement for Raf1 and Syk in how CLEC-2 signalling modulates IL-10 
production induced by TLR agonists. Firstly, I decided to examine if Raf1 is 
involved on the increased IL-10 production induced by LPS and CLEC-2 
triggering. As shown on figure 4.9A, Raf1 inhibitor did not impair the production 
of IL-10 induced by anti-CLEC-2 and LPS, suggesting that this pathway is not 
involved on CLEC-2 modulation of TLR responses. Consequently, I decided to 
evaluate the involvement of Syk on this modulation. As shown on figure 4.9B 
the incubation of GMCSF BMDC with LPS and anti-CLEC-2 Fab induced 
increased IL-10 and reduced IL-12/IL-23p40 production. The pharmacological 
inhibition of Syk significantly impaired the CLEC-2-induced increase of IL-10 in 
the presence of LPS, whilst it had no effect on IL-12/IL-23p40 production (figure 
4.9B). Accordingly, anti-CLEC-2 could not induce increased IL-10 production in 
Syk-/- DCs, whilst it greatly increased the IL-10 production by WT DCs. The 
Syk-/- DCs were not impaired on the production of IL-12/IL-23p40, as they 
produced increased amounts of this cytokine when compared to their WT 
counter-part (figure 4.9C). In fact, Syk-/- DCs have been reported to hyper-
produce IL-12/IL-23p40 upon TLR stimulation (Hamerman et al. 2005). 
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Figure 4.9 IL-10 modulation by CLEC-2 requires Syk and calcineurin, but not 
Raf1 
(A) FLT3L BMDCs were cultured for 18 hour with or without increasing amounts of 
LPS on wells coated with isotype or anti-CLEC-2 mAb. Raf1 inhibitor (GW5074) was 
used at 1µM. (B) GMCSF BMDCs were cultured for 18 hours with 10ng/ml of LPS on 
wells uncoated (control) or coated with control or anti-CLEC-2 Fab and Syk inhibitor 
(piceatannol) used at the indicated concentrations. (C) FLT3L BMDC from C57BL/6J 
mouse (WT) or Syk-/- were cultured as in A. (D) GMCSF BMDCs were culture as in 
(B) using calcineurin inhibitor (FK506) at the indicated concentrations. Cytokines were 
quantified on the supernatants by ELISA. Unpaired t-test was performed for statistical 
differences. *p<0.05, **p<0.01 
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As CLEC-2 triggering was able to induce Ca2+ flux and NFAT activation 
in a hemITAM-dependent way, I decided to examine if this pathway could be 
involved in CLEC-2 modulation of LPS. I made use of FK506, a strong 
immunossupressor that blocks NFAT activation (dephosphorylation) by 
inhibiting calcineurin (Liu et al. 1991). Strikingly, calcineurin inhibition by FK506 
strongly reverted the anti-CLEC-2 Fab-induced IL-10 production in the presence 
of LPS (figure 4.9D). In line with the inhibition of Syk, calcineurin inhibition did 
not change the production of IL-12/IL-23p40 (figure 4.9D), indicating that the 
drug is not toxic, at the tested concentrations. Collectively, these experiments 
indicate that Syk and calcineurin, but not Raf1, are required for CLEC-2 
signalling to modulate LPS responses. 
4.6 Genome-wide analysis of CLEC-2 modulation of LPS 
response 
To investigate different genes that CLEC-2 signalling can modulate I 
decided to do a microarray analysis. This approach allows me to do a genome-
wide screen of genes by monitoring mRNA levels. Therefore I can extend my 
findings to genes different from IL-10 and IL12/IL23p40. 
While the genome-wide screen assay can be easily performed, the 
design of the experiment is crucial for the subsequent analysis. As mRNA levels 
change during time, it is very important to analyse them at different time points. 
For this, I treated GMCSF BMDC with control or anti-CLEC-2 Fab and 10ng/ml 
of LPS for 3 or 6 hours prior to RNA extraction. As observed, CLEC-2 triggering 
greatly increased the induction of il2, whilst mildly changed the induction of il10 
observed at 3 hours. In contrast, il2 mRNA was barely induced at 6 hours, while 
the production of il10 mRNA even increased (figure 4.10A). Therefore, this 
indicate that CLEC-2 can modulate LPS response at the mRNA level opening 
the perspective to a broadly analysis of genes modulated by CLEC-2.  
The microarray assay was performed using RNA extracted from 3 and 6 
hours GMCSF BMDC culture with LPS on wells coated with control or anti-
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CLEC-2 Fab. The experiment was done twice and the samples were pooled to 
reduce variability. Therefore, I analysed mRNA samples from 2 independent 
experiments stimulated for different time points with LPS and anti-CLEC-2 Fab 
or control Fab (fig.4.10B). 
 
 
 
 
Figure 4.10 Genome-wide analysis of anti-CLEC-2 modulation of LPS responses 
(A) GMCSF BMDC were culture for 3 or 6 hours with 10ng/ml of LPS on wells coated 
with control or anti-CLEC-2 Fab before RNA extraction. The mRNA induction of il2 
and il10 were quantified by qPCR. (B) Scheme representing the samples used to 
perform the microarray. Cells were treated as in (A) and RNA was probed with 
Affymetrix microarray GeneChip mouse genome 430 2.0. 
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For the analysis of pathways and responses triggered by anti-CLEC-2 
and LPS treatment of DCs I considered genes that were changed 2-fold or 
more, discarding all the other genes. These genes, in collaboration with the 
Bioinformatics & Biostatistics Service, were analysed clustering according to a 
database of genes. This gene database characterise genes according to its 
published functions and ontology (Ekins et al. 2007). 
Analysis performed using 274 genes differentially modulated by CLEC-2 
at either 3 or 6 hours indicate a gene program that signalling downstream of 
CLEC-2 can elicit. The genes found differentially induced by CLEC-2 were 
genes involved on pathways of immune responses, resembling NFAT and 
PGE2 signalling (fig.4.11A). Appropriately, my results indicate that CLEC-2 
signalling via its hemITAM is able to induce calcium signalling that activates 
NFAT. Furthermore, using calcineurin inhibitors NFAT signalling was suggested 
to be implicated on the increased production of IL-10 induced by CLEC-2 and 
LPS. Interestingly, dectin-1 signalling also induces NFAT and PGE2 signalling 
(Goodridge, Simmons et al. 2007). The genes induced by CLEC-2 were also 
related to processes of inflammation/TREM-1 signalling and chemotaxis. 
Knowingly, the Syk-coupled receptor TREM-1 modulates LPS responses and is 
involved on endotoxic shock (Bouchon et al. 2001) and Syk signalling was also 
implicated on integrin activation and migration (Schymeinsky et al. 2006). 
The heatmap, represented in figure 4.11B, shows a list of significantly 
induced genes involved on the pathway related to immune response and NFAT 
signalling. As shown, CLEC-2 differentially induces the expression of two NFAT 
members (NFATc2 and NFATc1), signalling proteins leading to NFAT activation 
(LAT and Rcan1) and cytokines (IL-2 and IL-10).  
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Figure 4.11 CLEC-2 modulates LPS inducing NFAT signalling 
(A) The 274 genes found at least 2-folds differentially expressed upon anti-CLEC-2 Fab 
treatment were computationally compared with available data regarding these genes 
pathways and processes. Immune responses genes involved on NFAT and PGE2 
signalling pathways were found statistically enriched on these lists. Inflammation and 
chemotaxis were found to be statistically different processes that are modulated by 
genes found changed by CLEC-2 triggering. (B) Heatmap of genes involved on 
Immune responses – NFAT signalling. * represents genes detected by different probes. 
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Overall, the microarray clustering gave me a glimpse of processes that 
CLEC-2 signalling could modulate. Besides, this opened up perspectives for 
more refined analysis of genes found changed by microarray. Thus I decided to 
investigate the ability of CLEC-2 to induce certain genes without LPS co-
treatment. Therefore I cultured GMCSF BMDC for 3 hours on wells coated with 
control or anti-CLEC-2 Fab with or without 10ng/ml of LPS, and then obtained 
RNA. After quantitative PCR analysis I observed that the induction of NFAT-
inducible genes egr3, il2 and il10 by anti-CLEC-2 Fab did not need LPS. 
However, LPS co-treatment greatly increased the induction of il2 and il10 
(figure 4.12A and B). Interestingly, the induction of egr3 by CLEC-2 triggering 
was diminished by LPS co-treatment, although the difference between control 
and anti-CLEC-2 Fab treated with LPS remained the same (figure 4.12B). The 
analysis of induction of il33 revealed that CLEC-2 triggering induced very little 
amounts of il33 mRNA, although when LPS is added together a great induction 
is observed (figure 4.13A). Several other genes that were not found different by 
microarray analysis were tested to confirm the microarray result. I found 
negligible changes on the induction of tnf, ccl1, ccl12 and il12b by CLEC-2 
triggering. Moreover, the addition of LPS greatly increased the induction of 
these genes and CLEC-2 triggering did not show any effect (figure 4.12A and 
B). Additionally, I selected perp as gene that did not show any change by 
microarray to further validate the assay. This comparison showed that LPS 
and/or CLEC-2 signalling did not affect perp expression (figure 4.12A). 
Basically, the microarray analysis supported previous findings that 
CLEC-2 triggering can induce NFAT-dependent genes. Furthermore, it shows 
that CLEC-2 signalling can act independent of TLR signalling to induce genes 
and collaborate with TLR signalling to increase gene expression at mRNA level. 
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Figure 4.12 Analysis of CLEC-2 regulation of gene expression 
GMCSF BMDCs were culture on wells coated with control or anti-CLEC-2 Fab on the 
presence or absence of 10ng/ml of LPS. After 3 hours RNA were extracted and qPCR 
analysis was performed to quantify gene changes. (A) il12b and il10 gene changes were 
compared in relation to the constitutive HPRT expression. (B) gene changes were 
compared to GAPDH expression. 
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4.6.1 Summary and discussion 
CLEC-2 has two reported agonists: the snake venom toxin rhodocytin and 
the endogenous protein podoplanin. The outcome of the interaction of CLEC-2 
with these two agonists had been studied using platelets. Those studies 
revealed that CLEC-2 signalling via its intracellular tyrosine could couple to Syk 
signalling and mediated platelet aggregation (Ozaki et al. 2009). Herein, I 
showed that CLEC-2 signalling and function could be studied in myeloid cells by 
selective triggering by anti-CLEC-2. Moreover, CLEC-2 signalling induced Ca2+ 
flux and NFAT activation in a hemITAM-dependent fashion. The functional 
outcome of this signalling was observed in the increased production of IL-10 by 
DCs and macrophages co-treated with LPS. Finally, a microarray analysis 
showed that CLEC-2 modulation of LPS induces genes involved in NFAT 
signalling in immune responses. 
Firstly I tried to validate the described CLEC-2 agonists. Analysing 
cytokine production by DCs treated with rhodocytin I observed increased 
cytokine production. However, this was largely Syk-independent (see figure 
4.1), suggesting a CLEC-2-independent cytokine production. Rhodocytin is a 
tetramer that is reported to trigger multiple receptors (Suzuki-Inoue et al. 2001; 
Suzuki-Inoue, Fuller et al. 2006) and is purified from the snake venom through 
different steps and buffers (Eble et al. 2001), thus it is likely that it can get 
contaminated by either bacterial cell wall components (LPS and lipoproteins, 
TLR4 and TLR2 agonists) and/or bacterial DNA (TLR9 agonist). However, when 
cytokine production by Myd88-/- DCs is analysed there was still a measurable 
amounts of TNF and IL-12/IL-23p40, suggesting that rhodocytin might induce 
cytokine production by CLEC-2 and independently of TLR signalling. 
Accordingly, rhodocytin induced cytokine production on cell lines expressing 
CLEC-2 WT, but not CLEC-2 Y7F. Therefore, the cytokine measured in WT 
DCs might be a product of both Syk and Myd88 signalling, suggesting 
collaboration between CLEC-2 and TLR. In fact, other CLRs like dectin-1 
(Dennehy, Ferwerda et al. 2008) and DC-SIGN (Caparrós, Munoz et al. 2006) 
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have been already reported to collaborate with TLR to increase cytokine 
production. 
As my rhodocytin preparation triggered TLRs, I decided to examine the 
regulation of gene expression by DCs treated with more selective CLEC-2 
ligands, like anti-CLEC-2 mAb and the endogenous CLEC-2 agonist PDPN. 
PDPN treatment of DCs did not induce cytokine production by DCs (see figures 
4.2 and 4.3), while anti-CLEC-2 mAb induced different NFAT-dependent genes. 
This was curious, as PDPN was demonstrated to mediate platelet aggregation 
on a CLEC-2 dependent way (Suzuki-Inoue, Kato et al. 2007). However, 
platelets express higher levels of CLEC-2 than DCs. Moreover, PDPN.Fc was 
able to induce cytokine production on LK cells overexpressing CLEC-2, 
suggesting that CLEC-2 surface expression might play a role on the 
downstream function. However, comparison of agonistic activity of anti-CLEC-2 
and PDPN.Fc on different cell lines showed that anti-CLEC-2 was better 
stimulator of CLEC-2 than PDPN.Fc (see figures 4.5C and 4.8A). However, my 
preparation of PDPN.Fc had very low amounts produced on the supernatant, 
thus the poor agonistic activity can be due to the degree of CLEC-2 stimulation 
and my inability to better stimulate CLEC-2 with PDPN.Fc. 
ITAM signalling is commonly regulated by ITIM signalling (Ravetch and 
Lanier 2000), thus it is feasible that DCs differentially express regulatory 
mechanisms that does not allow PDPN to act as a CLEC-2 agonist on DCs. 
Intriguingly, B3Z.Syk.CLEC-2 WT cells had a higher basal activation of the 
NFAT reporter (figure 4.8A) and were never a homogeneous population (figure 
4.8B). Appropriately, Mori and colleagues revealed that the ITIM signalling 
receptor G6b-B, could inhibit constitutive CLEC-2 activation on cell lines (Mori 
et al. 2008). It will be important to examine the expression of G6b-B on DCs 
and analyse if its knockdown will enable PDPN regulation of gene expression 
on DCs. Moreover, analysis of gene induction by PDPN on DCs deficient of 
tyrosine phosphatases can also give clues of DC regulatory mechanisms of 
CLEC-2 signalling. 
Strikingly, anti-CLEC-2 mAb, compared to rhodocytin and PDPN, proved 
to be the best agonist of CLEC-2 regarding cytokine production and NFAT 
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stimulation (figure 4.5C and 4.8A). Consequently, it induces calcium flux and 
NFAT activation dependent of its hemITAM (figure 4.7). It will be important to 
evaluate the kind of calcium signalling induced by PDPN and anti-CLEC-2 on 
DCs. Tonic calcium signalling is proposed to be inhibitory of TLR signalling, 
whilst transient calcium signalling synergises with TLR signalling. Furthermore, 
the type of calcium signalling is related with the avidity of the ligand-receptor 
pair; low avidity ligands induce tonic calcium stimulation and high avidity ligands 
induce strong transient calcium signalling (Ivashkiv 2008). Thus, it is likely that 
anti-CLEC-2 mAb has higher avidity to CLEC-2 than PDPN.Fc.  
CLEC-2 triggering by anti-CLEC-2 Fab, without LPS, led to induction of 
some NFAT-dependent genes (fig.4.12), which provided a proof of principle that 
signalling downstream of hemITAM-containing receptors is able to regulate 
gene expression. Nevertheless, to formally demonstrate a CLEC-2 selective 
phenomenon this assay would need to be done using Syk-/- and Myd88-/- DCs. 
Undoubtedly, the most remarkable phenomenon of gene regulation by 
CLEC-2 is observed when anti-CLEC-2 is given with LPS. It is possible that 
because LPS increases CLEC-2 expression on myeloid cells, the TLR 
triggering would be needed prior to CLEC-2 triggering only to increase CLEC-2 
expression. Accordingly, CLEC-2 over-expression on LK cells confers then 
ability to regulate gene expression by CLEC-2 ligation without LPS co-triggering 
(fig.4.5C). It will be interesting to over-express, by retroviral transduction, 
CLEC-2 on DCs and evaluate the need for CLEC-2 and TLR co-triggering for 
gene induction.  
It is likely that CLEC-2 activation of NFAT and TLR activation of NFKB 
are simultaneously required for the gene modulation observed (see figure 4.13, 
for a model for CLEC-2 modulation of TLR). IL-10 gene binds to NFAT (Im et al. 
2004) and its production by macrophages has been shown to be dependent of 
NFAT (Goodridge, Simmons et al. 2007). Nevertheless, IL-2 is also an NFAT 
dependent gene (Rao et al. 1997) but it was not observed in the culture 
supernatants of DCs stimulated by anti-CLEC-2 and LPS. Recently, Saraiva 
and colleagues have shown that IL-10 production by T cells requires increased 
ERK activation and IL-12-induced signalling. At the same time, on these 
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assays, T cells produced less IL-2 (Saraiva et al. 2009). Therefore, it is likely 
that increased NFAT activation by induced by anti-CLEC-2 together with IL-12 
and ERK activation induced by LPS differentially induced IL-10 and not IL-2. 
Calcineurin inhibition was shown to increase TNF production 
downstream of TLR signalling (Kang et al. 2007), suggesting that NFAT can 
modulate TLR responses. My finding points to a modulation of TLR signalling 
by a CLEC-2-calcium-calcineurin-NFAT activation on the regulation of IL-10 
production, suggesting that the simultaneous ligation of CLEC-2 and TLR might 
be necessary. Considering that IL-10 can negative regulate TNF production 
(Gérard et al. 1993), it is possible that the increased TNF production observed 
upon calcineurin inhibition is due to diminished IL-10. 
 
 
 
 
Figure 4.13 Proposed model for CLEC-2 modulation of TLR responses 
NFKB activation by TLR and NFAT activation by CLEC-2 lead to augmented production of 
IL-10 and other NFAT-dependent genes (e.g. IL-2, egr3, glucagon, NFATc1, NFATc2) . 
CLEC-2 triggering by anti-CLEC-2 mAb leads to Ca2+ signalling, calcineurin and NFAT 
activation in a hemITAM-dependent manner. 
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Besides the similarities between dectin-1 and CLEC-2 regarding to 
collaboration with TLR and activation of NFAT, they appear to differ on the 
activation of NFκB. I failed to observe any induction of NFκB-dependent genes 
by selective CLEC-2 ligation with mAbs or PDPN, while dectin-1 signalling 
couples to NFκB activation (Leibundgut-Landmann, Groß et al. 2007). The 
activation of NFκB by dectin-1 was demonstrated to be via Card9-Bcl10-Malt1 
(Gross, Gewies et al. 2006). Similarly, Carma1 localisation on lipid rafts couples 
with Bcl10 and Malt1 to activate NFκB on T and NK cells (Gaide et al. 2002; 
Gross et al. 2008). Recently, dectin-1 was shown to localise on lipid rafts upon 
triggering, which was required for optimal dectin-1 signalling and cytokine 
production (Xu, Huo et al. 2009). Consequently, dectin-1 ability to couples to 
NFκB activation might be due to the ability of its agonists to induce lipid raft 
localisation and thus, Card9-NFκB activation. As the induction of calcium 
signalling and NFAT activation does not depend on CARD9 activation I 
hypothesize that anti-CLEC-2 mAb does not activate NFκB due to its inability to 
induce efficient CLEC-2 localisation to lipid rafts and where CARD9 is localised.  
Analysis of genome-wide screen for genes modulated by CLEC-2 during 
LPS treatment considered only genes changed 2-fold or more. Due to the 
limited sample replicates I considered that analysing these genes would be 
more robust. In fact there are many other genes that are changed less that 2-
fold that might play important role in CLEC-2 induced phenomenon.   The gene 
profile analysis pointed to an enrichment of genes involved on pathways of 
NFAT signalling. Besides, the processes of inflammation/TREM1 signalling and 
chemotaxis were found enriched on the genes modulated by CLEC-2 triggering. 
In line with my findings, TREM1 is a receptor that couples to Syk signalling via 
DAP12 (Bouchon et al. 2000) and modulates endotoxic shock responses 
(Bouchon, Facchetti et al. 2001). In addition, a chemotaxis gene induction 
profile was found enriched, which might be suggestive of a role of CLEC-2 on 
migratory processes in DCs. PDPN is expressed in the lungs (Ramirez et al. 
2003), skin (Gomaa et al. 2007), lymphatic endothelium (Schacht, Ramirez et 
al. 2003) and lymph node stroma (Lee, Epardaud et al. 2007) and it is possible 
that CLEC-2 might allow DC migration to these tissues. Significantly, very few 
Chapter 4. Study of CLEC-2 signalling and function on myeloid cells 
 122 
DCs on lymph nodes express CLEC-2 in steady state conditions (figure 3.9B, 
compare isotype/PBS with anti-CLEC-2/PBS), whereas in inflammatory 
conditions many of these DCs express CLEC-2. It is tempting to speculate that 
CLEC-2 expression might define a population of migratory DCs that enter the 
lymph nodes after encountering PDPN on the lymphatic vessels. In fact, Syk 
was involved on migration, as Syk deficiency impaired neutrophils and 
monocytes recruitment to inflamed tissues (Schymeinsky, Sindrilaru et al. 
2006). 
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5.1 Introduction 
Myeloid cells are distributed throughout tissues and perform several 
functions, which include cytokine production, phagocytosis of invading 
microorganisms and activation of adaptive immune responses. All these 
myeloid cell functions are mediated by signals from innate receptors, including 
CLRs (Robinson et al. 2006). Thus, identification of signals and innate 
receptors is of great importance for understanding immune responses. 
The CLR family has several members that are involved on the modulation 
of inflammation and TLR responses, as the case of dectin-1 (Dennehy et al. 
2008), DCAL-1 (CLEC12a) (Chen et al. 2006) and DC-SIGN (Gringhuis, den 
Dunnen et al. 2007). Previously, I showed that CLEC-2 signalling was capable 
of modulating TLR responses in DCs and macrophages, inducing an increased 
production of IL-10 via a Syk-calcineurin dependent mechanism (Chapter 4). 
This implied that CLEC-2 action on myeloid cells could modulate LPS-induced 
inflammation in vivo. Therefore it will be important to evaluate the capacity of 
CLEC-2 to act in vivo to modulate inflammation and to develop models to study 
CLEC-2 function in different cells.  
In this chapter I will describe the development of mouse models to study 
CLEC-2 function on the modulation LPS-induced responses. Besides, I will 
describe the generation of a CLEC-2 (clec1b) conditional KO mouse.  
5.2 Anti-CLEC-2 modulation of LPS-induced inflammation  
Previously, I showed that cross-linking of CLEC-2 could induce 
modulation of TLR signalling, resulting in increased production of IL-10 by 
different myeloid cells (Chapter 4). Therefore, I decided to test if anti-CLEC-2 
administration together with LPS could induce a similar phenomenon in mice. 
So, 3 hours after intra-peritoneal administration of mice with PBS, isotype-
matched or anti-CLEC-2 antibody together or not with LPS, I analysed serum 
amounts of IL-6, IL-10 and TNF. As shown in figure 5.1A, PBS or anti-CLEC-2 
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did not induce any detectable levels of these cytokines. Co-administration of 
anti-CLEC-2 or isotype-matched control antibodies with LPS did not show 
differences on the serum amounts of TNF or IL-6. Strikingly, increased serum 
IL-10 levels were present in mice injected with anti-CLEC-2 and LPS (fig. 5.1A).  
To better characterise the changes on the production of cytokines by 
anti-CLEC-2 and LPS administration, I decided to quantify several inflammatory 
mediators at the site of challenge (peritoneum) as well as systemically (serum). 
So, 3 hours after challenge I obtained peritoneal lavages and sera from mice 
challenged with LPS and anti-CLEC-2 or isotype-matched control antibodies. 
As observed before, IL-10 levels, but not IL-6 or TNF, are increased on the sera 
of mice challenged with anti-CLEC-2 and LPS compared with mice challenged 
with isotype-matched mAb and LPS. Also, different chemokines (MIP1β, KC, 
RANTES, MCP-1 and MIP1α) were quantified and no differences were 
observed on their production (fig.5.1B).  
Analysis of peritoneal lavages revealed a similar observation: increased 
IL-10 in mice treated with anti-CLEC-2 and LPS compared to mice treated with 
isotype-matched mAb and LPS (fig.5.1C). On the other hand, there was 
increased TNF on the peritoneal lavages of mice treated with LPS and anti-
CLEC-2 compared with mice treated with LPS and isotype-matched mAb 
(fig.5.1B). This differential effect on TNF in serum and peritoneum can be 
explained in different ways. Firstly, TNF might be differently modulated by 
CLEC-2 triggering on different cells. For example the triggering of peritoneum 
resident B cells (B1 cells) (Balabanian et al. 2002) by CLEC-2 and LPS might 
induce localised production of TNF. Additionally, CLEC-2 modulation can 
induce a differential recruitment of cells that can produce TNF when stimulated 
with LPS. Another possibility is that CLEC-2 might delay the production of TNF, 
thus production of TNF on the serum is due to the first localised production of 
TNF that happens later. So an increased production of TNF on the serum might 
be observed at later time points. On subsequent experiments I will try to 
examine the production of TNF on the serum on earlier and later time points to 
analyse this possibility. 
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Figure 5.1 Anti-CLEC-2 co-administration increases IL-10 levels induced by LPS 
in vivo 
(A) C57BL6/J mice were injected I.P with PBS, PBS with 300µg of isotype or anti-
CLEC-2 mAb. 20µg of LPS were added to the indicated treatments. Mice were 
sacrificed 3 hours after challenge and serum was obtained. (B) (C) Mice were treated as 
in (A) with LPS. Mice were sacrificed 3 hours after challenge and serum and peritoneal 
lavage were obtained. All inflammatory mediators were quantified by cytometric bead 
array (CBA). Data are means ± SD of at least three mice per group in two independent 
assays. Statistical differences were assessed with Mann-Whitney test. *p<0.05 
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5.3 Characterisation of anti-CLEC-2 modulation of LPS 
responses in vivo 
To further characterise the effect of anti-CLEC-2 in vivo, I tried to analyse 
the levels of different inflammatory mediators after challenging mice with anti-
CLEC-2 or isotype-matched antibodies and different amounts of LPS. With all 
LPS amounts there was increased levels of IL-10 induced by anti-CLEC-2 
treatment, compared to the isotype-matched treatment (fig.5.2). In contrast, at 
the highest and lowest LPS amounts (40µg and 10µg, respectively), an 
increased production of IL-6 was observed on mice challenged with anti-CLEC-
2, while a diminished production of MIP-1α was observed. There was also a 
sharp difference on the production of TNF when compared the challenge with 
40µg and 20µg of LPS. The mice challenged with 20µg of LPS and anti-CLEC-2 
produced less TNF than the isotype, while on the challenge with 40µg of LPS 
the mice treated with anti-CLEC-2 produced more TNF when compared to 
isotype-treated mice (fig.5.2). There are minor contrasts between the cell 
culture and the mouse model experiments of CLEC-2 modulation of LPS 
responses, but these contrasts might be explained by the complexity of cells 
and systems involved on the mouse model. Nevertheless, there was a 
fundamental similarity between the different system: the increased production of 
IL-10. This differential production of IL-10 is observed regardless of the myeloid 
cell type used (macrophages or DCs) as well as on the mouse, strongly 
indicating the qualitative different response that CLEC-2 triggering can induce 
on the presence of LPS. 
Chapter 5. Mouse models to study CLEC-2 function 
 127 
 
Figure 5.2 Anti-CLEC-2 modulates responses to different amounts of LPS 
C57BL/6J mice were injected I.P with 300µg of isotype or anti-CLEC-2 mAb and (A) 
40µg (B) 20µg and (C) 10µg of LPS. All inflammatory mediators were quantified by 
cytometric bead array (CBA) on serum samples. Data are means ± SD of at 4-6 mice 
per group in a single assay. Statistical differences were assessed with Mann-Whitney 
test. *p<0.05 **p<0.01. 
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Regardless of the differences on the production of other cytokines, the 
increased IL-10 level is the best read-out for CLEC-2 modulation of LPS 
response in this mouse model. Because of this, I decided to analyse IL-10 
levels modulated by LPS and different amounts of anti-CLEC-2. Consequently, 
there were no differences on IL-10 in the serum of mice challenged with 20µg of 
LPS and different amounts of anti-CLEC-2 (300µg, 150µg, 75µg or 37.5µg) 
(fig.5.3A). Subsequently, I used even lower amounts of anti-CLEC-2 trying to 
reach a point where the increased IL-10 level was no longer observed. Hence, 
the challenge with 10µg of anti-CLEC-2 already showed a reduced production 
of IL-10, whilst the administrations of 2.5µg of anti-CLEC-2 showed no affect 
whatsoever on the increased IL-10 level (fig.5.3B). Overall, these assays 
showed a minimal amount of anti-CLEC-2 able to induce the maximal effect on 
induction of increased IL-10 in the serum, allowing me to further characterise 
the time differences on the production of different mediators. 
 
Figure 5.3 Different amounts of anti-CLEC-2 increase IL-10 on LPS-induced 
inflammation in mice 
(A) C57BL/6J mice were injected I.P with 20µg of LPS and different amounts of  anti-
CLEC-2 mAb. (B) C57BL/6J mice were injected I.P with PBS, 40µg of isotype and 20 
µg of LPS or different amounts of anti-CLEC-2 mAb with 20µg of LPS. IL-10 was 
quantified by cytometric bead array from serum samples (CBA). Each dot represents a 
different mouse.  
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As discussed above, the observed modulation of endotoxic shock by 
anti-CLEC-2 might change according to the time point analysed or the tissue 
where the inflammatory mediator is quantified. To examine the first, I 
challenged mice with 20µg of LPS and 40µg of anti-CLEC-2 or isotype and 
analysed the production of cytokines on the serum. There were no differences 
on the production of IL-6 at 1 hour, 3 hours or 6 hours after challenge (fig.5.C). 
The production of IL-10 was increased 3 hours after challenge, as shown 
earlier, and also at 6 hours (fig.5.4A). Strikingly, the amounts of TNF were 
reduced 1 hour after challenge, but not later, in mice treated with anti-CLEC-2 
and LPS (fig.5.4B). Thus, the analysis at different time points revealed that 
CLEC-2 triggering could modulate the balance of TNF and IL-10 during 
endotoxic shock. This can be important, as TNF is an important mediator of 
mortality during endotoxemia, and IL-10 can revert TNF production and lethality 
(Gérard, Bruyns et al. 1993; Howard et al. 1993).  
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Figure 5.4 Kinetics of inflammatory mediators modulated by anti-CLEC-2 and 
LPS  
C57BL/6J mice were injected I.P with 20µg of LPS and 40µg of isotype or anti-CLEC-
2 mAb. Serum samples were obtained 1, 3 or 6 hours after injections. (A) IL-10, (B) 
TNF and (C) IL-6 were quantified by CBA. Data is representative of two independent 
assays. Each dot represents a different mouse. Statistical differences were assessed with 
Mann-Whitney test. *p<0.05. 
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5.4 Involvement of myeloid cells in CLEC-2 modulation of LPS 
responses 
Many cell types were demonstrated to produce IL-10, including NK cells, 
B cells, neutrophils, macrophages and DCs (Saraiva and O'Garra 2010). 
Considering a broad expression of CLEC-2 (Chapter 3), and that the LPS 
receptor TLR4 is widely expressed in immune cells as well as on epithelial cells, 
it is conceivable that many cells are involved in the increased production of IL-
10 during CLEC-2 modulation of LPS responses in vivo. 
 
Figure 5.5 DCs and macrophages are involved in the potentiation of IL-10 induced 
by anti-CLEC-2 and LPS 
(A) C57BL/6J mice were injected I.P with 300µl of PBS- or clodronate-liposomes. 
After 4 days the mice were challenged for 3 hours with 20µg of LPS and 40µg of 
isotype or anti-CLEC-2 mAb. Mice were sacrificed and spleen and serum samples were 
obtained. (B) Splenocytes were stained with anti-F4/80, anti-CD11c, anti-CD11b and 
7/4 and analysed by FACS. IL-10, TNF and IL-6 were measured by CBA. Data  is 
representative of two independent assays. Each dot represents a different mouse. 
Statistical differences were assessed with Mann-Whitney test. **p<0.01. 
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To analyse the involvement of myeloid cells in the modulation of IL-10 
responses to LPS by anti-CLEC-2 I decided to try depletion assays. I made use 
of clodronate-loaded liposomes that induce depletion of phagocytic cells (Van 
Rooijen and Sanders 1994). The most affected cells are the phagocytes that 
have a long half-life, like DCs and macrophages. Thus, I treated mice with PBS- 
or clodronate-liposomes and 4 days later I challenged them with LPS and 
isotype or anti-CLEC-2 antibody. Remarkably, clodronate-liposome treatment of 
mice completely prevented anti-CLEC-2 modulation of IL-10 production 
(fig.5.5A, left). No effect of clodronate-liposome treatment was observed on the 
serum levels of TNF or IL-6 (fig.5.5A). Furthermore, all mice challenged were 
sacrificed and their spleen were analysed for the presence of myeloid cells. As 
shown on figure 5.5B, the clodronate-liposome treatment induced the depletion 
of DCs and monocytes, but not neutrophils. 
The clodronate-liposomes depleted both monocytes/macrophages and 
DCs, making it impossible to evaluate the contribution of each cell type. To 
further discriminate these two cell types I made use of a more specific 
depletion, the transgenic mouse line expressing the diphtheria toxin receptor 
under the control of the CD11c promoter (CD11c-DTR-GFP). These mice have 
been demonstrated to deplete DCs after a single IP injection of diphtheria toxin 
(DT), while the monocytes population remains intact (Jung, Unutmaz et al. 
2002). Thus the specific depletion of DCs can help discriminate between the 
role of DCs and monocytes on CLEC-2 modulation of LPS responses in vivo. 
For this end, I generated bone marrow chimeras by irradiating C57Bl/6 mice 
(WT) and transferring bone marrow cells from WT or CD11c-DTR mice. After 12 
weeks I analysed the splenic DCs of these chimeras and observed that the 
great majority of DCs were derived from the CD11c-DTR-GFP mice, as the 
CD11c cells were expressing GFP, while the WT DCs were GFP negative 
(fig.5.6B, PBS column). Thus, I treated mice with 100ng of DT and 18 hours 
later I challenged the mice with LPS and isotype-matched or anti-CLEC-2 
antibody. Notably, DC-depleted mice showed reduced IL-10 levels compared to 
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DC-sufficient mice, while the TNF and IL-6 levels were unchanged (fig.5.6A). In 
line with that, the analysis of splenic DCs on these mice showed that DT 
treatment depleted DCs only in CD11c-DTR-GFP and not in WT chimeric mice 
(fig.5.6B, lower panel). 
On the whole, these data show that DCs and monocytes/macrophages 
are important targets of CLEC-2 modulation of endotoxic shock. Importantly, the 
depletion of DCs and monocytes/macrophages only affected the production of 
IL-10 and not of other mediators (TNF and IL-6), emphasizing the role of CLEC-
2 in the modulation of IL-10 production by TLR stimulation of myeloid cells. 
Chapter 5. Mouse models to study CLEC-2 function 
 134 
 
 
Figure 5.6 Involvement of DCs on CLEC-2 modulation of LPS-induced responses 
(A) CD11c-DTR-GFP or C57BL/6J(WT) bone marrow cells were used to reconstitute 
lethal irradiated WT mice. These mice were injected with PBS or 100ng of diphtheria 
toxin I.P and 18 hours later challenged with 20µg of LPS and 40µg of isotype or anti-
CLEC-2 mAb. 3 hours after the challenge the mice were sacrificed and spleen and 
serum samples were obtained. IL-10, TNF and IL-6 were measured on the serum by 
CBA. (B) Splenocytes were stained with anti-CD11c antibody and analysed by FACS. 
Data is representative of two independent assays. Each dot represents a different mouse. 
Statistical differences were assessed with Mann-Whitney test. *p<0.05. 
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5.5 CLEC-2 conditional knockout mouse 
The discovery of genetic manipulation of embryonic stem (ES) cells 
allowed generation of mouse lines with targeted mutations (Koller and Smithies 
1992). More recently, the CRE-loxP recombinase system has allowed scientists 
to generate mouse lines with genetic deletions conditioned by CRE expression, 
generating inducible or conditional KO mice (Rajewsky et al. 1996). So, based 
on my previous findings showing wide expression of CLEC-2 in haematopoietic 
cells and the fact that Pdpn-/- mice were not viable and showed a similar 
phenotype to Syk-/- mice (Schacht, Ramirez et al. 2003), I decided to generate 
a mouse line carrying a conditional deletion of the CLEC-2 gene (clec1b) that 
will allow me to impair CLEC-2 expression on certain cell types and/or 
conditions.  
The way I decided to do this was to insert one loxP site between exons 1 
and 2 and another loxP between exons 4 and 5. The clec1b gene is composed 
of 6 exons, with the exon 1 corresponding to the N-terminus, while the C-
terminus is encoded by the exon 6 (see 5.7A). The insertion of loxP sites 
between exons 1 and 2 and exons 4 and 5 allows the deletion of exons 2, 3 and 
4 encoding the transmembrane, neck and part of CTLD. Furthermore, exon1 
does not contain full codon sequences and with two nucleotides from exon 2 it 
will form a correct codon sequence (see figure 5.7B). Thus the deletion of exon 
2 will generate a frame shift that would impair CLEC-2 expression. 
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Figure 5.7 Schematic representation of clec1b targeted disruption 
(A) Schematic representation of targeting construct used to insert neomycin gene and 
loxP and FRT site on the clec1b (CLEC-2) gene locus on C57BL/6 embryonic stem 
(ES) cells. (B) Representation of aminoacids and domains encoded by each clec1b 
(CLEC-2) exon. 
 
As a part of cloning and selection, I inserted a resistance gene in the DNA 
vector used to target the ES cell genome. The resistance gene that I chose was 
the neomycin (NEO) gene being regulated by two different promoters, the gb2 
prokaryotic promoter and the pgk mammalian promoter. With these two 
promoters, the targeting construct can be selected on bacteria and ES cells. As 
a part of the strategy to generate CLEC-2 conditional and null mice, I decided to 
insert this NEO gene together with a loxP site between the exons 4 and 5. By 
using this approach I expect to generate CLEC-2 null mice when both CLEC-2 
alleles have the NEO insertion, as this NEO gene between CLEC-2 exons with 
a strong promoter and poly A tail is likely to impair the expression of CLEC-2 as 
demonstrated previously (Ohno et al. 1994). The NEO gene is flanked by FRT 
recombination sites, thus making it possible to excise the NEO cassette by 
expression of the Flp recombinase and this way generating the final conditional 
CLEC-2 KO mouse. 
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 After successful cloning and insertion of modifications on clec1b gene, 
we (myself and the London Research Institute Transgenic lab) successfully 
generated C57Bl/6 ES cells carrying mutated clec1b. These 3 corrected 
targeted ES cells were injected into 8-cell stage white fur embryos and then into 
pseudo-pregnant female mice. This strategy generated mice that was had 80% 
of its coat black, indicating that its genome was partially from the C57Bl/6 ES 
cell. Only 2 of the 3 ES cell clones could give rise to chimeric mice, and among 
these 2 chimeric mice only one transmitted the mutated clec1b gene to its litter, 
thus giving rise to clec1b loxP FRT-NEO-FRT loxP mouse, from now on 
referred as CLEC-2 NEO. 
As for PDPN -/- mice (Schacht, Ramirez et al. 2003), CLEC-2 deficient 
mice are not viable and show blood inside the lymphatics (Bertozzi et al. 2010; 
Suzuki-Inoue et al. 2010; Tang, Li et al. 2010). I decided to analyse CLEC-2 
deficient embryos. To do so, I mated two heterozygous wt/CLEC-2 NEO mice 
and obtained the embryos at embryonic day 15.5. I genotyped the embryos for 
the presence of inserted 5’ loxP site in the CLEC-2 gene locus. Among nine 
embryos genotyped, three embryos showed only amplification of the WT allele, 
five embryos showed amplification of both WT and targeted allele (with loxP 
insertion) and one showed only amplification of the targeted allele (figure 5.8A). 
Amongst these embryos, the one genotyped as homozygous for the targeted 
allele showed a localised bleeding on the area of development of the lymph sac 
(figure 5.8B, arrow). Accordingly, analysis of CLEC-2 expression obtained from 
foetal liver showed impaired CLEC-2 staining on the surface of CD41+ cells 
from embryo homozygous for the targeted allele, whilst WT and heterozygous 
embryos showed similar CLEC-2 surface expression (figure 5.8B, lower panel). 
Therefore, it implies that targeting CLEC-2 gene locus by insertion of a NEO 
cassette impairs CLEC-2 expression. Importantly, no mouse homozygous for 
CLEC-2 NEO was observed among more than one hundred mice born from the 
cross of two heterozygous wt/CLEC-2 NEO mice. Even though the bleeding of 
CLEC-2 NEO homozygous mice is localised and not as remarkable as the 
bleeding observed in Syk-deficient mice, this shows the importance of normal 
CLEC-2 expression for normal development of mice. 
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This single embryo analysed so far suggests that CLEC-2 deficiency led to 
a bleeding at the site where the lymphatics start to develop. It is worth point out 
that this suggests that my strategy to impair CLEC-2 expression in mouse has 
worked and, similarly to other reports led to bleeding on embryos (Bertozzi, 
Schmaier et al. 2010; Suzuki-Inoue, Inoue et al. 2010). It will be important to 
further examine more of these embryos. Additionally, it will be even more 
important to analyse embryos where CLEC-2 deficiency will be generated 
deletion of clec1b exons, for example by crossing to constitutive CRE-
expressing mice. Finally, the crossing to selective CRE lines will allow analysis 
of CLEC-2 function in different cell types. 
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Figure 5.8 NEO insertion on clec1b locus impair CLEC-2 expression and leads to 
bleeding on embryos 
Embryos were acquired at embryonic day 15.5 from breeding of heterozygous C57BL6J 
(+)/CLEC-2 NEO (NEO). (A) DNA was extracted from tails and analysed by PCR. 
Primers and genotyping strategy is represented in figure 2.4. (B) Embryos were 
analysed for gross bleeding defects on a low magnification upright microscope with 
external light source. Arrow indicates localised bleeding observed. Foetal livers cell 
suspensions were obtained and stained with anti-CD41-FITC and isotype-Alexa647 or 
anti-CLEC-2-Alexa647 antibodies. 
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5.5.1 Summary and discussion 
Beside the great data available regarding CLEC-2 signalling and function 
in platelets, there is a lack of reports analysing CLEC-2 functions in vivo. In this 
chapter I characterised some in vivo functions of CLEC-2 in myeloid cells. I 
described that CLEC-2 triggering induces increased serum levels of IL-10 in a 
mouse model on LPS-induced inflammation. This increased IL-10 levels were 
dependent on the presence of macrophages and DCs. Finally, I generated a 
conditional CLEC-2 KO mouse that will be used to further characterise CLEC-2 
function in different cell types. 
The involvement of CLEC-2 on modulation of TLR responses on 
macrophage and DCs culture led me to investigate the effect of CLEC-2 
triggering in mouse model LPS-induced inflammation. In this model, anti-CLEC-
2 mAb administration simultaneously with LPS increased IL-10 levels in the 
serum and peritoneum, similar to the cell culture observations. However, it is 
conceivable that the in vivo requirements for CLEC-2 modulation of LPS 
responses are different, and the anti-CLEC-2 treatment of mice is in fact 
blocking CLEC-2 function. It will be important to determine Syk activation on 
myeloid cells followed anti-CLEC-2 mAb administration. 
Based on the fact that anti-CLEC-2 administration might be acting as a 
CLEC-2 agonist in mice, I measured different inflammatory mediators to 
evaluate the modulation of LPS responses. The CLEC-2 triggering during 
endotoxemia increased IL-10 systemically (serum) and locally (peritoneal 
lavages). However, the levels of TNF were increased by anti-CLEC-2 mAb in 
the peritoneum, but not in the serum. Considering that LPS induces recruitment 
of cells to the peritoneum, CLEC-2 triggering might modulate this recruitment by 
increasing the recruitment of IL-10- and TNF-producing cells. Another attractive 
hypothesis is the recent find that engagement of integrins can modulate TLR 
responses inducing IL-10 via Syk signalling (Wang et al. 2010). Thus, 
modulation of expression/activation of integrins by CLEC-2 could account the 
increased IL-10 production observed. It also suggests that LPS-activated DCs 
migrating on lymphatics could potentially activate Syk via CLEC-2-PDPN 
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interaction, leading to increased IL-10 production and dampening of 
inflammation. The diminished TNF levels observed in the serum 1 hour after 
challenge might be due to a delayed activation of TNF-producing cells. This 
delayed activation might be due to increased IL-10 that is not observed 
because of consumption of this cytokine or to an impaired recruitment of TNF-
producing cells to the local inflammatory site (peritoneum). 
Myeloid cells migrate to inflammatory sites and produce different 
inflammatory mediators, thus these cell types were likely to be involved on the 
increased IL-10 production observed by anti-CLEC-2 and LPS in vivo. 
Accordingly, depletion of monocytes and DCs greatly impaired the increased IL-
10 production observed. Furthermore, the depletion of these cell types did not 
affect the LPS-induced production of IL-10, TNF or IL-6. This suggests that that 
monocytes and DCs are not the primary source of these cytokines in vivo, but 
CLEC-2 triggering can turn DCs and macrophages into IL-10 producers. 
Interestingly, CLR and TLR co-activation on neutrophils were shown to promote 
increased production of IL-10 (Zhang et al. 2009). Collectively my data shows 
that CLEC-2 stimulation during endotoxic shock induces an increased IL-10 
production and a transient diminishment of TNF production by acting on 
myeloid cells, constituting a potential therapy for different inflammatory 
conditions. 
To better study CLEC-2 function in vivo, I generated a mouse line carrying 
a NEO gene on the middle of CLEC-2 gene. This approach led to impaired 
CLEC-2 expression on cells and bleeding on embryos (figure 5.8A). 
Nevertheless, I observed a bleeding localised on the site of lymph sac 
development, different from reported data where the bleeding was observed on 
different sites (Bertozzi, Schmaier et al. 2010; Suzuki-Inoue, Inoue et al. 2010). 
Among the hypothesis to conciliate my findings with the reported data there is 
the fact that this embryo have another gene inserted on the middle of CLEC-2 
and this besides affecting CLEC-2 expression might affect other genes. 
Moreover, this is a single embryo analysed and further embryos shall be 
studied to draw further conclusions.  
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My ultimate goal is to generate mouse lines deficient of CLEC-2 by the 
excision of CLEC-2 exons by CRE-expression, thus excluding the potential 
effect of the NEO insertion on the mouse genome. So, CLEC-2 NEO mice will 
have the NEO insertion deleted by crossing with a mouse line that carries the 
Flp recombinase under the control of a constitutive expressed promoter (hAct-
Flpe, or human actin Flp mice). This will generate a mouse that carries a CLEC-
2 floxed gene that should show a normal CLEC-2 expression. The CLEC-2 
floxed mice will then be crossed to different CRE-expressing mice to generation 
of CLEC-2 conditional knockout mice. An attractive mouse line will be the 
DCCLEC-2-/- that will be generated by crossing CLEC-2 floxed mice with CD11c-
CRE mice. These mice will be assessed by their production of IL-10 during anti-
CLEC-2 mAb and LPS challenge, formally demonstrating the role of CLEC-2 on 
DCs on the induction of IL-10. 
Many CLRs play important role on the recognition of mislocalised proteins, 
as the case of DNGR-1 (CLEC9a) that recognises a pre-formed ligand only 
exposed upon loss of membrane permeability (Sancho et al. 2009). In line with 
that, CLEC-2 recognises the endogenous glycoprotein PDPN that has a 
restricted expression pattern. Therefore it is possible that induced PDPN 
expression on inflamed tissues can trigger CLEC-2 and modulate TLR 
responses like the Syk-coupled receptor TREM-1 (Bouchon, Facchetti et al. 
2001). Thus, ablation of CLEC-2 expression on mice by crossing CLEC-2 floxed 
mice with different myeloid specific CRE (CD11c-CRE for DCs, LysM-CRE for 
monocytes, MRP8-CRE for neutrophil) or a hematopoietic CRE (Vav-iCRE) will 
generate mice that will be tested for their role on the modulation of different 
inflammatory conditions, such as infection and cancer. 
As mentioned above, CLEC-2 -/- mouse line was very recently reported. 
These CLEC-2-/- mice showed developmental defects on the formation of 
lymphatics (Bertozzi, Schmaier et al. 2010; Suzuki-Inoue, Inoue et al. 2010) 
similar to the ones observed on Syk-/-, SLP76-/- and PDPN-/- mice. It is 
proposed that CLEC-2-expressing platelets aggregate upon encountering 
PDPN on the developing lymphatics, with this CLEC-2-induced platelet 
aggregation being required for the separation of the blood and lymphatic 
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vessels. This proposed model is likely by the fact that CLEC-2 signals via 
SLP76 (Suzuki-Inoue, Kato et al. 2007), and platelets defective on SLP76 show 
a similar phenotype to CLEC-2-/- mice (Bertozzi, Schmaier et al. 2010). 
However, Böhmer and colleagues identified by fate mapping of Syk that a 
myeloid cell population was responsible for the correct lymphatic development 
(Böhmer et al. 2010). This indicates that CLEC-2 expression on macrophages 
can also be responsible for the lymphatic development. On this lines, the 
ablation of CLEC-2 expression on platelets (by crossing CLEC-2 floxed with 
PF4-CRE) or different myeloid cells will help identify a role of a given cell type 
expressing CLEC-2 on the vascular development.
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Chapter 6. Discussion 
 
Inflammation is a response of multicellular organisms to changes in 
tissue homeostasis. It has mechanisms of detection of tissue damage, 
aggressors and metabolic changes and, as consequence, initiates a process of 
restoration of tissue homeostasis. One way applied to survey tissue 
homeostasis is to express receptor in myeloid cells (DCs, monocytes and 
neutrophils) that recognises homeostatic changes. These cells are capable of 
migrate to tissues, phagocyte and produce several inflammatory mediators 
upon detection of inflammatory triggers. Furthermore, in mammals DCs have an 
increased capacity to emigrate from inflamed tissue via lymphatics and activate 
adaptive immune responses. 
The study of innate receptors that signals to gene induction and 
production of inflammatory mediators had greatly developed in the past decade. 
The great advance was made when Ruslan Medzhitov and Charles Janeway 
identified the TLR signalling in myeloid cells controlled cytokine production and 
activation of adaptive immunity (Medzhitov et al. 1997). This provided the first 
molecular evidences that the innate immune system could influence production 
of inflammatory mediators and activation of adaptive immune response. 
Subsequently, several reports showed that TLRs recognise different 
endogenous and microbial-derived molecules, which developed the concept 
that innate immunity recognises and signals to different homeostatic changes in 
the organisms. Following that, the NLRs and RLRs were also shown to play 
directly role on this recognition and activation of inflammatory responses. 
More recently, the CLRs joined the other three family of receptor and 
were shown to signal to initiation of inflammation by recognition of microbes. 
The CLRs also interacts with endogenous molecules, which leads to different 
responses.  
At the beginning of my studies, my first hypothesis was that CLEC-2 
would act as dectin-1 and detect microbes. I was unable to confirm this 
hypothesis and the endogenous protein PDPN was shown to be a CLEC-2 
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ligand (Suzuki-Inoue, Kato et al. 2007). Nevertheless, in cell culture assays 
virus budding from PDPN-expressing cells carries the CLEC-2 ligand allowing 
virus interaction with CLEC-2 (Chaipan, Soilleux et al. 2006). Therefore, it is 
possible that CLEC-2 plays a role on the detection of viruses that infect 
cells/tissues were PDPN is expressed. This scenario might constitute a 
condition where myeloid cells are co-triggered by signals derived from CLEC-2 
and TLRs present on those viruses. 
Tissue damage products were shown to be detected by myeloid innate 
receptors and trigger inflammation. CLEC-2 expression on myeloid cells might 
constitute a surveillance mechanism to detect PDPN misexpression on different 
sites and detect homeostatic changes. In line with that, PDPN is expressed in 
carcinogenic skin and metastatic cancer cells (Breiteneder-Geleff, Soleiman et 
al. 1999; Durchdewald, Guinea-Viniegra et al. 2008), two conditions intrinsically 
linked to changes in tissue homeostasis.  
I showed that PDPN was expressed on peritoneal cells only upon LPS 
triggering (figure 3.6A). This suggests that inflammatory triggers, such as LPS, 
can induce the CLEC-2 agonist constituting a model where both CLEC-2 and 
TLR agonists are present inducing a cross talk between resident peritoneal 
cells and myeloid cells. Accordingly, DC-SIGN was shown to mediate DC 
maturation on a process dependent on ligation by MAC-1 on neutrophils (van 
Gisbergen et al. 2005). 
The studies of CLEC-2 function and signalling in myeloid cells focused 
on the premise that signals derived from hemITAM containing receptor can 
initiate inflammatory responses. A recent report showed that selective CLEC-2 
signalling could lead to initiation of inflammation. Kerrigan and colleagues 
showed that a chimeric receptor consisting of dectin-1 CTLD and CLEC-2 
hemITAM can induce TNF production by triggering with zymosan, implying that 
CLEC-2 signalling can lead to initiation on inflammation (Kerrigan, Dennehy et 
al. 2009). Here, I used mAbs and PDPN.Fc to selective trigger CLEC-2 
signalling in DCs and failed to observe any cytokine production. In fact, dectin-1 
triggering by B-glucan micro-particles also fails to induce cytokine production, 
whilst curdlan proved to be a strong dectin-1 agonist (LeibundGut-Landmann, 
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Gross et al. 2007; Hernanz-Falcón, Joffre et al. 2009). This suggests that the 
nature of CLEC-2 agonists might play a role on the outcome of its signalling. 
Despite the failure to confirm whether CLEC-2 signalling can initiate 
inflammatory responses, I showed that this signalling could modulate LPS-
induced inflammation increasing IL-10 levels. In a mouse model of LPS-induced 
inflammation, DCs and macrophages play crucial part in the IL-10 increase. IL-
10 is a potent anti-inflammatory cytokine produced by different cell types, 
including myeloid cells (Saraiva and O'Garra 2010). Therefore, it is likely that 
CLEC-2 might cooperate to control exacerbated inflammation. 
NFAT activation by CLRs is a sharp difference between the TLR and the 
CLR family. CLEC-2 modulation of TLR response is dependent of calcineurin 
and, probably, of NFAT activation. The production of PGE2, an important vessel 
dilation mediator, is greatly dependent of NFAT upon dectin-1 triggering 
(Goodridge, Simmons et al. 2007), suggestive of another role for CLRs in the 
control of inflammation. Recently, calcineurin and NFAT were also implicated in 
the resistance against fungal infection (Greenblatt et al. 2010), emphasizing the 
importance of this pathway for immunity. Consequently, CLEC-2 cooperation 
with TLRs might constitute a mechanism to induce NFAT activation during TLR 
triggering allowing a proper control of the inflammatory process. Recently, the 
LPS co-receptor CD14 was shown to activate NFAT and contribute to IL-2 
production and induction of DC death upon LPS challenge (Zanoni et al. 2009). 
This report suggests that NFAT activation during inflammation might be 
important to maintenance of DC population. 
The efficient control of inflammatory responses requires proper balance 
of effector cells and mediators. Dcir, a ITIM containing CLR, was shown to be 
important to maintain the homeostatic pool of DCs. Deficiency of this molecule 
leads to increased numbers of DCs and autoimmune diseases (Fujikado et al. 
2008). This suggests that unopposed tyrosine kinase signalling in DCs is 
involved on the increased DC numbers. A constitutive CLEC-2 signalling, 
triggered by PDPN or lack of regulatory mechanisms, might be involved in the 
increased DC population or even DC differentiation. In B lymphocytes, Syk 
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signalling is important for generation and maintenance of these cells (Turner, 
Mee et al. 1995; Turner et al. 1997). 
Inflammatory responses differ on many ways, which depends on the 
tissue and inflammatory triggers. A recent example is the different outcome of 
immune responses upon intravenous or intranasal Listeria monocytogenes 
infection (Pepper et al. 2010). PDPN restricted expression in certain tissues 
might be indicative of a differential localised function of CLEC-2. PDPN might 
influence a differential response in these tissues, as a required step for the 
specific inflammatory response on the given site.  
Another way that PDPN restricted expression might control inflammatory 
responses is through migration of myeloid cells to these sites. DC-SIGN, 
another CLR, had been implicated in the mediation of DC trafficking by 
interaction with ICAM-2 (Geijtenbeek et al. 2000). CLEC-2 interaction with 
PDPN can possibly mediate a similar phenomenon, providing adhesion of 
myeloid cells when these migrate to lung, kidney or lymphatics.  
Studies in cell mobilisation commonly focused in the immigration and 
extravasation of cells from blood to tissues. This is due to the fact that the 
majority of cells do not emigrate from tissues to vessels. Nevertheless, DCs 
have an increased ability to emigrate, from tissues to secondary lymphoid 
organs, carrying antigens to activate adaptive immunity. Recently, Pflicke & Sixt 
showed that DCs uses preformed portal in the lymphatic collectors to emigrate 
from tissues. These lymphatic collectors are blunt end lymphatic vessels 
characterised by increased PDPN expression. Moreover, Pflicke & Sixt showed 
that DC emigration is completely independent of integrins-mediated adhesion or 
movement (Pflicke and Sixt 2009). Therefore, up-regulation of CLEC-2 
triggered by inflammation might allow increased DC entry into lymphatics by 
mediating adhesion and movement of DCs on PDPN surfaces. 
It is very clear nowadays that CLRs are able to recognise and signal to 
start the inflammatory process. However, this family is much more diverse and 
contains many different signalling motifs and members (as seen on table 4). 
Furthermore, the study of CLRs is still on its infancy and there are many 
aspects yet to be described. 
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It is still unclear if all CLRs can in fact couple to signalling to downstream 
function, which is the case of mannose receptor, mouse DCAR2 and DEC205. 
In addition, several other members are still to have ligands and agonists 
described. As it stands, the manner that these receptors interact with their 
ligands/agonists is a crucial step for the outcome of the downstream signalling. 
Therefore, the identification of CLRs ligands/agonists will greatly benefit the 
identification of the function of these receptors. 
In this thesis, I developed several tools and models that helped on the 
study of CLEC-2 function. The generation of anti-CLEC-2 mAbs greatly helped 
the identification of cell types that express this receptor (Kerrigan, Dennehy et 
al. 2009). I also showed that these mAbs could be used as selective CLEC-2 
agonists, which was confirmed by others (Hughes et al. 2010). Moreover, the 
identification of CLEC-2 signalling via a Syk-Ca2+-calcineurin-NFAT pathway to 
modulate TLR responses by macrophages and DCs will greatly benefit future 
studies about the role of this receptor in the initiation of inflammation. The 
discovery that CLEC-2 can modulate LPS-induced inflammation in vivo 
dependently of myeloid cells will certainly draw more attention to the role of 
CLEC-2 in these cell types. Additionally, the generation of a conditional CLEC-2 
KO mouse line will significantly help the identification of in vivo functions of 
CLEC-2 on different cell types. 
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